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Abstract 
Patients who have been diagnosed with breast cancer have a range of treatment options available to 
them. Patient involvement in decision-making is considered best practice, however due to the 
complexity of the options, health professionals not involving patients, and the distress of the 
diagnosis of cancer, patients may not be as involved as they wish to be. The decision about whether 
to receive neoadjuvant systemic therapy is one decision where the preferences of the patient 
influences treatment choice. Interviews with patients with a history of breast cancer indicated a 
desire for more information and involvement in the decision about neoadjuvant systemic therapy. In 
preference-sensitive situations such as this, patient decision aids have been shown to improve 
decision-related outcomes.  
The aim of this research was to identify and support the decisional needs of patients and clinicians 
who are considering neoadjuvant systemic therapy for operable breast cancer. A systematic review 
found that no decision aid was available for patients considering neoadjuvant systemic therapy for 
breast cancer. A survey of clinicians found high levels of interest in neoadjuvant systemic therapy, 
and a need for patient decision support.  
The studies described above laid the foundation for the development of a patient decision aid, using 
the International Patient Decision Aid Standards collaboration criteria, for women considering 
neoadjuvant systemic therapy for operable breast cancer. The evaluation study demonstrated that 
the decision aid was acceptable to patients and clinicians, and was feasible to use in clinical practice. 
After using the decision aid, patients had decreased decisional conflict, increased participation, and 
high satisfaction. Knowledge scores were acceptable, and anxiety and distress decreased over time. 
vi 
This decision aid is a new, effective resource developed in response to an identified need for 
information and decision support for women with early stage breast cancer who are considering 
neoadjuvant systemic therapy. Future work will focus on methods to optimise the implementation 
of the decision aid in routine practice on a global scale. 
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Glossary 
Adjuvant Treatment given following surgery, aiming to reduce the risk of 
cancer relapse. 
Autologous 
reconstruction 
Breast reconstruction using the patient’s own tissue. 
Breast conserving 
surgery 
Surgery to remove a breast lump, leaving behind normal breast 
tissue. Also referred to as lumpectomy, partial mastectomy or wide 
local excision. 
Breast reconstruction One of several different surgical procedures to recreate a breast 
mound following mastectomy. 
Chemotherapy Medication given to destroy cancer cells. Can be intravenous 
(through a drip) or tablets. 
Downstaging Reduction in tumour size or nodal burden via chemotherapy. This 
may permit breast conserving surgery when mastectomy was initially 
required. 
Early stage breast 
cancer 
Breast cancer that is limited to the breast and/or nearby lymph 
nodes, treated with curative intent. 
Endocrine therapy Breast cancer treatment designed to prevent the stimulatory effect 
of oestrogen on breast cancer cells by either reducing the amount of 
circulating estrogen, or interfering with the signalling pathway on 
cancer cells. 
viii 
Immunohistochemistry Specific dyes or antibodies applied to a pathological specimen to 
highlight aspects of the tumour such as oestrogen receptor or HER2. 
Implant reconstruction Breast reconstruction using a surgically implanted prosthesis. 
Histopathology Examination of a tumour specimen, macroscopically and 
microscopically, to determine its nature. 
Local therapy Treatment such as surgery or radiotherapy that affects a limited 
region of the body. 
Lymph nodes Small glands located around the body that drain fluid from nearby 
areas. Often the lymph nodes under the arm are the first site that 
breast cancer occupies outside the breast. 
Lymph node dissection Surgical removal of the axillary lymph nodes. 
Luminal Typically, oestrogen positive breast cancer, classified as Luminal A 
(low proliferation rate), or Luminal B (high proliferation rate). 
Macrometastatic Cancer cells that have travelled beyond the organ of origin and are 
clinically evident using physical examination or medical imaging. 
Mastectomy Surgical removal of the entire breast. 
Metastatic/advanced 
breast cancer 
Breast cancer that has invaded surrounding tissues, or spread to 
distant sites such as the bones, liver or lungs, such that it cannot be 
cured. 
Micrometastatic Cancer cells that have travelled beyond the primary organ but are 
too small to be seen with the naked eye or with medical imaging. 
ix 
Neoadjuvant Treatment prior to surgery, with curative intent. In breast cancer, this 
can be with either chemotherapy or endocrine therapy. 
Oncoplastic Use of plastic surgery techniques at the time of breast cancer surgery 
to maintain cosmesis. 
Operable Able to be treated with a surgical approach. 
Pathological complete 
response (pCR) 
Absence of histologically detectable invasive malignancy following 
systemic therapy. 
Patient decision aid An evidence-based tool (document, website, video or other media) 
designed to help patients make specific and deliberated choices 
about healthcare options. 
Radiotherapy Ionising radiation treatment used to destroy cancer cells. A localized 
treatment that only affects the part of the body that the radiation is 
aimed at. 
Recurrence A cancer diagnosis subsequent to, and related to, a previously 
diagnosed cancer. 
Sentinel lymph node 
biopsy 
A procedure using injection of blue dye and/or radio-isotope into the 
breast, followed by removal of the lymph node(s) that accumulate 
dye and/or isotope. These are typically the first lymph nodes to 
contain a metastasis, and axillary dissection can be omitted if the 
sentinel node is free of cancer. 
Systemic therapy Treatment such as chemotherapy or endocrine therapy that acts 
throughout the body. 
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Chapter 1: Introduction 
1
1.1 Overview of thesis 
This thesis reports the findings of a body of work that describes the development of, and investigates 
the use of, a patient decision aid (DA) to support decision-making in women with breast cancer who 
have been offered neoadjuvant systemic therapy (NAST).  
A patient decision aid is defined by the International Patient Decision Aids Standards (IPDAS) 
Collaboration as:  
A tool to help people participate in decisions about health care options, with the goal of 
promoting deliberation between patients, health care providers and others about these options. 
They provide information about the options and help patients to construct, clarify, and 
communicate the personal values they associate with the different features of the options. 
Patient decision aids do not advise people to choose one option over another, nor are they 
meant to replace practitioner consultation. Rather, they provide structured guidance in the 
steps of decision-making and to prepare patients to make informed, values-based decisions with 
their practitioner. (Volk et al., 2013) 
This work is presented as a thesis by publication. 
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 1.2  List of publications included in thesis 
 
This thesis comprises five publications and one conference paper. The publication versions included in 
this thesis are the author submitted manuscripts, after changes made in response to journal reviewers’ 
comments. 
Two additional publications relevant to the thesis, but not forming part of it, are included as Appendices 
B and C. One additional conference abstract is included as Appendix D. 
Author contribution statements are included as Appendix E. 
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 1.3  Ethics 
 
The research protocols for the interviews with patients, the clinician survey and the decision aid 
evaluation study were each approved by the Hunter New England Local Health District Human Research 
Ethics Committee (HREC). HREC approval letters are included as Appendix F. 
 
Voluntary informed consent was obtained from all participants. The studies were conducted according 
to the principles of the International Conference on Harmonisation Good Clinical Practice, and according 
to the principles of the Declaration of Helsinki (World Medical Association, 2013, Therapeutic Goods 
Administration, 2000). 
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 Chapter 2: Background 
  
6
  
2.1 Introduction 
This chapter describes the epidemiology, staging and natural history of breast cancer. It explains the 
range of treatment options available, to place neoadjuvant systemic therapy in context. Shared decision 
making is introduced, followed by a description of the role of patient decision aids in treatment 
decisions. 
 
2.2  Overview of breast cancer epidemiology and management 
In 2012, approximately 1.67 million people worldwide were diagnosed with breast cancer (International 
Agency for Research on Cancer, 2012). A more recent statistical projection estimated that 17,730 people 
will be diagnosed with breast cancer in 2017 in Australia (Australian Institute of Health and Welfare, 
2017). Approximately 100 females are diagnosed for each male breast cancer (Australian Institute of 
Health and Welfare, 2017). Age-standardised breast cancer incidence rates increased in developed 
nations up until 2005, at which time incidence stabilised. Incidence in low and middle income countries 
has continued to increase (Internationa Agency for Research on Cancer, 2012). Despite increasing 
incidence over the past 30 years, breast cancer recurrence and mortality rates have declined over this 
time by an average of 2% per year (Australian Institute of Health and Welfare, 2014, International 
Agency for Research on Cancer, 2012). This decline is due to the introduction of population screening 
programs and the emergence of new and improved systemic treatments that are curing more women of 
their cancer (Australian Institute of Health and Welfare, 2014, Torre et al., 2016).  
 
Patients with breast cancer can be categorised into two broad groups according to the extent of their 
disease: early stage (stage I-IIIA), and advanced (stage IIIB-IIIC) or metastatic (stage IV) (Giuliano et al., 
7
2017, National Cancer Institute, 2018). Stage refers to the size of the breast tumour, whether it has 
spread to nearby or distant tissue, and the number and location of involved lymph nodes, if any. 
Patients with early stage breast cancer have disease which is limited to the breast or adjacent lymph 
nodes while those with advanced or metastatic cancer have disease which has spread to distant organs 
(Giuliano et al., 2017).  
Stage Tumour diameter Lymph node involvement Distant organ 
involvement 
5-year relative
survival 
I ≤2cm No, or ≤2mm No 99% 
IIA ≤2cm 1-3 nodes No 93% 
>2-≤5cm No No 
IIB >2-≤5cm 1-3 nodes No 
>5cm No No 
IIIA ≤5cm 4-9 nodes No 72% 
>5cm 1-9 nodes No 
IIIB Direct invasion to 
nearby structures 
0-9 nodes No 
IIIC Any size >9 nodes or supraclavicular No 
IV Any size Any nodes Yes 22% 
Table 1. Breast cancer stage description (Giuliano et al., 2017) and relative survival by stage 
(Howlader et al., 2016). 
8
 The most recent edition of the American Joint Committee on Cancer staging manual for breast cancer 
also includes subtype and molecular characteristics in stage differentiation (Giuliano et al., 2017). Stage 
grouping has prognostic relevance, with increasing stage corresponding with lower rates of survival 
(Walters et al., 2013). 
 
Patients with early stage breast cancer are 
treated with curative intent, while those 
with metastatic disease are given treatment 
to prolong survival, delay cancer 
progression, improve quality of life and 
control cancer-related symptoms (Curigliano 
et al., 2017a). Ninety percent of women 
diagnosed with breast cancer in Australia 
have early stage disease (Lord et al., 2012). 
Despite the improved efficacy of breast 
cancer treatments that are now available in 
Australia, between 2 and 4 percent of patients will experience a localised or metastatic relapse each 
year following diagnosis, as shown in Figure 1 (Kemp-Casey et al., 2016, Lord et al., 2012). Including both 
early stage and metastatic patients, this equates to an estimated 193,730 women living with a diagnosis 
of breast cancer in the 31 years leading up to 2012 (Australian Institute of Health and Welfare, 2014). 
 
Women with breast cancer are typically offered one or more treatment modalities including surgery, 
chemotherapy, endocrine therapy, radiotherapy and supportive care (Curigliano et al., 2017a), as shown 
Figure 1. Cumulative incidence plot of breast cancer recurrence 
according to lymph node involvement. Kemp-Casey et al. 2016, 
with permission. 
9
 in Figure 1. These treatments may be given alone, sequentially or concurrently depending on the 
tumour stage and overall treatment plan (Figure 2). This thesis will focus on early stage breast cancer, 
for which treatment is given with curative intent. In early stage breast cancer, the traditional treatment 
sequence consists of surgery, followed by chemotherapy, then radiotherapy and then endocrine therapy 
(Curigliano et al., 2017a, National Comprehensive Cancer Network, 2017). The indication for all 
treatments other than surgery depends on both the clinical context and patient preferences. Patients 
may have the option of breast conserving or oncoplastic surgery if the tumour is small enough, and in an 
appropriate position for an acceptable cosmetic outcome (Fisher et al., 2002). The alternative breast 
operation is a mastectomy (Figure 3). Breast reconstruction, using a variety of autologous- or implant-
based techniques, may be performed at the time of mastectomy, or in a staged procedure (Seidel et al., 
2017). Radiotherapy to the breast is recommended after breast conserving surgery to reduce the risk of 
local recurrence, and after mastectomy in the presence of a larger, more aggressive phenotype or with 
locoregional lymph node burden (Clarke et al., 2005).  
 
 
Figure 2. Diagnostic and treatment schema for early stage breast cancer. *If oestrogen and/or progesterone receptor positive; 
†if HER2-receptor positive; ‡one or more regions, if indicated. 
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 The selection of systemic therapy depends on the subtype 
of breast cancer and the extent to which it has spread 
(stage). Historically, subtype has been determined by 
microscopic histopathological examination, proliferation 
rate and immunohistochemical staining for features such 
as oestrogen, progesterone, and HER2 receptors (Table 2). 
Now, breast cancer treatments are increasingly influenced 
by the intrinsic subtype and recurrence risk profile of the 
cancer, as determined by genomic testing such as PAM50 
Risk of Recurrence score, or Mammaprint (Liu et al., 2015, 
Cardoso et al., 2016), in conjunction with 
clinicopathological information (Curigliano et al., 2017a). Such gene-based testing of individual breast 
cancers can identify patients who have such a good prognosis that adjuvant chemotherapy is unlikely to 
provide a substantial benefit. Tumour subtype and stage must then be interpreted in light of the clinical 
context, including patient comorbidities and age, to determine a treatment plan. 
 
One major aim of systemic therapy is to eradicate any microscopic tumour deposits that may be present 
beyond the breast and nearby lymph nodes (Schabel, 1977). The higher the stage, the higher the risk of 
micrometastatic disease that has the potential to progress into incurable macrometastatic disease if left 
untreated. Therefore, with increasing relapse risk, the need for systemic therapy is greater. On average, 
modern chemotherapy regimens proportionally reduce breast cancer mortality by about one-third (Early 
Breast Cancer Trialists’ Collaborative Group, 2012). The absolute benefit for an individual depends on 
their recurrence risk, which means that if the recurrence risk is low, then the benefit is small. For 
example, endocrine therapy is only indicated in women with oestrogen and/or progesterone receptor 
Figure 3. Breast conserving surgery vs mastectomy 
11
 positive breast cancer, but its choice may depend on risk factors such as tumour size and nodal status 
(Early Breast Cancer Trialists’ Collaborative Group, 2005, Davies et al., 2013). Furthermore, breast cancer 
tumour subtypes with a lower proliferative rate such as Luminal A do not tend to gain as much benefit 
from chemotherapy as other more highly proliferative subtypes such as triple negative breast cancer. 
For women with hormone receptor positive breast cancer, endocrine therapy with an aromatase 
inhibitor reduces breast cancer mortality proportionally by a further 40% beyond the benefit from 
chemotherapy (Early Breast Cancer Trialists’ Collaborative Group, 2015). 
 Oestrogen and/or progesterone receptor 
Positive Negative 
HER2 
receptor 
Positive Luminal B/HER2 
Chemotherapy, HER2-targeted therapy and 
endocrine therapy 
HER2 
Chemotherapy and HER2-
targeted therapy 
Negative Luminal A (low 
proliferative rate) 
Endocrine therapy 
Luminal B (high 
proliferative rate) 
Endocrine therapy (and 
chemotherapy) 
Triple negative/basal 
Chemotherapy 
Table 2. Major breast cancer subtypes and corresponding commonly used systemic treatments 
(italics). HER2: Human epidermal growth factor 2. 
 
Surgery and radiotherapy are classified as local therapies that aim to prevent progression or recurrence 
of the primary tumour, which in turn helps to prevent some patients from relapsing with metastatic 
12
disease (Early Breast Cancer Trialists’ Collaborative Group, 2014). The primary goal of systemic therapies 
such as chemotherapy and endocrine therapy is to prevent systemic recurrence, increasing the 
probability of cure (Early Breast Cancer Trialists’ Collaborative Group, 2005). Patients are offered 
systemic therapy on the basis of recurrence risk, however there is currently no test available to reliably 
determine if occult cancer is present in distant sites such as bones, liver or lung (Bychkovsky and Lin, 
2017). Some women relapse despite receiving chemotherapy, and some women would never have 
relapsed even if they had not received chemotherapy (Curigliano et al., 2017b). Similarly, there is no test 
to reliably indicate whether that residual cancer has been eradicated by adjuvant therapy (Penault-
Llorca and Radosevic-Robin, 2016). This means that there is substantial uncertainty about the possibility 
of recurrence for women during and after adjuvant therapy (Ellegaard et al., 2017). Better methods are 
needed to determine which women need chemotherapy and which could safely omit it (Krop et al., 
2017). Likewise, better tests are needed to determine which women have been cured by chemotherapy, 
and which require additional treatment to maximize their chance of cure. As a result of this uncertainty, 
along with the threat to life inherent in a cancer diagnosis, fear of cancer recurrence is a significant 
problem for women in this setting despite a falling rate of recurrence (Koch et al., 2013). Fear of 
recurrence has little correlation with objective risk of recurrence and remains relatively stable over time 
(Crist and Grunfeld, 2013). 
The complexity inherent in this broad range of treatment options means that patients may not be able 
to become as informed or involved in decision-making as they would like to be (Tariman et al., 2010, 
Krop et al., 2017). The difficulty patients face with these decisions is compounded by the need to 
proceed with treatment within days or weeks, rather than months (Bleicher et al., 2016). Patients with 
early stage breast cancer are not physically unwell, and treatment is not a medical emergency (Brazda et 
al., 2010), but there is often psychological pressure to proceed rapidly to treatment (Harcourt, 1999).  
13
Patients who have limited time to make treatment decisions, following a recent diagnosis of cancer, 
need strategies to become informed about their options and involved in the decision-making (Elwyn et 
al., 2014, Butow and Tattersall, 2005, Barry  and Edgman-Levitan 2012).  
2.3 Shared decision making 
Patient-centred care is a core indicator of quality health care, as defined by the United States Institute of 
Medicine report Crossing the Quality Chasm (Institute of Medicine, 2001) and by the Australian 
Commission on Safety and Quality in Health Care (2011). The Picker Institute/Commonwealth Program 
has been instrumental in advancing the research and implementation of patient centred care (Beatrice 
et al., 1998). The Picker Institute defines patient-centred care as containing the following components: 
• Respect for patients’ values, preferences and needs
• Coordination and integration of care
• Information, communication and education
• Physical comfort
• Emotional support and alleviation of fear and anxiety
• Involvement of family and friends
• Continuity and transition
• Access to care (Gerteis et al., 1993).
The first point in the list above refers to shared decision making, which is an important component of 
patient-centred care, in which decisions about medical treatments are made during a dialogue between 
the patient, doctor(s) and other relevant parties (Barry  and Edgman-Levitan 2012). Including the 
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 patient’s perspective is central to preserving their autonomy, which is widely regarded as a key principle 
of medical ethics (Entwistle et al., 2010, Beauchamp and Childress, 2013). 
  
Shared decisions are based on the medical 
literature and the personal views of the 
people involved in the decision, often within 
a complex clinical context, Figure 4 
(Satterfield et al., 2009). The overlying 
concept of clinical expertise is an 
acknowledgement of the clinician’s 
experience in drawing these components 
together into a comprehensible, unified 
whole. Shared decision making is a process 
whereby the patient and healthcare provider 
engage and communicate within the clinical context to meet the information and decisional control 
needs of the patient, enabling them to be as involved in decisions about their care as they prefer to be 
(Charles et al., 1997). Preferences for information, involvement and decisional control vary between 
patients, and change in individuals over time (Butow et al., 1997). Shared decision-making encounters 
include discussion about treatment options with different possible outcomes, with an element of 
uncertainty about the ‘best’ option (Charles et al., 1997). Patients may prefer physician-led, shared, or 
patient-led decision making, but ideally the patient should have the opportunity to decide how decisions 
are made about their care (Chewning et al., 2012). If the clinician asks the patient to shoulder more 
responsibility than they are prepared to, the burden of the decision may increase, along with the 
negative consequences of that decision-making (Thorne et al., 2013, Entwistle et al., 2010). 
Figure 4. Model of shared decision-making (SDM). Adapted from 
Satterfield et al. 2009. 
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 Charles et al. (1997) describe four key characteristics of shared decision-making: 
“ 1. At least two participants, physician and patient, be involved; 
2. Both parties share information; 
3. Both parties take steps to build a consensus about the preferred treatment; 
and 
4. An agreement is reached on the treatment to implement. 
 
 
 
ˮ 
 
Within each breast cancer treatment modality (surgery, systemic therapy, radiotherapy, supportive 
care), multiple options may be available that differ in efficacy, toxicity or patient preference (Curigliano 
et al., 2017a). Therefore, for decisions about breast cancer treatment, women’s personal values and 
preferences may have greater potential impact than survival outcomes on the choice of one option over 
the other (Whelan et al., 1999). These decisions should still take the available scientific literature into 
account, to inform outcome probabilities with each option, but not to the exclusion of patient 
preference and clinical context (Barratt, 2008). 
 
The decision about mastectomy or breast conserving surgery is one example of a decision that depends 
on individual values and preferences (Hamelinck et al., 2014). The survival and recurrence outcomes are 
equivalent, but functional, treatment and cosmetic outcomes differ (Fisher et al., 2002). One woman 
may prefer neoadjuvant therapy to facilitate breast conserving surgery to avoid the potential for 
reduced shoulder mobility after autologous breast reconstruction (Shin et al., 2013, Sherman et al., 
2014). Another woman with a strong family history may wish to have a bilateral mastectomy to 
minimize her risk of ipsilateral or contralateral breast cancer recurrence (Ager et al., 2016, Boughey et 
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 al., 2016). Both women, informed of the options, and their benefits and risks, will have made an 
appropriate treatment decision (Covelli et al., 2014). 
 
Some women may not wish to make the final decision, but still wish to be fully informed about their 
options (Chewning et al., 2012). Being given too much decisional control can be a burden, especially 
when a patient is distressed, time pressured and vulnerable after a recent diagnosis of a life-threatening 
condition such as breast cancer (Brocken et al., 2012, Charles et al., 1997). Despite this, the majority of 
breast cancer patients prefer to be involved in decision-making about their treatment (Degner et al., 
1997a, Hack et al., 2006, Katz et al., 2005). One study has shown that sociodemographic variables do not 
predict which patients prefer a greater degree of involvement (Degner and Sloan, 1992). Another more 
recent study indicated that women younger than 45 were less involved than they wanted to be, while 
women with only high school education were more involved than they preferred (Hawley et al., 2007). 
Over time, preferences for involvement change. Patients who have experienced a recent deterioration 
in their condition have been found to prefer less involvement in decision-making (Butow et al., 1997). 
 
Shared decision-making does not leave all responsibility to the patient, but rather offers joint 
responsibility for the decision (Charles et al., 1997). Health professionals train for many years to fully 
understand the evidence relevant to treatment decisions, which is nearly impossible for patients to 
match (Haskard et al., 2008). So patients will almost always need to rely on interpretation and 
summarizing of the literature by one or more health professionals so that they are as informed as 
possible about their choices (Epstein et al., 2004).  
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 Decision-making is influenced by more than just the doctor-patient dyad. Other influences include family 
and friends, the media, past experience with health care, perceived social norms, other information 
sources and credibility of those information sources (Epstein and Gramling, 2013). Unless involved 
parties are cognisant of the range of influences, these factors may contribute to a mismatch between 
doctor and patient on what constitutes best treatment (Degner et al., 1997a). 
 
Shared decision making has advantages and disadvantages. Patient benefits from shared decision 
making include: greater quality of life (Street and Voigt, 1997, Hack et al., 2006); greater satisfaction 
with medical consultations and with the information received, compared with those who made the 
decision entirely themselves or their doctor made the decision (Gattellari et al., 2001); greater decisional 
satisfaction and less decisional regret in patients who were at least as involved as they wanted to be 
(Brown et al., 2012). A systematic review of patient outcomes from shared decision-making found that 
52% of the patient-reported outcomes that were assessed were positive, while only 21% of observer-
rated and 0% of clinician-reported outcomes were positive (Shay and Lafata, 2015). It has been 
suggested that application of the principles of shared decision making can also reduce unnecessary 
treatments and thereby reduce healthcare costs (Oshima Lee  and Emanuel 2013). Shared decision-
making helps to reduce the power imbalance between clinician and patient (Emanuel and Emanuel, 
1992). Shared decision making is supported by patients (Chewning et al., 2012), consumer advocates 
(Thorne et al., 2013), health professionals (Elwyn et al., 2012), professional organisations and 
government (McCaffery et al., 2011).  
 
On the other hand, as mentioned previously, patients may see shared decision making as burdensome. 
Therefore, the clinician must be mindful of their patients’ desire, and ability, to participate in the 
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decision-making process. Uncertainty may be introduced into the consultation, at a time when patients 
might expect doctors to be decisive and give clear direction (Epstein and Gramling, 2013). This is not to 
say that shared decision making is inappropriate for these patients, but that they may need a tailored 
approach to information and the degree of decisional control (Thorne et al., 2013). From a clinician’s 
point of view, shared decision making may take additional time for an individual patient when there are 
other patients in need of medical care (Legare et al., 2008). Many clinicians have not been trained in 
shared decision making, so find it difficult to integrate the principles into routine clinical scenarios 
(Elwyn et al., 2004). Even when clinicians are aware of these principles, giving patients greater control 
over the decision can appear to be a threat to the traditional paternalistic medical consultation model. 
Clinicians might worry that patients will be overloaded with information (Caldon et al., 2011). 
There are situations where shared decision-making is not appropriate, such as in some medical 
emergencies where seconds count (Kraus and Marco, 2016). There are patients who are not able to be 
involved due to cognitive impairment, however in this situation a family member or other responsible 
person may still participate actively in treatment decision-making (Petriwskyj et al., 2014). Beyond these 
scenarios, a patient may choose not to participate in decision-making, leaving all decisions to their 
health care professionals (Levinson et al., 2005). This ability to choose still represents an element of 
shared decision-making. However, shared decision-making is appropriate in the majority of medical 
encounters: taking a completely clinician-directed approach is still not optimal for patient outcomes. 
Shared decision-making has not traditionally been a part of the clinical encounter, therefore a change in 
practice is required at individual and group levels to introduce this practice widely (Elwyn et al., 2008). 
The implementation of shared decision making into routine practice remains suboptimal (Legare et al., 
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 2008). Shared decision making has not been universally adopted (Elwyn et al., 2013). Public access to 
decision support is lacking (Morris et al., 2008). The Australian Commission on Safety and Quality in 
Health Care considers patient-centred care to be a fundamental aspect of high quality health care 
(Australian Commission on Safety and Quality in Health Care, 2011). The United States Institute of 
Medicine also emphasizes the importance of shared decision-making (Institute of Medicine, 2013). 
Federal and State legislation in the United States includes provisions to support shared decision making 
in an attempt to systematically incorporate this model of care into routine practice (Frosch et al., 2011).  
 
Patient-, clinician- and system-related barriers can prevent the implementation of shared decision-
making principles into clinical consultations (Charles et al., 2004). This means that despite the evidence 
that shared decision-making is beneficial, patients are not always able to achieve those benefits.  
 
Patient barriers to shared decision-making include limited access to information that is appropriate to a 
patient’s sociocultural background and level of health literacy (Legare et al., 2008). Patients have 
difficulty gaining knowledge about their options, and even more difficulty gaining power within the 
clinical encounter, both of which are highly relevant to shared decision-making (Joseph-Williams et al., 
2014a). Not all patients want to participate in the decision (Chewning et al., 2012). One North American 
study that enrolled a sample taken from the general population found wide variation in preferences for 
shared decision-making, with 52% preferring to leave the final decision to their treating doctor (Levinson 
et al., 2005). It is not known what the preferences would have been if these respondents had been 
supported in shared decision making. More recent data indicates a trend for increasing patient interest 
in shared decision-making: in 85% of studies published after 2000, a majority of cancer patients 
preferred a shared role, compared with 63% prior to 2000 (Chewning et al., 2012). 
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Clinician barriers include a perception that shared decision-making will consume too much of their 
limited time, lack of applicability to patient population, and difficulties applying shared decision-making 
principles within the clinical situation (Legare et al., 2008). In a systematic review of treatment decision 
aids (which are described in the next section), studies that included time-based outcomes indicated a 
median 2.6 minute (7.5%) increase in consultation time (Stacey et al., 2017). One study showed 
consultations were shorter if the decision aid was used prior to the consultation (Green et al., 2005). 
There was no difference seen in several studies. Consultations were longer on average if the decision aid 
was used during the consultation (Bekker et al., 2004, Kaner et al., 2007). Whilst time is valuable, the 
use of principles of shared decision-making is not costly, as distinct from many new drugs and other 
treatment strategies, with most studies that included economic analysis showing neutrality or a cost 
saving, compared with usual care (Stacey et al., 2017). Not all clinicians have been trained in shared 
decision-making or may not be aware of the decision support resources available (Caldon et al., 2011). 
Some clinicians take a paternalistic approach to the medical encounter, suggesting the treatment that 
they believe is best, rather than engaging in a dialogue with the patient and others (Quill and Brody, 
1996). Part of this problem is a concern that poor outcomes may result from the decision being taken 
out of the control of the clinician, leading to decisions that are based on biased or incorrect information 
(Caldon et al., 2011).  
Systemic barriers include a lack of time and resources, including staff, for shared decision-making to be 
fully integrated into health care. Use of a decision aid, for example, may require a change in 
appointment scheduling, to give patients time to digest the information in the decision aid outside of 
the consultation (Herrmann et al,. 2017). Whilst some studies have shown that giving patients a decision 
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 aid prior to their first consultation can shorten the consultation time (Green et al., 2005), this would 
require additional staff and a system set up to determine which patients should receive a decision aid, 
and which decision aid is most appropriate (Belkora et al., 2007). Ideally a clinical assessment should be 
made to determine which decision aid that patients might benefit from, if any (Belkora et al., 2012). 
Other barriers include lack of health professional training, lack of research and lack of ready access to 
tools such as decision aids (Barratt, 2008). 
 
Strategies are needed to overcome these barriers to optimise the implementation of shared decision 
making into routine medical care (Legare et al., 2008, Elwyn et al., 2013). These strategies need to be 
individualised, integrated and multifaceted. Strategies that may help incorporate shared decision-
making into clinical consultations include: educational meetings, feedback to health professionals, 
learning materials and use of patient decision aids (Legare et al., 2010). Shared decision-making training 
programs are increasing worldwide, but vary widely in their approach (Diouf et al., 2016). These 
programs mainly focus on the patient/health professional dyad, rather than a multidisciplinary group. 
Use of patient decision aids will be described in detail in the next section.  
 
2.4  Decision aids for treatment decisions 
In decisions with legitimate options that may be valued differently by individuals, decision aids can 
improve patients’ involvement in making the decision. A decision aid is an evidence-based document, 
device or other resource that presents balanced information to help patients make a specific and 
considered decision about two or more healthcare options (Volk et al., 2013). In this thesis, the term 
‘decision aid’ refers to decision aids that have been designed for patient use, as distinct to those that 
have been developed for health professionals. 
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The international Patient Decision Aid Standards (IPDAS) Collaboration was established to set an 
evidence-based framework for the development and assessment of patient decision aids (Elwyn et al., 
2006). The standards were updated and expanded upon in 2013 (Volk et al., 2013). The core 
components of a patient decision aid are: an explicit statement of the choice being made; a balanced 
presentation of the options (Feldman-Stewart et al., 2013); an explanation of outcome probabilities 
(Trevena et al., 2013); and a values clarification exercise (Fagerlin et al., 2013).  
A decision aid may be in the form of a booklet, ‘decision board’, multimedia presentation, audio, video 
or interactive internet-based tool. Decision aids are widely available on the internet, which has allowed 
broad distribution of individual decision aids (Hoffman et al., 2013). The Ottawa Decision Aid Inventory 
is one example of an online central repository for decision aids, in which decision aids are given a score 
based on IPDAS criteria for content, development process and effectiveness (Volk et al., 2013). 
However, additional evidence to support internet-based decision aids is needed (Syrowatka et al., 2016). 
Decision aids are intended to supplement, rather than replace, the clinical interaction.  
Several decision aids have been developed for women with breast cancer at different treatment 
decision points, including: breast and axillary surgery; chemotherapy; endocrine therapy; radiotherapy; 
and reconstruction surgery. These are described in detail later in this thesis in the publication titled: ‘A 
systematic review of decision aids for patients making a decision about treatment for early breast 
cancer’. 
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 A series of systematic reviews have been published at regular intervals, to summarise and report the 
effect of decision aids in people who are faced with medical treatment or screening decisions (O’Connor 
et al., 2001, O’Connor et al., 2003, O’Connor et al., 2009, Stacey et al., 2011, Stacey et al., 2014, Stacey 
et al., 2017). These have shown good evidence that decision aids improve patients’ knowledge about 
their treatment options, and reduce decisional conflict (Stacey et al., 2017). There is moderate evidence 
that decision aids allow patients to be more active in decision making and increase the accuracy of risk 
perception. No differences in outcomes were seen between decision aids that were used in preparation 
for a consultation or within the consultation (Stacey et al., 2017). Of relevance to the implementation of 
new treatments into practice, decision aids can act as normative instruments that give patients and 
clinicians permission to make decisions based on content rather than past experience or prevailing 
wisdom (Boivin et al., 2008). This thesis will focus on a decision aid to assist women making one 
particular breast cancer treatment decision: whether to have neoadjuvant systemic therapy or surgery 
as the first treatment. These treatment options are described in detail below. 
 
2.5  Neoadjuvant systemic therapy for breast cancer 
Neoadjuvant systemic therapy is a treatment option for selected women with operable early stage 
breast cancer (Read et al., 2015). Systemic therapy in this context includes both endocrine therapy 
and/or chemotherapy given prior to surgery with curative intent. This treatment schedule has become a 
standard treatment option for selected patients as an alternative to a surgery-first approach (Simmons 
et al., 2015, Cancer Australia, 2017, Arbeitsgemeinschaft Gynaecologische Onkologie, 2015, National 
Comprehensive Cancer Network, 2017). Neoadjuvant therapy is also a standard treatment for 
inoperable locally advanced breast cancer with the aim of downstaging to allow an operation (Kaufmann 
et al., 2012). This thesis will focus on neoadjuvant therapy in the context of an operable cancer. The use 
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of neoadjuvant therapy is supported by consumers (Perlmutter et al., 2012), clinicians (Read et al., 2015) 
and clinical practice guidelines (Cancer Australia, 2017, Arbeitsgemeinschaft Gynaecologische Onkologie, 
2015, National Comprehensive Cancer Network, 2017), yet it is not made routinely available to women 
outside of specialist centres in Australia (Kaufmann et al., 2012, Read et al., 2015). In other countries, 
such as Germany and the United States, it is more commonplace for neoadjuvant systemic therapy to be 
offered to patients with operable breast cancer (Arbeitsgemeinschaft Gynaecologische Onkologie, 2015, 
Mougalian et al., 2015). 
Patient selection for neoadjuvant therapy may be based on clinical grounds or patient preference. The 
decision is influenced by a combination of the goals of treatment and the likelihood of clinical and 
pathological response. Patients with ductal carcinoma (Petrelli and Barni, 2013), high rate of 
proliferation (Bonnefoi et al., 2014), human epidermal growth factor receptor 2 (HER2) amplification 
and triple negative cancer (oestrogen, progesterone and HER2 receptor negative) are more likely to 
experience a response (Cortazar et al., 2014). Conversely, patients with lobular carcinoma (Petrelli and 
Barni, 2013), oestrogen receptor positivity and a low rate of proliferation are less likely to respond 
(Cortazar et al., 2014). Patients with a greater likelihood of response are more likely to benefit in terms 
of downstaging and conversion to breast conserving surgery. These patients are therefore more likely to 
be offered neoadjuvant therapy (Kaufmann et al., 2012). 
Neoadjuvant therapy is offered to women for one or more of a number of reasons. The primary intent 
of chemotherapy for early stage breast cancer is to treat clinically apparent cancer in the breast and 
locoregional lymph nodes, along with occult micrometastatic disease elsewhere in the body (Read et al., 
2015). Systemic therapy can decrease the size of the breast tumour to allow a patient to have breast 
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conserving surgery, when she would otherwise have required a mastectomy (Golshan et al., 2015). The 
axillary lymph nodes can be similarly downstaged, although there is limited evidence on the safety of 
reducing the extent of surgery in patients who are rendered axillary node negative (Beatty et al., 2009). 
Neoadjuvant therapy allows access to highly effective systemic therapy sooner than if the patient were 
to have surgery first and then wait for sufficient recovery to allow chemotherapy to commence. 
Minimising the time between diagnosis and systemic therapy improves survival in patients with highly 
proliferative tumours such as triple negative and HER2 positive (Gagliato et al., 2014). Neoadjuvant 
systemic therapy can facilitate planning, consideration and feasibility of immediate breast 
reconstruction (Giacalone et al., 2010, Monrigal et al., 2011). Patients who are candidates for genetic 
testing to identify a germline breast cancer susceptibility may benefit from neoadjuvant chemotherapy 
because the results can influence the decision about whether to have a unilateral or contralateral 
mastectomy (Schwartz et al., 2004).  
Patients who receive neoadjuvant systemic therapy may be able to see or feel whether the tumour is 
responding to treatment, as distinct from during adjuvant therapy, where there is no apparent disease 
to follow.  Clinically apparent disease can be monitored during treatment using physical examination 
and medical imaging such as mammogram, ultrasound and magnetic resonance imaging (MRI) to 
determine the extent of response. Neoadjuvant therapy is followed by surgery to remove the sites of 
any clinically apparent cancer in the breast and lymph nodes, unless distant metastatic disease has 
become apparent prior to the completion of therapy (Caudle et al., 2011).  Both MRI and breast 
ultrasound have moderately good ability to identify that there is cancer remaining after neoadjuvant 
therapy, with a positive predictive value of 70-80%. The ability of these scans to identify pathological 
complete response is poor, with a negative predictive value of around 40-50% (Croshaw et al., 2011, 
Vriens et al., 2016). Because of this relatively poor overall accuracy, surgery is recommended in all 
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patients due to an unacceptably high local recurrence rate in patients who have a complete clinical 
response but did not proceed to surgery (Daveau et al., 2011, Mauriac et al., 1999). Some studies have 
begun to explore whether surgery might be omitted in exceptional responders, given the high 
pathological complete response rate with some regimens (van la Parra and Kuerer, 2016). Following 
surgery, the tumour specimen is examined histopathologically to determine the extent of macroscopic 
and microscopic response (von Minckwitz et al., 2012).  
Pathologic response to neoadjuvant systemic therapy has been measured in several ways. The definition 
used in clinical trials may include invasive disease only or both invasive disease and ductal carcinoma in 
situ (DCIS); it may include only the breast or the breast and lymph nodes. The definition of pathological 
complete response (pCR) with the greatest prognostic power is the absence of histopathologically 
detectable cancer in both the breast and lymph nodes, irrespective of whether residual DCIS is present 
(von Minckwitz et al., 2012). In the case of residual viable tumour, response can be quantified using the 
residual cancer burden score (Symmans et al., 2007) or the clinicopathologic score-estrogen grade (CPS-
EG) (Mittendorf et al., 2011). These scores provide greater detail of the extent of response, which is 
more relevant in hormone receptor positive breast cancer due to the low rate of pCR in this subtype. 
The likelihood of response correlates with the breast cancer subtype, including oestrogen receptor, 
HER2 and grade. Following standard neoadjuvant therapy, a pCR is expected in 11% of women with 
hormone receptor positive cancer, 33% with HER2 positive cancer and 31% with triple negative cancer.  
Irrespective of subtype, a pathological complete response predicts for a higher rate of disease-free and 
overall survival (Cortazar et al., 2014). Disease response has greater correlation with prognosis in highly 
proliferative tumours such as triple negative, HER2 positive and luminal B (Cortazar et al., 2014). In the 
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meta-analysis by Cortazar et al, patients with triple negative breast cancer who experience a pCR have 
an 85% 5-year survival, compared with 50% for those with non-pCR.  
This ability to measure response during and after systemic therapy is a boon to clinical triallists who 
would otherwise have had to follow early stage breast cancer patients for many years before concluding 
a result (DeMichele et al., 2015). Much of our present evidence to support the benefit of treatments for 
early stage breast cancer is based on traditional adjuvant trials (Early Breast Cancer Trialists’ 
Collaborative Group, 2005). Adjuvant trials typically take a treatment regimen that is active against 
metastatic breast cancer, and administer it following surgery for early stage disease. Participants are 
randomised to the experimental treatment or standard treatment, and are then followed to record the 
number of patients in each group who relapse or die. These trials must randomise thousands of patients 
to achieve sufficient statistical power to reach a conclusion within an acceptable timeframe.   
Response to neoadjuvant systemic therapy provides an earlier indication of the anti-cancer activity of an 
experimental treatment regimen. Many trials have used this approach, with increasing sophistication. 
Traditionally, neoadjuvant trials have taken a frequentist statistical approach, aiming to demonstrate a 
significant difference in pathological complete response rate as a surrogate for survival outcomes 
(DeMichele et al., 2015). Some of these studies have also continued follow-up to report on disease-free 
and overall survival outcomes, despite small sample sizes rendering them underpowered (de Azambuja 
et al., 2014, Gianni et al., 2016). More recently, novel trial designs are being used. For example, the 
neoadjuvant I-SPY trials use a Bayesian statistical design to determine the likelihood of a treatment 
succeeding in a phase III trial. Inactive drugs or combinations of drugs can then be removed from further 
testing after a trial involving hundreds of patients, rather than thousands, in a much shorter timeframe 
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 (Esserman et al., 2012). Treatments that appear active are moved into larger trials that are fully 
powered to demonstrate superiority. This strategy is also ethically advantageous as it exposes fewer 
patients to a potentially inactive treatment.  
 
Whilst difference in pathological complete response rate has not yet been shown to be a surrogate 
marker for survival outcomes (Cortazar et al., 2014), statistical modelling indicates that it still has 
potential (DeMichele et al., 2015). The United States Food and Drug Administration (FDA) have indicated 
that in breast cancer subtypes that are highly proliferative, pathological complete response can be used 
as a surrogate marker for accelerated approval of treatments (Prowell and Pazdur, 2012). A case in point 
is the approval of pertuzumab for neoadjuvant treatment of HER2 positive breast cancer, based on an 
absolute increase in pathological complete response of 17% in the NeoSphere trial (Gianni et al., 2012). 
The adjuvant APHINITY study, which evaluated the disease-free survival impact of adding pertuzumab to 
standard adjuvant therapy, demonstrated a small but statistically significant benefit to pertuzumab (von 
Minckwitz et al., 2017). 
 
Trials have also tested the hypothesis that switching chemotherapy may improve outcomes in the 
presence of suboptimal response during neoadjuvant therapy (von Minckwitz et al., 2013), or post-
neoadjuvant salvage therapy with zoledronic acid for patients with non-pCR (von Minckwitz et al., 2016). 
Unfortunately, trials using a switch strategy prior to breast surgery for non-responders have not 
demonstrated improved disease-free or overall survival outcomes. Recently, a Japanese study found 
that six months of adjuvant capecitabine chemotherapy improved overall survival in patients who had a 
suboptimal pathological response to neoadjuvant chemotherapy (Masuda et al., 2017). PenelopeB is an 
ongoing study (NCT01864746) evaluating the efficacy of palbociclib, a CDK4/6 inhibitor, in combination 
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with endocrine therapy as salvage therapy in patients with HR-positive breast cancer who achieve a 
suboptimal pathological response to neoadjuvant chemotherapy. 
One third of women who would have required a mastectomy up-front are able to be downstaged to 
facilitate breast conserving therapy (Golshan et al., 2015). The rate of breast conserving surgery is higher 
in patients with triple negative and HER2 amplified tumours than in those with hormone receptor 
positive, HER2 normal tumours (Boughey et al., 2014). Breast conservation has equivalent survival and 
recurrence outcomes to mastectomy, but improves cosmesis, which is desired by many patients (Curran 
et al., 1998). Despite the possibility of breast conserving therapy, one third of women who become 
eligible for breast conserving surgery after neoadjuvant systemic therapy still elect to have a 
mastectomy (Golshan et al., 2015). Reasons for this choice include fear of local recurrence, desire to 
avoid radiotherapy or future chemotherapy, and the influence of the surgeons’ treatment 
recommendation (Rippy et al., 2014). 
Neoadjuvant therapy may also downstage the axilla, meaning that fewer axillary lymph nodes can be 
removed in selected patients (Beatty et al., 2009). Axillary sentinel lymph node biopsy or sampling has 
lower morbidity, such as pain and lymphoedema, compared with the more extensive axillary dissection 
procedure. Sixteen percent of women who have an axillary dissection experience lymphoedema using 
arm volume measurements, compared with 5% of those who have a sentinel node biopsy (McLaughlin 
et al., 2008). 
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Neoadjuvant systemic therapy is typically given for a period of between 4 and 6 months (Kaufmann et 
al., 2012). This allows time for consideration of surgical options, which is not generally available if a 
surgery-first approach is taken. Surgical options include breast conserving surgery or mastectomy, which 
then has implications about radiotherapy and breast reconstruction surgery (Whelan et al., 1999). 
Breast reconstruction may take time to arrange, and there are a variety of options; women may wish to 
take their time to consider which one they prefer (Sherman et al., 2014). Women who are candidates for 
genetic testing for a breast cancer predisposition such as BRCA1/2 may wish to have the results prior to 
making a decision about surgery (Schwartz et al., 2004). Genetic testing requires pre-test genetic 
counselling, and results often take weeks to months to return. If the result indicates a high risk of 
subsequent breast cancer, it may be preferable to have a bilateral mastectomy to reduce the risk of 
future breast cancers (Smith and Isaacs, 2011). This procedure can be done in a single step following 
neoadjuvant therapy, rather than as a breast cancer operation followed by risk reducing surgery at a 
later date if neoadjuvant therapy is not given (Giacalone et al., 2010). Patients who are found to have a 
deleterious BRCA gene mutation have a higher pathological response rate with neoadjuvant 
chemotherapy, however a difference in disease-free or overall survival has not yet been demonstrated 
(Hahnen et al., 2017). Higher response rates and overall survival have been noted for metastatic BRCA-
positive patients using the poly(adenosine diphosphate-ribose) (PARP) inhibitor olaparib, raising the 
possibility that these patients may also derive additional benefit from neoadjuvant PARP inhibitor 
(Robson et al., 2017, Rugo et al., 2016). The phase 2 neoadjuvant ISPY2 study found an increased 
pathological complete response rate in patients with a “BRCA1ness” signature treated with neoadjuvant 
veliparib (another PARP inhibitor) and carboplatin (Severson et al., 2017). Therefore, early identification 
of a germline BRCA-related predisposition to breast cancer in newly diagnosed patients may alter both 
systemic and local therapy. 
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 A systematic review and meta-analysis of trials that compared the efficacy outcomes of neoadjuvant 
and adjuvant systemic therapy found that disease-free and overall survival were equivalent whether 
chemotherapy or surgery were the first treatment, as long as adequate local and systemic treatment 
was given to all patients (Mauri et al., 2005). One trial included in this meta-analysis reported that 20% 
of patients who received neoadjuvant therapy experienced a local recurrence, however these patients 
had the option of omitting surgery if they had a complete clinical response (Mauriac et al., 1999). Due to 
this unacceptable local recurrence rate in patients who omit surgery, as noted above, all patients with 
resectable disease are recommended to have surgery after neoadjuvant therapy (Kaufmann et al., 
2012). 
 
Disadvantages of the neoadjuvant approach include: potential for anxiety, fear of progression or actual 
progression whilst receiving neoadjuvant therapy (Chintamani et al., 2011). In some treatment centres 
or geographical areas neoadjuvant systemic therapy is used infrequently, meaning that clinicians may 
not feel comfortable presenting it as an option to their patients as a result of inexperience (Read et al., 
2015). Patients can lose confidence in their doctor if their doctor is uncertain, meaning that treatment 
recommendations are less likely to be followed (Ogden et al., 2002). Also, patients and their family 
members may not have heard about neoadjuvant therapy in this context, and feel that their case is 
unusual or that they have a worse prognosis than average because their doctor has offered them a 
treatment that they did not expect. Most women with early stage breast cancer are referred to a 
surgeon, with the implication that they will have an operation to remove their cancer as soon as 
possible. They may then be surprised if an alternative is presented. Some patients may worry about 
their ability to tolerate surgery, and about surgical complications following neoadjuvant therapy, 
however the rate of complications is no different in patients who have surgery or chemotherapy first 
(Bowen et al., 2017). 
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Chemotherapy is associated with a broad range of adverse effects in the short and long term. Short term 
effects include nausea, hair loss and severe infections, while long term effects include fatigue, cardiac 
damage, nerve damage, premature menopause and chronic insomnia (Friese et al., 2017, Azim et al., 
2011). Anecdotally, some women are fearful of these adverse effects and opt for surgery first in the 
hope that their risk profile, as determined by analysis of their surgical pathology specimen, will allow 
them to avoid chemotherapy. There is a small risk of discordance in receptor status, grade, and staging 
between core needle biopsy and the surgical specimen that may lead to uncertainty in some patients 
(Munch-Petersen et al., 2014, Diepstraten et al., 2014, Knuttel et al., 2016, Golshan et al., 2004). If there 
is uncertainty about the indication for chemotherapy due to intermediate risk cancer, or subtype, it may 
be more prudent to proceed to surgery first so that systemic treatment decisions can be informed by 
the final breast and axillary histopathology. 
 
Breast cancer is not universally sensitive to systemic therapy. Concern over the potential for breast 
cancer progression and subsequent poor outcomes in individuals with chemo-resistant breast cancer led 
to a retrospective review to determine the impact of progression during neoadjuvant chemotherapy 
(Caudle et al., 2011). The authors found that of 1928 patients with stage I-III operable breast cancer 
treated at their institution, 1762 (91%) had a partial or complete response while 107 (6%) had stable 
disease. Of the remaining 59 (3%) whose cancer progressed, 5 (0.26%) became inoperable either due to 
local progression or development of distant metastases. These patients exhibited such poor prognosis 
disease that they would not have benefited from surgery even if it were done at the time of diagnosis 
(Caudle et al., 2011). In fact, they may well have benefited by receiving earlier systemic therapy. Breast 
surgery is not generally indicated in the setting of metastatic disease, so these women were able to 
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avoid the potential morbidity of unnecessary surgery. These data show a very small chance of 
progression on neoadjuvant chemotherapy, which can usually be managed by proceeding to surgery. 
This is reassuring for both clinicians and patients who are contemplating this treatment strategy. 
2.6 Patient perspectives on neoadjuvant systemic therapy for breast cancer 
Given the advantages and disadvantages of both adjuvant and neoadjuvant therapy, with equivalent 
survival outcomes, in many cases the decision appears dependent on patients’ preferences. Little data 
were available about the factors that women take into account when considering neoadjuvant systemic 
therapy. In preliminary work done prior to enrolment, I investigated this issue in a qualitative, in-depth 
interview-based study (Zdenkowski et al., 2016). Because this qualitative study directly informs the 
subsequent body of research that forms this thesis, the study publication is included as Appendix B and 
will be described in detail here. Word count restrictions precluded a detailed description of the 
methodology and results in the publication, so these have been expanded upon in this section. 
With increasing numbers of women receiving neoadjuvant systemic therapy for early stage breast 
cancer, the potential for psychological impact must be considered. Prior to this study being conducted, 
data on the psychological impact of neoadjuvant therapy was lacking, so anecdote and expert opinion 
was relied upon for the rationale for the study. In clinical practice, it was noted that patients may not 
have the opportunity to engage in shared decision-making prior to the decision about whether to have 
neoadjuvant systemic therapy. Patients’ subsequent psychological and decision-related outcomes were 
also not known. Before embarking on a study to explore these outcomes in detail and provide potential 
solutions, it was considered necessary to conduct an exploratory preliminary study. 
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Previously, little was known about how the decision about neoadjuvant therapy was being made, or 
whether women were given a choice at all. The aim of this study was to understand women’s decision-
making process, information needs and information sources, and reasons for and against having 
neoadjuvant therapy. The interview results were intended to inform the development of the 
neoadjuvant decision aid and the study to evaluate it. Responses were also intended to give context to 
the application of the decision aid within the clinical workflow in the trial and in real world clinical 
practice.  
 
Participants were recruited via an email invitation sent to members of Breast Cancer Network Australia 
(BCNA) Review and Survey Group. This Group is a mailing list of women who are willing to participate in 
research related to breast cancer, many of whom have a history of breast cancer. BCNA is the major 
Australian national consumer breast cancer advocacy and support organisation. 
 
Included participants had been diagnosed with early stage invasive breast cancer in the preceding five 
years, and had been offered neoadjuvant or adjuvant therapy. A purposeful sample was taken to include 
representative groups of women who had received neoadjuvant therapy, were offered neoadjuvant 
therapy and elected to have surgery first, and women who were not offered neoadjuvant therapy. This 
method was used to include a wide range of experiences and opinions from patients. 
 
Interviews followed a semi-structured guide that included questions on demographics, tumour 
information, treatments and outcomes, decision-making preferences and information needs. Open-
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ended questions were used to promote in depth responses, which could then be followed with 
additional lines of detailed questioning. Responses to questions guided the inclusion of additional 
questions in subsequent interviews so that as many possible themes could be identified. Patients were 
asked about whether they were interested in additional decision support such as a decision aid, and 
whether they felt sufficiently involved in the decision about NAST.  
A qualitative approach was selected in this initial work to give an in-depth perspective on the issues that 
women considered relevant to their decision about neoadjuvant therapy. Several different qualitative 
approaches have been described including grounded theory, narrative research, phenomenology, 
ethnography and case studies (Connor et al., 2001). The approach used depends on the research topic 
purpose (Lewis, 2015). Compared with quantitative methods, a qualitative approach gives an 
opportunity to explore topics that patients raise, pursuing lines of questioning that would not be 
possible with a prospectively defined quantitative questionnaire (Connor et al., 2001). Quantitative 
research uses relatively large numbers of participants to infer meaning, whilst qualitative research seeks 
to gain a deep understanding from a smaller number of participants. 
In qualitative research, open questions can be used, and the answers interpreted in the context of 
previous responses, which can then inform future questions for the current and subsequent interviews 
(DiCicco-Bloom and Crabtree, 2006). This method can give an understanding of a phenomenon that does 
not have substantial literature, which can then translate into hypotheses to be tested in subsequent 
quantitative studies (Morgan, 1998).  
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 Qualitative studies can be judged by quality criteria to ensure that the design is rigorous, and the results 
are reliable and valid (Thomas and Magilvy, 2011, Kmet et al., 2004). The model for qualitative rigor 
proposed by Lincoln and Guba consists of the concepts of credibility, transferability, dependability and 
confirmability (Lincoln and Guba, 1985). In practical terms, qualitative rigor can be upheld using a variety 
of established techniques (Thomas and Magilvy, 2011). Credibility is the ability of others to interpret the 
data and reach similar conclusions to the primary researcher. Methods to establish credibility of the 
data include: reflexivity, member checking and peer examination. Transferability is the applicability of 
the research findings from one group to another, achieved through detailed description of the study 
population to allow other researchers to interpret the results in context. Dependability, or reliability, is 
the degree to which another research can follow the same methods and achieve the same or similar 
results. The primary strategies for dependability are a detailed description of methods and an audit trail 
of how the data were collected and interpreted. Confirmability is the achievement of credibility, 
transferability and dependability, which aims to convey a sense of trust in the results and their 
applicability. This requires the adoption of a reflexive view of how the research has been influenced by 
the researcher’s preconceptions. 
 
Qualitative descriptive methodology was chosen for this analysis (Neergaard et al., 2009, Sandelowski, 
2010), to gain an in-depth understanding of women’s experiences and preferences with the decision 
about neoadjuvant therapy, as there are little existing data are available on the topic (Sandelowski, 
2000). Data themes were summarised, supported by characteristic quotes, determined by a systematic 
process of comparing and contrasting issues arising in the transcripts.  
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Interviews from the present study were recorded and transcribed verbatim. Detailed notes were taken 
during and after interviews regarding content (descriptive category) and emerging themes 
(interpretation or meaning). The researchers then met, and agreed on a coding frame through 
discussion, based on consistency, commonality, and the function and effects of specific themes. 
Transcripts were coded using NVivo version 10 (QSR International, Doncaster, VIC, Australia). Initial 
coding occurred after each interview, remaining close to the data. Subsequent interviews were modified 
based on prior responses. A second senior experienced researcher (Professor Butow) reviewed several 
transcripts to identify coding categories; discrepancies were resolved through discussion. A second 
round of coding was undertaken from each transcript, line by line, at a higher level of abstraction after 
all interviews were completed. All researchers involved in this study then discussed any new themes and 
re-evaluated the whole thematic structure in light of the literature. Core themes were then developed 
from the data based on categories identified in coding. These themes were illustrated by quotes and 
interpreted with the intent of explaining the concept of the neoadjuvant decision-making process from 
the point of view of the patient. Differences between respondents were also identified. Three key 
informants from the study population were asked to comment on the themes identified in analysis.  
Twenty-two women were interviewed in July and August 2013, at which point interviews stopped 
because thematic saturation was reached. Thematic saturation was defined as three consecutive 
interviews in which no new major themes were identified. Thirteen women had received NAST, six had 
been offered it and elected to have surgery first, and three had not been offered NAST. Participants 
were aged between 29 and 66, with high levels of education, many were employed and most had 
private health insurance. Many had children, including some with very young children. All had been 
diagnosed with invasive breast cancer, and all major breast cancer subtypes were represented. 
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Women with a past diagnosis of breast cancer who participated in interviews about neoadjuvant 
systemic therapy endorsed the neoadjuvant approach, but found that they were not able to be as 
informed or involved in the decision-making as they would have liked. Reasons given by patients for 
receiving neoadjuvant therapy included downstaging from mastectomy to breast conserving surgery, to 
observe the effect of chemotherapy, earlier access to effective systemic therapy, and to have more time 
to make decisions about surgical options. Reasons against the neoadjuvant approach included: lack of 
awareness of the option, lack of information, a desire to receive perceived mainstream treatment, and a 
desire to have the cancer removed as soon as possible. These patients supported the development of a 
shared decision-making tool such as a decision aid, targeted to the decision about neoadjuvant therapy. 
 
Major identified themes were: lack of information with desire for additional reliable information; trust in 
clinicians as a proxy for involvement in decision-making; feeling of marginalisation due to being offered 
NAST; and interest in knowing about the effect of chemotherapy. Study participants endorsed the 
neoadjuvant approach, despite few having heard of having systemic therapy prior to surgery. They had 
difficulty finding patient information relevant to NAST, and indicated that patient material such as a 
decision aid would have been helpful. Some respondents felt marginalised by the offer of NAST, and 
assumed that their cancer was worse than other women’s. Women were not as involved as they would 
have liked to be in the decision about NAST. Women seemed to place trust in their treating clinician(s) 
to act as proxy decision-maker in this situation, leading to high levels of satisfaction with treatment 
decision-making, despite their lack of involvement in the decision.  
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 Hence, a decision aid was considered to be a potential solution to allow women greater involvement in 
the decision-making process, to normalise the option of NAST, and to give targeted information. These 
interview results provided a rationale for moving forward to the next phase in the research program, to 
gather more information about neoadjuvant decision-making and decision aids for breast cancer. 
 
 
2.7 Patient information about neoadjuvant systemic therapy for breast cancer 
Neoadjuvant systemic therapy is increasingly used as part of routine care and in clinical trials in Australia 
and around the world (Mougalian et al., 2015). Despite the complexity inherent in the decision about 
NAST, little patient information material is available. In Australia, the Cancer Institute NSW eviQ cancer 
information website has a brief information sheet. The Breast Cancer Network Australia mentions NAST 
briefly within the ‘MyJourney’ kit that is routinely distributed to women diagnosed with breast cancer 
(often after surgery, which is too late for a discussion about NAST). Whilst useful, these information 
sources do not contain important components of shared decision-making tools such as outcome 
probabilities and a values clarification exercise (Elwyn et al., 2006). Therefore, we felt that a decision aid 
was warranted to optimise the decision-related outcomes of women with operable breast cancer who 
are candidates for neoadjuvant systemic therapy. 
 
2.8  A decision aid for patients considering neoadjuvant systemic therapy for operable breast cancer 
As described above, the choice between neoadjuvant and adjuvant systemic therapy is a preference 
sensitive decision for women with operable breast cancer. Decision aids are an established strategy that 
can be used to improve the quality of shared decision making in the context of preference sensitive 
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decisions (Stacey et al., 2017). Prior to the body of work that constitutes this thesis, a decision aid for 
women who are candidates for neoadjuvant systemic therapy was not available. Therefore, we aimed to 
fill that gap by producing a custom-designed decision aid, based on the prevailing evidence, the views of 
clinicians and patients, and the IPDAS criteria for decision aid content. This thesis will describe the 
development and evaluation of that decision aid, including a systematic review of decision aids for 
breast cancer, a survey of clinicians and a prospective study of the decision aid. 
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 2.9  Publication 1: A systematic review of decision aids for patients making a decision about 
treatment for early breast cancer 
 
Zdenkowski N, Butow P, Tesson S, Boyle FM. A systematic review of decision aids for patients making a 
decision about treatment for early breast cancer. The Breast. 2016;26:31-45 
 
This systematic review was conducted as part of the background to this body of research. It aimed to 
identify, evaluate and integrate the available literature on decision aids for patients making a treatment 
decision about breast cancer. This review identified that a decision aid for neoadjuvant systemic therapy 
was lacking. The results informed the design of the neoadjuvant decision aid and the study that 
evaluated that decision aid. 
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 Abstract 
Objectives 
Several complex treatment decisions may be offered to women with early stage breast cancer, about a 
range of treatments from different modalities including surgery, radiotherapy, and endocrine and 
chemotherapy. Decision aids can facilitate shared decision-making and improved decision-related 
outcomes. We aimed to systematically identify, describe and appraise the literature on treatment 
decision aids for women with early breast cancer, synthesise the data and identify breast cancer 
decisions that lack a decision aid. 
 
Materials and Methods 
A prospectively developed search strategy was applied to MEDLINE, the Cochrane databases, EMBASE, 
PsycINFO, Web of Science and abstract databases from major conferences. Data were extracted into a 
pre-piloted form. Quality and risk of bias were measured using Qualsyst criteria. Results were 
synthesised into narrative format. 
 
Results 
Thirty-three eligible articles were identified, evaluating 23 individual treatment decision aids, comprising 
13 randomised controlled trial reports, seven non-randomised comparative studies, eight single-arm 
pre-post studies and five cross-sectional studies. The decisions addressed by these decision aids were: 
breast conserving surgery versus mastectomy (+/- reconstruction); use of chemotherapy and/or 
endocrine therapy; radiotherapy; and fertility preservation. Outcome measures were heterogeneous, 
precluding meta-analysis. Decisional conflict decreased, and knowledge and satisfaction increased, 
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without any change in anxiety or depression, in most studies. No studies were identified that evaluated 
decision aids for neoadjuvant systemic therapy, or contralateral prophylactic mastectomy. 
Conclusion 
Decision aids are available and improved decision-related outcomes for many breast cancer treatment 
decisions including surgery, radiotherapy, and endocrine and chemotherapy. Decision aids for 
neoadjuvant systemic therapy and contralateral prophylactic mastectomy could not be found, and may 
be warranted. 
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Introduction 
Over the last 40 years, breast cancer survival rates in developed nations have improved by at least 30% 
due to earlier detection and better treatments (Jemal, Center et al. 2010). Along with these gains, an 
increasing array of treatment options have become available for patients and their doctors (Goldhirsch, 
Winer et al. 2013). While patient choice is integral to the shared decision-making model of modern 
medicine (Chewning, Bylund et al. 2012), this choice can be a burden on patients (Livaudais, Franco et al. 
2013). Patient decision aids (DAs) have been developed for a range of health conditions including breast 
cancer. These have been successful in informing, involving and empowering patients to participate in 
decision-making, particularly in the cancer context (O'Brien, Whelan et al. 2009, Stacey, Legare et al. 
2014). 
DAs are suited to decisions that are preference-sensitive (i.e. there are legitimate options with different 
outcomes, which individuals may value differently). One example of such a decision is breast conserving 
surgery (BCS) versus mastectomy, which have equivalent survival outcomes in suitable patients, but 
differ in cosmesis and recurrence risks (Whelan, Levine et al. 1999). Women may also be asked to define 
the risk-benefit ratio at which they will accept treatment, which in the case of adjuvant chemotherapy, 
is variable and depends on individual values (Duric, Stockler et al. 2005).  
Decisions about individual early stage breast cancer treatments do not take place in isolation, but often 
depend on other modalities. Over the past 20 years, the number of breast cancer treatment DAs has 
multiplied. However, these DAs generally target only one decision choice. It is not clear how these 
complement each other to provide women with complete coverage of all the relevant breast cancer 
decisions, nor whether there are any DAs which attempt to address more than one treatment decision.  
Recent reviews of DAs for patient treatment and screening decisions across all health conditions (Stacey, 
Legare et al. 2014) and for cancer decisions (Trikalinos, Wieland et al. 2014) found good evidence that 
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 DAs increase knowledge and decrease decisional conflict, and moderate evidence that they increase 
active participation in decision-making and improve accuracy of risk perception. These reviews discuss 
individual DAs only briefly. Prior reviews have focussed on surgical decision-making in early stage breast 
cancer (Waljee, Rogers et al. 2007, Obeidat, Finnell et al. 2011), but other closely related DAs were not 
evaluated, such as for radiotherapy or systemic therapy. Therefore a review of DAs for early stage breast 
cancer, including all treatment options, was considered important to facilitate better access and 
integration of DAs across modalities. 
We aimed to assess the effects of treatment DAs on decision-related outcomes in women making 
treatment decisions for early stage breast cancer. We also aimed to determine which breast cancer 
treatment decisions had an appropriately evaluated DA available and identify any gaps in the evidence. 
 
Methods 
This systematic review was designed and conducted according to the principles of the PRISMA 
statement for reporting of systematic reviews and meta-analyses (Moher, Liberati et al. 2009). The 
protocol was prospectively registered and is available on the Prospero register of systematic reviews 
(www.crd.york.ac.uk/PROSPERO, CRD42014009474). By using broad search terms and including 
published papers and conference abstracts, the search strategy (Appendix A) was designed to be 
maximally inclusive. Studies were eligible if: (i) original research was reported; (ii) a comparative or non-
comparative design was used; and (iii) patient outcome data were reported related to the use of a 
patient treatment DA for early stage breast cancer. A DA was defined as: a tool or technology, including 
paper-based, video, audio, electronic or multimedia; and containing information about two or more 
options and the associated relevant outcomes (Elwyn, O'Connor et al. 2006). Quantitative and 
qualitative papers were eligible. Studies of DAs for breast cancer prevention or metastatic breast cancer 
48
 were excluded due to major differences in the treatment intent of these decisions compared with early 
stage breast cancer.  
The following databases were searched: Cochrane Central Register of Controlled Trials, Database of 
Abstracts of Reviews of Effects, the Cochrane Database of Systematic Reviews, EMBASE, MEDLINE, 
PsycINFO, Web of Science, and the Ottawa Decision Aid Library Inventory 
(http://decisionaid.ohri.ca/index.html). Databases were searched from their inception to 25th February 
2015. Conference abstracts from 2011-2015 were searched by hand: ASCO Meeting Library, the San 
Antonio Breast Cancer Symposium Library, European Breast Cancer Conference, European Society of 
Medical Oncology Annual Meeting. The EMBASE database includes abstracts from relevant conferences 
including the World Congress on Psycho-Oncology and the annual meeting of the Multinational 
Association of Supportive Care in Cancer. Reference lists were searched for additional papers not 
identified in the database search.  
After removing duplicate results, titles and abstracts were screened to identify potentially eligible 
papers. The full text of potentially eligible papers was then reviewed to create a list of original research 
articles for inclusion in the review. Studies were rejected if they: did not report on patient outcomes; did 
not evaluate a treatment DA; were a review article without original research results; or were duplicate 
results, for example a conference abstract reporting on the same results as a published article. 
A pre-piloted form was developed and used to extract data from eligible studies. Quality and risk of bias 
were assessed at a study level using the Qualsyst scoring system, which is designed for use on a variety 
of study types including randomised, non-randomised comparative, cohort and qualitative studies 
(Kmet, Lee et al. 2004). Qualsyst produces a score between zero and one, with a higher score indicating 
higher study quality and lower risk of bias. This scoring system was chosen to maintain consistency, with 
the expectation that qualitative and quantitative data would be included. Data extraction and quality 
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 scoring were performed independently by two authors, with duplicate extraction and scoring of 20% of 
papers. Differences in results were resolved through discussion. 
Data points included: study type, study location, decision support type, decision being targeted, 
population characteristics, primary and secondary outcomes assessed and bias assessment. Data were 
synthesised using a narrative description, due to the heterogeneity of outcome measures. The term 
‘decision aid (DA)’ will be used in this paper to describe tools, systems, technologies, interactive decision 
support and other terms used for decision support modalities. This paper will describe reported patient 
outcomes from DA use. 
 
Results 
After removing 394 duplicates, 1791 unique records were identified (Figure 1). Titles and abstracts were 
screened to identify 73 potentially eligible records. Full text review of these records resulted in inclusion 
of 33 eligible original research articles for analysis, in which 23 individual treatment DAs were evaluated 
(Table 1). Outcome measures were heterogeneous across studies, precluding meta-analysis. Seven 
additional DAs were identified on the Ottawa Decision Aid Library for which no corresponding literature 
was identified. These DAs have not been evaluated here. 
Eleven DAs were developed for women deciding about surgical options such as mastectomy or BCS; nine 
were for adjuvant systemic therapy decisions such as chemotherapy and/or endocrine therapy; three 
were for radiotherapy decisions; three were for breast reconstruction and one targeted fertility 
preservation. Some DAs addressed more than one breast-cancer treatment decision, such as the DA by 
Vodermaier et al (Vodermaier, Caspari et al. 2011) for both surgery and adjuvant chemotherapy, and the 
DA by Wong for adjuvant endocrine therapy and radiotherapy (Wong, D'Alimonte et al. 2012). 
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Fifteen studies were led by researchers from the USA, seven from Canada, five from Australia, two from 
the United Kingdom, two from Hong Kong and one each from Germany and The Netherlands. Ten were 
randomised controlled trials (RCTs), including four cluster randomised trials. Four papers reported on 
different data taken from a single cluster randomised trial evaluating Adjuvant!Online, resulting in a 
total of 13 publications reporting on RCTs. Seven studies used a non-randomised comparative design, 
eight were single arm pre-post studies, and five were cross-sectional cohort studies.  
Study quality 
Qualsyst scores for study quality ranged from 0.23 to 1.0 (possible range 0.0-1.0, Tables 2 and 3). RCTs 
typically had the highest Qualsyst scores, predominantly due to greater methodological rigour in study 
design, sampling method (e.g., population sampling), control for potential confounders, and greater 
detail in reporting of results, including estimates of variance. Studies that scored lower on Qualsyst 
items generally did not specify whether and how investigators and/or participants were blinded, defined 
outcomes poorly, did not use well-validated outcome measures and/or employed measure subscales or 
hybrid measures without justification.  
Outcome measures 
Treatment choice was the most frequently used outcome measure type (17 studies) (Irwin, Arnold et al. 
1999, Molenaar, Sprangers et al. 2001, Lee, Chen et al. 2010), suggesting that it was considered 
important in determining whether a DA is effective. However, if patients are making truly value-based 
decisions, then treatment choice is not necessarily a primary consideration. The decisional conflict scale, 
developed by O’Connor specifically to evaluate DAs, was used in 13 studies (O'Connor 1995). This scale 
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consists of five subscales: uncertainty, informed, values clarity, support and effective decision. The use 
of this scale suggests that indecision is another primary measure of the efficacy of DAs. Other relevant 
outcomes included knowledge (16 studies), satisfaction with decision-making and decisional regret. 
Knowledge items necessarily varied across studies with minimal standardization. The satisfaction with 
decision (eight studies) (Holmes-Rovner, Kroll et al. 1996), and decisional regret (Brehaut, O'Connor et 
al. 2003) scales measure how satisfied a person is with their decision before and after the consequences 
of that decision have been experienced, respectively. Acceptability was reported in 14 studies, using a 
variety of non-standardized questionnaires. When assesssed, values-choice agreement was not 
generally measured using a standardized, validated instrument. Although anxiety and depression are not 
expected to be reduced through use of a DA, anxiety (eight studies) and depression (five studies) were 
used as safety measures to ensure that DAs did not negatively affect psychological wellbeing.  
The decision aids 
DA format 
Nine DAs took the format of an interactive computer system. Three were in booklet form, two involved 
one-on-one consultations with patient advocates, one was an audiotape and workbook, one was video-
based and seven used a decision board format.  
Internet based formats varied widely. Jibaja-Weiss et al created an ‘education entertainment’ DA which 
used a novel strategy of a virtual jewellery box where patients could ‘store’ issues of importance, and 
soap opera style episodes with information about options and outcomes (Jibaja-Weiss, Volk et al. 2011). 
The BRECONDA (Breast Reconstruction ONline DA) contains written information and graphics, with links 
to animations and interviews with a breast reconstruction surgeon. (Sherman, Harcourt et al. 2013, 
Sherman, Harcourt et al. 2014). Adjuvant!Online provides an individualised risk estimate of breast 
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 cancer recurrence and mortality over the subsequent 10 years based on clinical and pathological factors, 
and gives an individual estimate of the benefits of adjuvant chemotherapy and/or endocrine therapy 
(Peele, Siminoff et al. 2005). 
Patients who used interactive computer program DAs reported satisfaction with this method of delivery 
(Street, Voigt et al. 1995, Molenaar, Sprangers et al. 2001, Heller, Parker et al. 2008, Lee, Chen et al. 
2010, Sivell, Edwards et al. 2012, Sherman, Harcourt et al. 2013, Sherman, Harcourt et al. 2014). 
Ethnically diverse and/or low literacy American women found a computer-based format universally 
acceptable (Dhage, Castaneda et al. 2013). However, a pilot study of a surgical DA for Chinese women 
found that these women preferred graphics over text, and paper-based over other formats (Au, Lam et 
al. 2011, Lam, Chan et al. 2013).  
The decision board style DA is a board with four panels that are revealed sequentially: treatment choice, 
side effects, impact of treatment choice on the breast, and impact of treatment choice on survival 
(Levine, Gafni et al. 1992, Whelan, Levine et al. 1995, Whelan, Levine et al. 1999, Whelan, Sawka et al. 
2003, Whelan, Levine et al. 2004). Harwood et al supplemented a decision board format with take home 
information (Harwood, Douglas et al. 2011) but did not find that this addition improved knowledge and 
decisional conflict over historical controls who had used a decision board only. 
Goel et al developed an audiotape and workbook DA, and compared versions which did and did not 
include probability diagrams and a values clarification exercise (Goel, Sawka et al. 2001). There were no 
differences between these versions in decision-related outcome measures, which calls into question the 
benefit of these components; however this result awaits corroboration from other studies.  
Belkora et al developed four videos targeting different decisions for early stage breast cancer (DCIS, 
breast surgery, reconstruction surgery, adjuvant systemic therapy), and one for advanced breast cancer, 
which were reported to be acceptable and useful (Belkora, Volz et al. 2012). The videos were sent to 
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patients prior to their clinic visit, depending on an assessment over the telephone by a “Decision 
Services” staff member identifying the decision that would be addressed at that visit. Finally, Sheppard 
et al  developed a culturally sensitive patient support intervention for Latina and African American 
women that used one-on-one decision support consultations of between 40 and 120 minutes in 
duration; these were acceptable to women but time intensive (Sheppard, Figueiredo et al. 2008, 
Sheppard, Williams et al. 2010). 
Since very few studies have directly compared different DA formats, or asked patients to review a range 
of formats and express a preference, the optimal format for DAs remains unclear; it may well be that a 
variety of formats will be effective or that certain formats are effective for certain populations.  
Clinician involvement in DA use 
All DAs were offered to patients by clinical staff, but clinicians had variable involvement in their use. DA 
use ranged from predominantly within the consultation, to predominantly outside the consultation. 
Examples of DAs used predominantly within the consultation include Adjuvant!Online, which is designed 
for data input and interpretation by the clinician within a consultation with a printout of results available 
for the patient to take home for future reference (Siminoff, Gordon et al. 2006). The decision boards are 
also designed for use within the consultation, to introduce information to the patient sequentially rather 
than overwhelm them with all information at once (Levine, Gafni et al. 1992, Whelan, Levine et al. 1995, 
Whelan, Levine et al. 1999, Whelan, Sawka et al. 2003, Whelan, Levine et al. 2004). The disadvantage to 
this approach is that restricted consultation time limits the amount of time that patients have to absorb 
and digest information. 
An alternative is for clinicians to identify patients for whom a DA might be useful and then to introduce 
it briefly before giving the patient access to it for use prior to a follow-up consultation where the 
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 decision will be made (Molenaar, Sprangers et al. 2001, Peate, Meiser et al. 2012, Sivell, Edwards et al. 
2012, Sherman, Harcourt et al. 2013). A third option for clinician involvement is for patient suitability for 
a DA to be assessed prior to their clinic attendance, so that the patients can be sent and review the DA 
before they attend the consultation. Whilst patient satisfaction was not measured, knowledge increased 
and decisional conflict decreased in those who received a DA in the single study that used this last, novel 
approach (Belkora, Volz et al. 2012). Impacts on consultation time or clinician-related outcomes were 
poorly reported, so it is not clear how and whether these different approaches might impact on routine 
implementation of DAs within the healthcare system.  
 
Decision aids for different treatment modalities 
Several DAs evaluated surgical decision-making for women considering one or more of the options of 
BCS, mastectomy, (Whelan, Levine et al. 1999, Goel, Sawka et al. 2001, Molenaar, Sprangers et al. 2001, 
Whelan, Levine et al. 2004, Jibaja-Weiss, Volk et al. 2011, Sivell, Edwards et al. 2012, Dhage, Castaneda 
et al. 2013) and/or axillary surgery choice (Harwood, Douglas et al. 2011) and/or reconstruction (Au, 
Lam et al. 2011, Lam, Chan et al. 2013). The decision about reconstruction is distinct from management 
decisions for early breast cancer, because more time may be available for information-seeking and 
consideration of options. Three DAs were developed to assist women deciding amongst breast 
reconstructive options, all of which employed computer-based technologies (Heller, Parker et al. 2008, 
Lee, Chen et al. 2010, Sherman, Harcourt et al. 2013, Sherman, Harcourt et al. 2014). 
Numerous DAs targeted women’s decisions for adjuvant systemic therapy, including two DAs for 
chemotherapy (Levine, Gafni et al. 1992, Whelan, Sawka et al. 2003, Sheppard, Figueiredo et al. 2008, 
Sheppard, Williams et al. 2010), one for the decision between doxorubicin/cyclophosphamide (AC) and 
cyclophosphamide/methotrexate/5FU (CMF) (Irwin, Arnold et al. 1999), and five studies evaluating a 
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 single DA for chemotherapy and/or hormone therapy (Peele, Siminoff et al. 2005, Siminoff, Gordon et al. 
2006, Vickers, Elkin et al. 2009, Lipkus, Peters et al. 2010, Belkora, Hutton et al. 2011). Whilst the 
decision about AC versus CMF is now rarely offered, due to the emergence of more effective treatment 
regimens, the use of DAs is likely to be relevant to other decisions between currently offered adjuvant 
chemotherapy regimens. 
Two studies evaluated the utility of a DA for women deciding on radiotherapy treatment options 
following BCS: one for women over the age of 70 (Wong, D'Alimonte et al. 2012), and one which 
included endocrine therapy along with the decision about radiotherapy (Whelan, Levine et al. 1995). 
Two studies examined a DA booklet for fertility-preservation decisions prior to adjuvant chemotherapy 
(Peate, Meiser et al. 2011, Peate, Meiser et al. 2012). Belkora et al report on sustained implementation 
of five separate video DAs in a single practice, using a pre-post design (Belkora, Volz et al. 2012). 
 
DA efficacy 
Twelve out of the 17 comparative studies reported a positive primary outcome, most commonly 
knowledge or decisional conflict score (Whelan, Levine et al. 1995, Whelan, Sawka et al. 2003, Whelan, 
Levine et al. 2004, Peele, Siminoff et al. 2005, Heller, Parker et al. 2008, Lee, Chen et al. 2010, Belkora, 
Hutton et al. 2011, Jibaja-Weiss, Volk et al. 2011, Vodermaier, Caspari et al. 2011, Peate, Meiser et al. 
2012, Sivell, Edwards et al. 2012, Sherman, Harcourt et al. 2013). Two additional studies in this group 
reported positive secondary outcomes: Lam et al found that decisional conflict decreased with a DA 
(Lam, Chan et al. 2013), and Siminoff et al found that their DA altered adjuvant systemic therapy choices 
(Siminoff, Gordon et al. 2006). 
Three out of the five studies did not demonstrate a significant difference in decision-related findings 
(Street, Voigt et al. 1995, Goel, Sawka et al. 2001, Vickers, Elkin et al. 2009). These studies included an 
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 interactive computer DA for women considering mastectomy or BCS with radiotherapy (Street, Voigt et 
al. 1995); an audiotape and workbook comparing mastectomy and BCS (Goel, Sawka et al. 2001); and a 
subgroup analysis that aimed to model the effects of the Adjuvant!Online resource on expected survival 
(Vickers, Elkin et al. 2009). 
Treatment choice was altered by the DA in six out of the twelve comparative studies that reported it as 
an outcome measure. Changes included: a decrease in mastectomy uptake combined with immediate 
reconstruction (Lam, Chan et al. 2013); an increased mastectomy rate (Jibaja-Weiss, Volk et al. 2011); 
increased use of breast conserving surgery (Whelan, Levine et al. 2004); increased use of flap-based 
reconstruction surgery (Lee, Chen et al. 2010); lower use of adjuvant systemic therapy in lower risk 
patients (Peele, Siminoff et al. 2005); and a decrease in the use of adjuvant chemotherapy in those who 
were more accurate at estimating the survival benefit of chemotherapy (Belkora, Hutton et al. 2011). 
Notably, the direction of treatment decision change in the mastectomy versus BCS studies were 
contradictory. 
The following section describes features common to those studies where DAs were effective. Low 
baseline knowledge predicted a greater benefit. For decisions where information is not readily available, 
or for populations who have low health literacy, larger incremental reductions in decisional conflict were 
seen. This is exemplified by the fertility DA (Peate, Meiser et al. 2012), and the DAs for minority groups 
(Jibaja-Weiss, Volk et al. 2011, Belkora, Volz et al. 2012, Lam, Chan et al. 2013). Whilst knowledge scores 
were heavily dependent on the questions asked, Peate et al found a low mean knowledge score of 50% 
of questions correct in both groups at baseline, increasing more in the DA group over time (Peate, 
Meiser et al. 2012). However, in the Chinese patients targeted by Au et al, decisional conflict decreased, 
but knowledge did not increase (Lam, Chan et al. 2013). 
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 DAs that were used within the consultation, such as the series of decision boards, reduced decisional 
conflict and increased knowledge (Levine, Gafni et al. 1992, Whelan, Levine et al. 1995, Whelan, Levine 
et al. 1999, Whelan, Sawka et al. 2003, Whelan, Levine et al. 2004). A predominantly ‘in consultation’ 
model is also used with Adjuvant!Online; an internet-based DA for women who are candidates for 
adjuvant therapy (i.e., chemotherapy and/or endocrine therapy) following surgery for early breast 
cancer. Patients who used this DA were more likely to base treatment decisions on actual recurrence 
risk rather than relying on lymph node status to decide whether to have chemotherapy (Peele, Siminoff 
et al. 2005, Siminoff, Gordon et al. 2006, Vickers, Elkin et al. 2009, Lipkus, Peters et al. 2010, Belkora, 
Hutton et al. 2011).  
The DAs that were less effective also shared some common features. For a decision such as delayed 
breast reconstruction where there is often time for decision-making, a DA was less effective (Heller, 
Parker et al. 2008). Both the DA group and the control group were highly satisfied with the available 
information, their ability to make a decision and their satisfaction with choices (Heller, Parker et al. 
2008).   
The amount of information in the control group influenced the benefit seen. One study was unable to 
demonstrate a difference in decisional conflict, knowledge or decisional regret when testing the benefit 
of adding a values clarification exercise and risk/benefit diagrams to identical written information (Goel, 
Sawka et al. 2001). 
In summary, the major factors in the success of a DA are: use within the consultation, use in a 
population with low prior knowledge or a lack of available information, and use when time for decision-
making is limited. There was no clear correlation between format and effectiveness. 
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Gaps in the Literature 
Multiple DAs have been developed for decisions about breast cancer surgery, endocrine therapy and 
chemotherapy (Table 4). One has been developed for fertility preservation, three for breast 
reconstruction surgery and three for radiotherapy. No DAs were found for neoadjuvant systemic 
therapy, scalp cooling to prevent chemotherapy-induced alopecia or for contralateral prophylactic 
mastectomy after a breast cancer diagnosis. 
Study Recency 
The majority of DAs did not list their date of most recent update. The exceptions were: ‘A patchwork of 
life’, which was updated in 2013 according to the Ottawa Decision Aid Inventory; and Adjuvant!Online, 
updated in 2005 (with an update planned for 2015). An estimate of recency was made by cross-
referencing the time period that the DAs were developed and the publication dates of significant 
literature impacting on that decision. Evidence that mastectomy is equivalent to BCS and radiotherapy 
has not changed since the late 1990s (Fisher, Anderson et al. 2002), although improvements in 
radiotherapy technique are likely to reduce the associated toxicity (Darby, McGale et al. 2005). For 
decisions about systemic therapy, Adjuvant!Online is based on historical survival and recurrence data, 
which continues to improve (Youlden, Cramb et al. 2012). It does not include HER2 status, which has 
emerged as an important prognostic and predictive factor (Coates, Winer et al. 2015). Modern 
chemotherapy has superior efficacy to CMF, rendering the DA comparing AC to CMF obsolete (EBCTCG 
2012). Standard chemotherapy options have changed since 2005, so DAs that have not been updated 
since then are likely to be out of date (Group, Peto et al. 2012). Data about fertility preservation options 
continue to evolve, therefore fertility DAs are unlikely to contain up to date data unless ongoing review 
and revision occurs (Kasum, von Wolff et al. 2015). 
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Discussion 
Early breast cancer patients face a number of complex treatment decisions. Recognition of this has led 
to the development of DAs for surgical, endocrine therapy, chemotherapy, radiotherapy, reconstruction 
and fertility preservation treatment decisions.  Despite the importance of examining the decision 
resources available to early breast cancer patients and of holistically presenting available options in 
these decision resources, the present study is the first review that describes breast cancer treatment 
DAs across multiple treatment modalities. Overall, the evidence suggests that DAs for early stage breast 
cancer treatment decisions increase knowledge about options, decrease decisional conflict and are 
acceptable to patients, without increasing anxiety. The effect on treatment decisions is variable. 
These treatment DAs were delivered using a variety of media, including online web-based technologies, 
educational multimedia tools, decision-boards and paper-based information resources. These formats 
were effective and were considered acceptable by patients, but because they were not compared 
directly it is not possible to draw conclusions about the superiority of any one format. Anecdotally, the 
most widely used treatment DA for women with early breast cancer is Adjuvant!Online. Adjuvant!Online 
does not take the traditional format of description of options, outcome probabilities, positives, 
negatives and values clarification exercise proposed by the International Patient Decision Aid Standards 
(IPDAS) collaboration (Volk, Llewellyn-Thomas et al. 2013). Rather, it presents an individualised set of 
recurrence and survival probabilities which the clinician interprets and puts into context to facilitate a 
final decision. The popularity of this DA may be due to the information that it provides to both the 
clinician and the patient, on the probability of relapse and death with and without treatment based on 
individual clinicopathological factors. Treatment decisions were altered by this DA, with patients placing 
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a greater emphasis on survival benefit, rather than using axillary lymph node positivity as a marker of 
sufficiently high risk to warrant the use of chemotherapy.  
Decisions about early breast cancer treatment are not usually made in isolation, because one treatment 
modality may impact on another. For example, the decision between mastectomy and BCS also requires 
consideration of radiotherapy treatment, which is more likely to be given after BCS. Elderly patients who 
decide not to have radiotherapy might have different opinions about systemic therapy compared with 
those who decide to have radiotherapy. Yet only three DA studies addressed decisions across multiple 
modalities. This may be helpful for women who are likely to consider several treatment modalities for 
their breast cancer treatment. The study by Belkora et al. used 5 separate DA videos which could be 
used on their own, or be combined with one another if required (Belkora, Volz et al. 2012). The study by 
Vodermaier et al. included information on both surgery and chemotherapy (Vodermaier, Caspari et al. 
2011), while another DA addressed radiotherapy and endocrine therapy for women over the age of 70. 
Whilst these are steps towards an integrated approach, they do not represent a single multimodality 
breast cancer DA. Thus there is a clear need for DAs addressing multiple treatment options to 
comprehensively assist women in this complex clinical scenario. Moreover, there are clear gaps in the 
literature in the treatment options addressed, with no DA available to assist women deciding on 
neoadjuvant systemic therapy and contralateral prophylactic mastectomy, despite evidence that these 
are challenging decisions (Hawley, Jagsi et al. 2014, Zdenkowski, Butow et al. 2015). 
Several DAs were designed specifically for use by patients with low literacy or belonging to particular 
ethnic groups (Jibaja-Weiss, Volk et al. 2006, Sheppard, Figueiredo et al. 2008, Sheppard, Williams et al. 
2010, Au, Lam et al. 2011, Jibaja-Weiss, Volk et al. 2011, Lam, Chan et al. 2013). Targeting these smaller 
populations allows use of more targeted information, but it also limits the dissemination of the DA to 
the size of that population. Another option is to apply the DA to a more general population, but ensure 
that it is approachable using a reading age of grade 8 or below (Stossel, Segar et al. 2012). A 
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 disadvantage to this approach may be difficulties in comprehensively addressing complex treatment 
options and subsequent impact on which patients are offered the DA in clinical practice.  
The accessibility of DAs for patients is another salient issue. In order for patients to have the opportunity 
to access DAs as required, they should be made readily available from a central trusted source such as 
the Ottawa Decision Aid Inventory (ODAI, https://decisionaid.ohri.ca), with links from other relevant 
sites. The ODAI, however, appears designed for health professionals rather than patients. The ODAI 
contains an assessment of the quality of each DA, measured against the IPDAS criteria and provides an 
indication of whether evidence exists to support an improvement in knowledge and congruence 
between values and final decision. It does not have an assessment of the quality of the literature 
supporting those DAs, nor of the individual outcomes from the available literature. Eight breast cancer 
treatment DAs were listed on the ODAI at the time of writing. Only one, ‘A Patchwork of Life’, had 
supporting literature that enabled its inclusion in this review. The majority of the DAs identified in this 
review were not listed on the ODAI or other readily accessible central locations, limiting their 
widespread availability. 
Online or computer-based, interactive DAs have the potential to be widely accessible and are able to be 
individualised to users’ needs. We found nine DAs of this type, with data to support acceptability of this 
mode of delivery (Street, Voigt et al. 1995, Molenaar, Sprangers et al. 2001, Siminoff, Gordon et al. 
2006, Heller, Parker et al. 2008, Lee, Chen et al. 2010, Sivell, Edwards et al. 2012, Sherman, Harcourt et 
al. 2013, Sherman, Harcourt et al. 2014). These studies did not compare online delivery to other DA 
formats, so it is not possible to claim that any method of delivery is superior. Patients appear to have 
difficulty finding DAs on the internet, due to a lack of uniform labelling and the variety of hosting 
locations (Morris, Drake et al. 2008). More evidence is therefore needed to evaluate the effectiveness of 
internet-based delivery of DAs to patients (Hoffman, Volk et al. 2013). 
62
Finally, the content of DAs is crucial for success, both in terms of patient outcomes and implementation. 
A systematic review of DA content raised concerns about the completeness of information, balance and 
accuracy of DAs (Feldman-Stewart, Brennenstuhl et al. 2007). Feldman-Stewart et al found that 
potential benefits were emphasised more than harms in half of cases, and external consultation either 
was not conducted, or was heavily reliant on health professionals over patients and consumer 
advocates. Information within DAs may become out-dated as new treatment options become available. 
Several of the breast cancer DAs identified in the present review are likely to contain out-dated 
information. If the content is out of date, then the options and probabilities presented in the DA will 
lose relevancy. The consequence will be either a negative impact on usage or utility. Probabilities may 
change with new evidence, and choices that were once commonplace may not have the same clinical 
equipoise that they once did. For example, in the time since the paper by Irwin et al. was published 
(Irwin, Arnold et al. 1999), it has become evident that AC has superior efficacy to CMF, and is now 
commonly used with taxanes, rendering the DA obsolete. Ideally DAs would be available online as 
required, and updated regularly.  
Conclusion 
DAs for early stage breast cancer treatment decisions increase knowledge about options, decrease 
decisional conflict and are acceptable to patients, without increasing anxiety. Treatment decisions 
addressed included surgical, endocrine therapy, chemotherapy, radiotherapy, reconstruction and 
fertility-preservation decisions. Contralateral prophylactic mastectomy and neoadjuvant systemic 
therapy treatment options may be suited to a DA, however we were unable to identify a DA for these 
topics. We are currently evaluating a DA for women who have been offered neoadjuvant systemic 
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 therapy for operable breast cancer to fill this gap. A more integrated approach to breast cancer DAs 
across all modalities may lead to greater implementation and more effective shared decision-making. 
64
 Ta
b
le
s 
Ta
b
le
 1
. I
n
cl
u
d
ed
 s
tu
d
ie
s 
o
f 
p
at
ie
n
t 
d
ec
is
io
n
-a
id
s 
fo
r 
tr
ea
tm
en
t 
o
f 
ea
rl
y 
st
ag
e 
b
re
as
t 
ca
n
ce
r 
A
u
th
o
r,
 y
ea
r,
 
lo
ca
ti
o
n
 
D
ec
is
io
n
; t
yp
e 
o
f 
d
ec
is
io
n
 s
u
p
p
o
rt
 
C
o
m
p
ar
at
o
r 
St
u
d
y 
ty
p
e 
P
o
p
u
la
ti
o
n
 
N
u
m
b
er
 o
f 
p
ar
ti
ci
p
an
ts
 
O
u
tc
o
m
e(
s)
, r
es
u
lt
 
Q
u
al
sy
st
 
sc
o
re
 
Su
rg
er
y 
(A
u
, L
am
 e
t 
al
. 2
0
1
1)
 
H
o
n
g 
K
o
n
g 
B
C
S,
 m
as
te
ct
o
m
y,
 
re
co
n
st
ru
ct
io
n
; 
B
o
o
kl
et
 –
 
in
fo
rm
at
io
n
, 
o
u
tc
o
m
e 
p
ro
b
ab
ili
ti
es
, v
al
u
es
 
cl
ar
if
ic
at
io
n
 
R
ev
is
ed
 D
A
 
Si
n
gl
e 
ar
m
 
co
h
o
rt
 
co
m
p
ar
is
o
n
 o
f 
o
ri
gi
n
al
 D
A
 
w
it
h
 r
ev
is
io
n
 
O
p
er
ab
le
 E
B
C
 
st
ag
e 
0
-I
I, 
B
C
S 
ca
n
d
id
at
e,
 H
o
n
g 
K
o
n
g 
p
u
b
lic
 
cl
in
ic
 
O
ri
gi
n
al
 D
A
: 
9
5
  
R
ev
is
ed
 D
A
: 
3
8
 
A
cc
ep
ta
b
ili
ty
: N
o
 d
if
fe
re
n
ce
 
b
et
w
ee
n
 g
ro
u
p
s 
at
 4
-7
 d
ay
s 
p
o
st
 D
A
 U
ti
lit
y:
 N
o
 d
if
fe
re
n
ce
 
b
et
w
ee
n
 g
ro
u
p
s 
A
n
xi
et
y/
d
ep
re
ss
io
n
: N
o
 
d
if
fe
re
n
ce
 b
et
w
ee
n
 b
as
el
in
e 
an
d
 4
-7
 d
ay
 v
is
it
 
0
.5
9
 
(L
am
, C
h
an
 
et
 a
l. 
2
01
3
) 
H
o
n
g 
K
o
n
g 
A
s 
ab
o
ve
 
St
an
d
ar
d
 
in
fo
rm
at
io
n
 
b
o
o
kl
et
 
R
C
T 
A
s 
ab
o
ve
 
D
A
: 1
38
  
C
o
n
tr
o
l: 
1
38
  
Tr
ea
tm
en
t 
d
ec
is
io
n
-m
ak
in
g 
d
if
fi
cu
lt
y 
at
 1
 w
ee
k:
 n
o
 
d
if
fe
re
n
ce
. 
D
C
S:
 1
5
.8
 (
D
A
) 
v 
1
9
.9
 
(c
o
n
tr
o
l)
 (
p
=0
.0
16
).
 
K
n
o
w
le
d
ge
: n
o
 d
if
fe
re
n
ce
. 
D
ec
is
io
n
al
 r
eg
re
t:
 a
t 
1
 
m
o
n
th
, n
o
 d
if
fe
re
n
ce
; 4
, 1
0
 
m
o
n
th
s,
 g
re
at
e
r 
re
gr
et
 in
 
co
n
tr
o
ls
. 
0
.8
9
 
65
 C
h
o
ic
e 
o
f 
su
rg
er
y:
 n
o
n
-
si
gn
if
ic
an
t 
d
if
fe
re
n
ce
, B
C
S 
4
3%
 (
D
A
) 
vs
 5
1%
, p
=0
.1
3
1
. 
A
n
xi
et
y/
d
ep
re
ss
io
n
: n
o
 
d
if
fe
re
n
ce
. 
(D
h
ag
e,
 
C
as
ta
n
ed
a 
et
 
al
. 2
0
1
3)
 
U
SA
 
M
as
te
ct
o
m
y 
vs
 B
C
S;
 
Su
rg
ic
al
 D
ec
is
io
n
 
Su
p
p
o
rt
 S
ys
te
m
: 
m
ed
ic
al
 
in
te
rp
re
ta
ti
o
n
 a
n
d
 
co
m
p
u
te
r-
b
as
ed
 
an
im
at
io
n
s 
N
il 
P
re
-p
o
st
 
co
h
o
rt
 
N
ew
ly
 
d
ia
gn
o
se
d
 
b
re
as
t 
ca
n
ce
r 
p
at
ie
n
ts
, s
in
gl
e 
ce
n
tr
e,
 lo
w
 
En
gl
is
h
 
p
ro
fi
ci
en
cy
 
an
d
/o
r 
et
h
n
ic
al
ly
 
d
iv
e
rs
e 
D
A
: 7
0 
(3
9
 
co
m
p
le
te
d
 
al
l 
as
se
ss
m
en
ts
) 
P
re
p
ar
at
io
n
 f
o
r 
d
ec
is
io
n
-
m
ak
in
g:
 1
0
0%
 f
el
t 
p
re
p
ar
ed
 
p
ri
o
r 
to
 s
u
rg
er
y.
 D
C
S:
 
d
ec
re
as
ed
 o
ve
r 
ti
m
e 
(n
o
n
-
si
gn
if
ic
an
t)
. S
at
is
fa
ct
io
n
 w
it
h
 
D
A
: 1
00
%
 s
at
is
fa
ct
io
n
 p
ri
o
r 
to
 s
u
rg
er
y.
 
0
.2
3
 
(G
o
el
, S
aw
ka
 
et
 a
l. 
2
00
1
) 
U
SA
 
M
as
te
ct
o
m
y 
vs
 B
C
S.
 
A
u
d
io
ta
p
e 
an
d
 
w
o
rk
b
o
o
k.
 
P
am
p
h
le
t 
co
n
ta
in
in
g 
id
en
ti
ca
l 
in
fo
rm
at
io
n
 
b
u
t 
n
o
 
n
u
m
b
er
s,
 
gr
ap
h
ic
s 
o
r 
va
lu
es
 
cl
ar
if
ic
at
io
n
 
C
lu
st
e
r 
R
C
T 
(r
an
d
o
m
is
ed
 
b
y 
su
rg
eo
n
) 
EB
C
, s
u
it
ab
le
 f
o
r 
B
C
S 
o
r 
m
as
te
ct
o
m
y,
 
su
rg
eo
n
 w
it
h
in
 
1
50
km
 o
f 
To
ro
n
to
, 
C
an
ad
a.
 
5
7
 S
u
rg
eo
n
s 
D
A
: 8
6 
 
C
o
n
tr
o
l: 
5
0
 
D
C
S 
48
-7
2
 h
o
u
rs
 p
o
st
 D
A
: n
o
 
d
if
fe
re
n
ce
, 1
.9
8
 D
A
 v
s 
2
.0
8
 
co
n
tr
o
l (
p
=0
.2
2
),
 n
o
 
d
if
fe
re
n
ce
 in
 s
u
b
sc
al
es
. 
K
n
o
w
le
d
ge
: n
o
 d
if
fe
re
n
ce
 
(p
=0
.4
3
).
 A
n
xi
et
y:
 n
o
 
d
if
fe
re
n
ce
 (
p
=n
r)
. D
ec
is
io
n
al
 
re
gr
et
: n
o
 d
if
fe
re
n
ce
 o
n
 a
n
y 
it
em
 (
p
=0
.3
2
-0
.9
3
) 
0
.6
4
 
(H
ar
w
o
o
d
, 
D
o
u
gl
as
 e
t 
al
. 2
0
1
1)
 
A
u
st
ra
lia
 
M
as
te
ct
o
m
y 
vs
 B
C
S;
 
A
LN
D
 v
s 
SL
N
B
; 
d
ec
is
io
n
 f
o
llo
w
in
g 
p
o
si
ti
ve
 S
LN
B
. 
N
il 
P
ro
sp
ec
ti
ve
 
co
h
o
rt
 w
it
h
 
h
is
to
ri
ca
l 
co
n
tr
o
ls
 
EB
C
, c
h
o
ic
e 
o
f 
B
C
S 
o
r 
m
as
te
ct
o
m
y,
 
an
d
/o
r 
A
LN
D
 o
r 
D
A
: 1
1
 
C
o
n
tr
o
l: 
2
8
 
Su
rg
ic
al
 c
h
o
ic
e:
 n
o
 d
if
fe
re
n
ce
 
(p
=0
.7
 f
o
r 
b
re
as
t 
an
d
 p
=0
.1
 
fo
r 
ly
m
p
h
 n
o
d
e 
su
rg
er
y)
. D
A
: 
K
n
o
w
le
d
ge
 (
2
3
.9
/3
5)
, 
m
o
d
if
ie
d
 D
C
S 
(1
.3
/5
) 
an
d
 
0
.5
9
 
66
 D
ec
is
io
n
 b
o
ar
d
s,
 
su
p
p
le
m
en
ta
ry
 
in
fo
rm
at
io
n
, t
ak
e 
h
o
m
e 
b
o
o
kl
et
. 
SL
N
B
, s
in
gl
e 
ce
n
tr
e.
 
sa
ti
sf
ac
ti
o
n
 w
it
h
 t
h
e 
D
A
 
(4
.7
/5
).
 
(J
ib
aj
a-
W
ei
ss
, V
o
lk
 
et
 a
l. 
2
00
6
) 
U
SA
 
M
as
te
ct
o
m
y 
vs
 B
C
S 
fo
r 
lo
w
 li
te
ra
cy
 
p
at
ie
n
ts
. 
‘A
 p
at
ch
w
o
rk
 o
f 
lif
e’
 
co
m
p
u
te
r 
D
A
 
fo
cu
ss
in
g 
o
n
 v
al
u
es
 
cl
ar
if
ic
at
io
n
. 
N
il 
P
re
-p
o
st
 
co
h
o
rt
 p
ilo
t 
st
u
d
y 
St
ag
e 
I-
III
A
 E
B
C
, 
su
rg
ic
al
 
ca
n
d
id
at
e,
 
En
gl
is
h
 o
r 
Sp
an
is
h
 s
p
ea
ke
r.
 
D
A
: 5
1
 
U
se
 o
f 
je
w
e
lle
ry
 b
o
x 
to
 
id
en
ti
fy
 is
su
es
 r
el
at
e
d
 t
o
 
th
ei
r 
d
ec
is
io
n
: 5
9
%
 u
se
d
 it
 t
o
 
fl
ag
 a
 m
ed
ia
n
 o
f 
4
 is
su
es
. 
D
C
S 
u
n
ce
rt
ai
n
ty
 s
u
b
sc
al
e:
 
3
.1
0
 p
re
, 1
.9
8
 p
o
st
 (
p
<0
.0
0
1
).
 
D
C
S 
u
n
cl
ea
r 
ab
o
u
t 
va
lu
es
: 
3
.1
9
 p
re
, 0
.8
0
 p
o
st
 (
p
<0
.0
0
1
).
 
0
.6
8
 
(J
ib
aj
a-
W
ei
ss
, V
o
lk
 
et
 a
l. 
2
01
1
) 
U
SA
 
A
s 
ab
o
ve
. 
U
su
al
 c
ar
e.
 
R
C
T 
A
s 
ab
o
ve
. 
D
A
: 5
1
 
C
o
n
tr
o
l: 
4
9
 
Su
rg
ic
al
 c
h
o
ic
e:
 D
A
 g
ro
u
p
 
m
o
re
 li
ke
ly
 c
o
n
tr
o
l g
ro
u
p
 t
o
 
o
p
t 
fo
r 
m
as
te
ct
o
m
y 
th
an
 B
C
S 
th
an
 (
60
%
 v
s 
4
0%
, p
=0
.0
1
8)
. 
K
n
o
w
le
d
ge
: n
o
 d
if
fe
re
n
ce
 a
t 
b
as
el
in
e,
 b
et
te
r 
in
 D
A
 g
ro
u
p
 
af
te
r 
D
A
, n
o
 d
if
fe
re
n
ce
 a
t 
1 
ye
ar
. 
Sa
ti
sf
ac
ti
o
n
 w
it
h
 d
ec
is
io
n
-
m
ak
in
g:
 n
o
 d
if
fe
re
n
ce
. 
D
C
S:
 D
A
 g
ro
u
p
 h
ig
h
er
 
In
fo
rm
ed
 s
u
b
sc
al
e 
p
o
st
 D
A
. 
0
.5
7
 
(M
o
le
n
aa
r,
 
Sp
ra
n
ge
rs
 e
t 
al
. 2
0
0
1)
 
M
as
te
ct
o
m
y 
vs
 B
C
S.
 
In
te
ra
ct
iv
e 
C
D
-R
O
M
. 
U
su
al
 c
ar
e.
 
Q
u
as
i-
ex
p
er
im
en
ta
l, 
EB
C
 s
ta
ge
 I-
II,
 
ca
n
d
id
at
e 
fo
r 
D
A
: 9
2
 
C
o
n
tr
o
l: 
8
8
 
C
h
o
ic
e 
o
f 
tr
ea
tm
en
t:
 D
A
 7
5%
 
ch
o
se
 B
C
S 
vs
 c
o
n
tr
o
l 6
8
%
 
ch
o
se
 B
C
S 
(p
=0
.2
9
).
 
0
.8
6
 
67
 Th
e 
N
et
h
er
la
n
d
s 
lo
n
gi
tu
d
in
al
, 
p
re
/p
o
st
. 
m
as
te
ct
o
m
y 
o
r 
B
C
S.
 
Sa
ti
sf
ac
ti
o
n
: O
ve
ra
ll 
p
o
si
ti
ve
 
ef
fe
ct
 o
f 
D
A
. 
G
en
er
ic
 a
n
d
 b
re
as
t 
q
u
al
it
y 
o
f 
lif
e:
 D
A
 g
ro
u
p
 h
ig
h
er
 s
co
re
. 
(S
iv
e
ll,
 
Ed
w
ar
d
s 
et
 
al
. 2
0
1
2)
 
U
n
it
ed
 
K
in
gd
o
m
 
M
as
te
ct
o
m
y 
vs
 B
C
S.
 
O
n
lin
e 
in
te
ra
ct
iv
e 
D
A
. 
N
il.
 
O
b
se
rv
at
io
n
al
 
co
h
o
rt
 s
tu
d
y,
 
p
re
/p
o
st
. 
EB
C
, e
lig
ib
le
 f
o
r 
m
as
te
ct
o
m
y 
o
r 
B
C
S.
 
D
A
: 6
2
 
R
ea
d
in
es
s 
to
 d
ec
id
e:
 p
re
 
6
5
.9
, p
o
st
 7
6
.6
 (
<0
.0
0
1)
. 
K
n
o
w
le
d
ge
: p
re
 8
.3
, p
o
st
 8
.5
 
(p
=0
.2
).
 
In
te
n
ti
o
n
 f
o
r 
m
as
te
ct
o
m
y:
 n
o
 
ch
an
ge
. 
0
.6
8
 
(S
tr
ee
t,
 V
o
ig
t 
et
 a
l. 
1
99
5
) 
U
SA
 
M
as
te
ct
o
m
y 
vs
 B
C
S.
 
In
te
ra
ct
iv
e 
co
m
p
u
te
r 
p
ro
gr
am
. 
B
ro
ch
u
re
. 
R
C
T 
EB
C
 s
ta
ge
 I-
II 
D
A
: 3
0
 
C
o
n
tr
o
l: 
3
0
 
C
h
o
ic
e 
o
f 
B
C
S:
 D
A
 7
6
%
, 
co
n
tr
o
l 5
8
%
 (
n
o
t 
si
gn
if
ic
an
t)
. 
O
p
ti
m
is
m
: n
o
 d
if
fe
re
n
ce
. 
K
n
o
w
le
d
ge
: n
o
 d
if
fe
re
n
ce
 
b
et
w
ee
n
 g
ro
u
p
s,
 s
ig
n
if
ic
an
t 
im
p
ro
ve
m
en
t 
o
ve
r 
ti
m
e.
 
0
.6
1
 
(W
h
el
an
, 
Le
vi
n
e 
et
 a
l. 
1
99
9
) 
C
an
ad
a 
M
as
te
ct
o
m
y 
vs
 B
C
S.
 
D
ec
is
io
n
 b
o
ar
d
. 
N
il 
Si
n
gl
e 
ar
m
 
co
h
o
rt
  
EB
C
 s
ta
ge
 I-
II 
D
A
: 1
75
 
SD
M
: M
ak
e 
fi
n
al
 d
ec
is
io
n
 
(5
1%
),
 s
h
ar
e 
d
ec
is
io
n
 w
it
h
 
su
rg
eo
n
 (
3
6%
).
 
C
o
m
p
re
h
en
si
o
n
: 8
4%
 c
o
rr
ec
t.
 
Sa
ti
sf
ac
ti
o
n
: i
n
fo
rm
at
io
n
 
(9
7%
),
 d
ec
is
io
n
-m
ak
in
g 
p
ro
ce
ss
 (
97
%
).
 
C
h
o
se
 B
C
S 
+
 r
ad
io
th
er
ap
y:
 
7
3%
. 
0
.6
4
 
68
 (W
h
el
an
, 
Le
vi
n
e 
et
 a
l. 
2
00
4
) 
C
an
ad
a 
A
s 
ab
o
ve
 
U
su
al
 c
ar
e.
 
C
lu
st
e
r 
R
C
T 
(r
an
d
o
m
is
ed
 
b
y 
su
rg
eo
n
, 
m
at
ch
ed
 f
o
r 
ag
e 
an
d
 
ge
n
d
er
) 
EB
C
 s
ta
ge
 I-
II 
p
ri
o
r 
to
 s
u
rg
ic
al
 
tr
ea
tm
en
t 
Su
rg
eo
n
s:
 2
0
 
D
A
: 9
4
 
C
o
n
tr
o
l: 
1
07
 
K
n
o
w
le
d
ge
: D
A
 6
6
.9
, c
o
n
tr
o
l 
5
8
.7
 (
p
<0
.0
0
01
).
 
P
o
st
 c
o
n
su
lt
 D
C
S:
 D
A
 1
.4
, 
co
n
tr
o
l 1
.6
2
 (
p
=0
.0
2
).
 
D
ec
is
io
n
al
 s
at
is
fa
ct
io
n
: D
A
 
4
.5
, c
o
n
tr
o
l 4
.3
2
 (
p
=0
.0
5
).
 
C
h
o
se
 B
C
S:
 D
A
 9
4
%
, c
o
n
tr
o
l 
7
6%
 (
p
=0
.0
3
).
 
A
n
xi
et
y/
d
ep
re
ss
io
n
: n
o
 
d
if
fe
re
n
ce
. 
0
.7
5
 
B
re
as
t 
R
ec
o
n
st
ru
ct
io
n
 s
u
rg
er
y 
(H
el
le
r,
 
P
ar
ke
r 
et
 a
l. 
2
00
8
) 
U
SA
 
R
ec
o
n
st
ru
ct
io
n
 
su
rg
er
y.
 
In
te
ra
ct
iv
e 
d
ig
it
al
 
sy
st
em
. 
St
an
d
ar
d
 
p
at
ie
n
t 
ed
u
ca
ti
o
n
 
o
n
ly
. 
R
C
T 
EB
C
, c
an
d
id
at
e 
fo
r 
b
re
as
t 
re
co
n
st
ru
ct
io
n
 
D
A
: 6
6
 
C
o
n
tr
o
l: 
6
7
 
K
n
o
w
le
d
ge
: D
A
 g
ro
u
p
 
kn
o
w
le
d
ge
 in
cr
ea
se
d
 t
o
 a
 
gr
ea
te
r 
ex
te
n
t 
th
an
 c
o
n
tr
o
l 
(p
=0
.0
2
).
 
Sa
ti
sf
ie
d
 w
it
h
 m
o
d
e 
o
f 
d
el
iv
er
y:
 D
A
 g
ro
u
p
 9
7
%
 v
s 
co
n
tr
o
l 8
6
%
 (
p
=0
.0
3
).
 
P
le
as
ed
 w
it
h
 c
h
o
ic
e:
 D
A
 9
5%
 
vs
 c
o
n
tr
o
l 8
3%
. 
A
n
xi
et
y:
 n
o
 d
if
fe
re
n
ce
 
b
et
w
ee
n
 g
ro
u
p
s,
 d
ec
re
as
e
 
o
ve
r 
ti
m
e.
 
0
.5
7
 
(L
ee
, C
h
en
 e
t 
al
. 2
0
1
0)
 
R
ec
o
n
st
ru
ct
io
n
 
su
rg
er
y.
 
U
su
al
 c
ar
e.
 
N
o
n
-
ra
n
d
o
m
is
ed
 
Im
m
ed
ia
te
 o
r 
d
el
ay
ed
 b
re
as
t 
re
co
n
st
ru
ct
io
n
 
D
A
: 2
16
 
C
o
n
tr
o
l: 
1
20
 
P
at
ie
n
t 
in
vo
lv
em
en
t 
in
 
d
ec
is
io
n
: g
re
at
er
 in
 t
h
e 
D
A
 
gr
o
u
p
 (
p
<0
.0
01
).
 
0
.3
6
 
69
 U
SA
 
C
o
m
p
u
te
r-
b
as
ed
 
le
ar
n
in
g 
m
o
d
u
le
. 
 
co
m
p
ar
at
iv
e 
co
h
o
rt
. 
af
te
r 
m
as
te
ct
o
m
y 
fo
r 
EB
C
. 
Su
rg
ic
al
 c
h
o
ic
e:
 D
A
 g
ro
u
p
 
m
o
re
 li
ke
ly
 t
o
 c
h
o
o
se
 
au
to
lo
go
u
s 
fl
ap
 s
u
rg
er
y.
 
Sa
ti
sf
ac
ti
o
n
 w
it
h
 
in
fo
rm
at
io
n
: M
o
st
ly
/v
er
y 
- 
D
A
 9
1
%
 v
s 
co
n
tr
o
l 8
5
%
 
(p
<0
.0
0
1)
. 
G
en
er
al
 s
at
is
fa
ct
io
n
: n
o
 
d
if
fe
re
n
ce
. 
(S
h
er
m
an
, 
H
ar
co
u
rt
 e
t 
al
. 2
0
1
4)
 
A
u
st
ra
lia
 
R
ec
o
n
st
ru
ct
io
n
 
su
rg
er
y.
 
O
n
lin
e 
in
te
ra
ct
iv
e 
D
A
 
(B
R
EC
O
N
D
A
).
 
N
il 
M
ix
ed
-
m
et
h
o
d
s 
p
ilo
t 
st
u
d
y.
 
EB
C
 o
r 
D
C
IS
, 
sc
h
ed
u
le
d
 f
o
r 
m
as
te
ct
o
m
y,
 
el
ig
ib
le
 f
o
r 
re
co
n
st
ru
ct
io
n
. 
D
A
: 2
8
 
A
cc
ep
ta
b
ili
ty
: m
ea
n
 4
.1
/5
. 
U
se
fu
ln
es
s:
 m
ea
n
 3
.9
7
/5
. 
Ea
se
 o
f 
u
se
: m
ea
n
 4
.5
8/
5
. 
Su
ff
ic
ie
n
t 
in
fo
rm
at
io
n
: m
ea
n
 
3
.8
9
/5
. 
0
.5
7
 
(S
h
er
m
an
, 
H
ar
co
u
rt
 e
t 
al
. 2
0
1
3)
 
A
u
st
ra
lia
 
A
s 
ab
o
ve
. 
G
en
er
al
 
ed
u
ca
ti
o
n
al
 
p
am
p
h
le
t.
 
R
C
T 
(c
o
n
fe
re
n
ce
 
ab
st
ra
ct
) 
W
o
m
en
 
d
ia
gn
o
se
d
 w
it
h
 
b
re
as
t 
ca
n
ce
r,
 
p
la
n
n
ed
 f
o
r 
o
r 
p
o
st
- 
m
as
te
ct
o
m
y.
 
P
re
-
m
as
te
ct
o
m
y:
 
3
1
 
P
o
st
-
m
as
te
ct
o
m
y:
 
1
07
 
(n
u
m
b
er
 p
er
 
ar
m
 N
R
) 
R
ec
o
n
st
ru
ct
io
n
 p
at
ie
n
ts
 (
16
 
D
A
, 1
0
 c
o
n
tr
o
l)
 
D
C
S:
 D
A
 2
7
.3
, c
o
n
tr
o
l 3
4
.6
 
(p
=0
.0
1
5)
. 
Sa
ti
sf
ac
ti
o
n
 w
it
h
 
in
fo
rm
at
io
n
: D
A
 4
.0
2
, c
o
n
tr
o
l 
3
.7
4
 (
p
=0
.0
3
).
 
K
n
o
w
le
d
ge
: n
o
 d
if
fe
re
n
ce
. 
  
0
.2
9
 
70
Sy
st
em
ic
 t
h
er
ap
y 
(P
ee
le
, 
Si
m
in
o
ff
 e
t 
al
. 2
0
0
5)
 
U
SA
 
A
d
ju
va
n
t 
en
d
o
cr
in
e 
th
er
ap
y 
an
d
/o
r 
ch
em
o
th
er
ap
y.
 
A
d
ju
va
n
t!
O
n
lin
e 
– 
o
n
lin
e 
p
ro
gn
o
st
ic
/p
re
d
ic
ti
ve
 
ca
lc
u
la
to
r 
P
am
p
h
le
t 
co
n
ta
in
in
g 
n
o
n
-
n
u
m
er
ic
 
in
fo
rm
at
io
n
 
C
lu
st
e
r 
R
C
T 
(r
an
d
o
m
is
ed
 
b
y 
st
u
d
y 
si
te
) 
EB
C
, c
o
m
p
le
te
d
 
p
ri
m
ar
y 
su
rg
ic
al
 
in
te
rv
en
ti
o
n
s,
 
ca
n
d
id
at
e 
fo
r 
A
T 
1
4
 S
it
es
 
D
A
: 2
26
 
C
o
n
tr
o
l: 
1
60
 
D
ec
is
io
n
 t
o
 r
ec
e
iv
e 
A
T 
in
 lo
w
 
tu
m
o
u
r 
se
ve
ri
ty
 g
ro
u
p
: 5
8%
 
D
A
 v
 8
7
%
 c
o
n
tr
o
ls
 (
p
<0
.0
1
).
 
Lo
gi
st
ic
 r
eg
re
ss
io
n
: D
A
 g
ro
u
p
 
le
ss
 li
ke
ly
 t
o
 c
h
o
o
se
 A
T 
w
it
h
 
lo
w
 s
ev
er
it
y 
tu
m
o
u
r,
 m
o
re
 
lik
e
ly
 t
o
 c
h
o
o
se
 A
T 
w
it
h
 h
ig
h
 
se
ve
ri
ty
 t
u
m
o
u
r 
0
.7
9
 
(S
im
in
o
ff
, 
G
o
rd
o
n
 e
t 
al
. 
2
00
6
) 
U
SA
 
A
s 
ab
o
ve
 
A
s 
ab
o
ve
 
A
s 
ab
o
ve
 
A
s 
ab
o
ve
 
1
4
 S
it
es
 
D
A
: 2
34
 
C
o
n
tr
o
l: 
1
71
 
D
ec
is
io
n
 n
o
t 
to
 r
ec
e
iv
e 
A
T:
 
P
ts
 w
h
o
 r
e
fu
se
d
 A
T 
w
e
re
 
m
o
re
 li
ke
ly
 n
o
d
e 
n
eg
at
iv
e 
an
d
 s
m
al
le
r 
tu
m
o
u
rs
, o
ld
er
, 
lo
w
er
 in
co
m
e,
 t
re
at
ed
 in
 
ac
ad
em
ic
 c
en
tr
es
. 
A
cc
ep
ta
b
ili
ty
 a
n
d
 u
ti
lit
y 
o
f 
D
A
 
v 
co
n
tr
o
l: 
D
A
 m
o
re
 h
el
p
fu
l, 
an
d
 m
o
re
 in
fl
u
en
ti
al
 o
n
 
d
ec
is
io
n
. N
o
 d
if
fe
re
n
ce
 in
 
ea
se
 o
f 
u
n
d
er
st
an
d
in
g 
o
r 
co
m
fo
rt
 w
it
h
 in
fo
rm
at
io
n
. 
0
.7
9
 
(V
ic
ke
rs
, 
El
ki
n
 e
t 
al
. 
2
00
9
) 
U
SA
 
A
s 
ab
o
ve
 
A
s 
ab
o
ve
 
A
s 
ab
o
ve
 
A
s 
ab
o
ve
 
1
4
 s
it
e
s 
D
A
: 2
26
 
C
o
n
tr
o
l:
 1
60
 
Ex
p
ec
te
d
 b
en
ef
it
 r
eq
u
ir
ed
 t
o
 
re
ce
iv
e 
A
T:
 3
%
 (
n
=1
2
) 
re
fu
se
d
 A
T 
d
es
p
it
e 
a 
la
rg
e 
lo
ss
 in
 s
u
rv
iv
al
. N
u
m
b
er
s 
to
o
 
sm
al
l t
o
 f
it
 a
 s
ta
ti
st
ic
al
 
m
o
d
el
. Q
u
al
it
at
iv
e 
an
al
ys
is
: 
A
T 
re
fu
se
rs
 t
en
d
 t
o
 b
e 
w
o
m
e
n
 w
it
h
 E
R
+ 
EB
C
 w
h
o
 
0
.7
1
 
71
o
p
t 
fo
r 
ch
em
o
th
er
ap
y 
b
u
t 
n
o
t 
A
ET
. 
(L
ip
ku
s,
 
P
et
er
s 
et
 a
l. 
2
01
0
) 
U
SA
 
A
s 
ab
o
ve
 
N
il 
2
-s
ta
ge
 p
re
-
p
o
st
p
ro
sp
ec
ti
ve
co
h
o
rt
Si
n
gl
e 
ac
ad
em
ic
 
ce
n
tr
e,
 E
B
C
, T
1
-
3
, N
0
-2
, E
R
+ 
P
ilo
t 
1:
 6
0
 
(A
d
ju
va
n
t!
 
al
o
n
e)
 
P
ilo
t 
2:
 4
5
 
(P
re
-
co
n
su
lt
at
io
n
 
vi
d
eo
 a
n
d
 
A
d
ju
va
n
t!
) 
Tr
ea
tm
en
t 
e
xp
ec
ta
ti
o
n
s:
 
m
o
re
 n
u
m
er
at
e 
p
at
ie
n
ts
 
m
o
re
 li
ke
ly
 t
o
 c
o
rr
el
at
e 
A
ET
/C
T 
w
it
h
 b
et
te
r 
su
rv
iv
al
. 
C
o
m
p
ar
is
o
n
 b
et
w
ee
n
 h
ig
h
 
an
d
 lo
w
 n
u
m
er
ac
y:
 h
ig
h
er
 
n
u
m
er
ac
y 
m
o
re
 li
ke
ly
 t
o
 
m
at
ch
 A
d
ju
va
n
t!
 w
it
h
 s
el
f-
es
ti
m
at
e 
o
f 
su
rv
iv
al
. 
0
.7
3
 
(B
el
ko
ra
, 
H
u
tt
o
n
 e
t 
al
. 
2
01
1
) 
U
SA
 
A
s 
ab
o
ve
 
P
am
p
h
le
t 
Su
b
se
t 
an
al
ys
is
 o
f 
P
ee
le
 
p
ar
ti
ci
p
an
ts
 
EB
C
 s
ta
ge
 I-
III
, 
lo
w
 r
is
k 
(>
8
5
%
 
1
0
-y
ea
r 
su
rv
iv
al
 
es
ti
m
at
e)
. 
D
A
: 2
8
 
C
o
n
tr
o
l: 
2
0
 
Su
rv
iv
al
 b
en
ef
it
 a
cc
u
ra
cy
: 
5
7%
 D
A
, 2
5
%
 c
o
n
tr
o
l 
(p
=0
.0
4
).
 T
re
at
m
en
t 
ch
o
ic
e 
as
 a
 f
u
n
ct
io
n
 o
f 
p
ro
gn
o
st
ic
 
ac
cu
ra
cy
: 6
2%
 o
f 
th
o
se
 w
h
o
 
w
e
re
 a
cc
u
ra
te
 c
h
o
se
 A
T 
co
m
p
ar
ed
 w
it
h
 8
9
%
 o
f 
th
o
se
 
w
h
o
 w
e
re
 in
ac
cu
ra
te
 
(p
=0
.0
4
).
 
0
.4
6
 
(F
el
d
m
an
, 
St
an
fo
rd
 e
t 
al
. 2
0
0
2)
 
U
n
it
ed
 
K
in
gd
o
m
 
C
h
em
o
th
er
ap
y.
 
P
ro
gn
o
st
ic
 t
ab
le
 
b
as
ed
 o
n
 a
ge
 a
n
d
 
N
o
tt
in
gh
am
 
P
ro
gn
o
st
ic
 In
d
ex
 
U
su
al
 c
ar
e 
R
et
ro
sp
ec
ti
ve
 
co
h
o
rt
 w
it
h
 
h
is
to
ri
ca
l 
co
n
tr
o
l g
ro
u
p
 
EB
C
, t
re
at
ed
 
w
it
h
 s
u
rg
er
y,
 
ca
n
d
id
at
e 
fo
r 
A
T,
 <
7
0
yr
s.
 
D
A
: 2
88
 
C
o
n
tr
o
l: 
3
01
 
C
h
em
o
th
er
ap
y 
u
p
ta
ke
: 
In
cr
ea
se
 w
it
h
 D
A
 in
 p
at
ie
n
ts
 
w
it
h
 4
%
 s
u
rv
iv
al
 a
d
va
n
ta
ge
 
(4
2%
 v
s 
6
4%
, p
=n
r)
. 
D
es
cr
ip
ti
ve
 d
at
a 
ab
o
u
t 
re
fe
rr
al
s:
 2
%
 c
h
em
o
th
er
ap
y 
su
rv
iv
al
 b
en
ef
it
, 4
8
%
 r
ef
e
rr
ed
 
to
 o
n
co
lo
gi
st
; 4
%
 b
e
n
ef
it
, 
9
1%
 r
ef
er
re
d
. N
o
d
e 
p
o
si
ti
vi
ty
 
0
.4
1
 
72
 w
as
 w
ei
gh
te
d
 lo
w
er
 f
o
r 
d
ec
is
io
n
 w
h
en
 D
A
 u
se
d
. 
(I
rw
in
, 
A
rn
o
ld
 e
t 
al
. 
1
99
9
) 
C
an
ad
a 
A
d
ju
va
n
t 
ch
em
o
th
er
ap
y 
(A
C
 v
s 
C
M
F)
. 
D
ec
is
io
n
 B
o
ar
d
. 
N
il 
Si
n
gl
e 
ar
m
 
co
h
o
rt
 
P
re
m
en
o
p
au
sa
l 
n
o
d
e 
p
o
si
ti
ve
 
EB
C
 t
re
at
e
d
 w
it
h
 
su
rg
er
y 
re
fe
rr
ed
 
fo
r 
m
ed
ic
al
 
o
n
co
lo
gy
 
o
p
in
io
n
. 
D
A
: 4
6 
 
In
fo
rm
at
io
n
 r
ec
al
l: 
al
l >
8
0%
. 
H
el
p
fu
ln
es
s 
o
f 
D
A
: 
Q
u
it
e
/v
er
y 
h
el
p
fu
l 9
8%
. 
D
if
fi
cu
lt
y 
o
f 
th
e 
d
ec
is
io
n
: 
Q
u
it
e
/v
er
y 
d
if
fi
cu
lt
 3
2
%
. 
Tr
ea
tm
en
t 
d
ec
is
io
n
: 5
0
%
 A
C
, 
4
6%
 C
M
F,
 4
%
 n
o
 t
re
at
m
en
t.
 
0
.6
9
 
(L
ev
in
e,
 
G
af
n
i e
t 
al
. 
1
99
2
) 
C
an
ad
a 
A
d
ju
va
n
t 
ch
em
o
th
er
ap
y 
vs
 n
o
 
ch
em
o
th
er
ap
y.
 
D
ec
is
io
n
 b
o
ar
d
. 
N
il 
P
re
-p
o
st
 in
 3
 
p
ar
ts
. 
P
ilo
t:
 E
B
C
 S
ta
ge
 
I-
II,
 c
o
m
p
le
te
d
 
ch
em
o
th
er
ap
y.
 
St
u
d
y 
1
: h
ea
lt
h
y 
vo
lu
n
te
e
rs
. 
St
u
d
y 
2
: 
C
o
n
se
cu
ti
ve
 
h
ig
h
 r
is
k 
n
o
d
e 
n
eg
at
iv
e 
EB
C
. 
P
ilo
t:
 6
 
St
u
d
y 
1
: 3
0
 
St
u
d
y 
2
: 3
7
 
P
ilo
t:
 1
00
%
 a
cc
ep
ta
b
ili
ty
. 
St
u
d
y 
1
: C
h
em
o
th
er
ap
y 
(y
es
/n
o
) 
w
it
h
 5
%
 a
b
so
lu
te
 
re
cu
rr
en
ce
 b
en
ef
it
 –
 5
7%
 
ye
s,
 4
3
%
 n
o
. 
St
u
d
y 
2
: 9
7
%
 e
as
y/
ve
ry
 e
as
y 
to
 u
n
d
er
st
an
d
; 8
7%
 
h
el
p
fu
l/
ve
ry
 h
el
p
fu
l f
o
r 
d
ec
is
io
n
. 
0
.2
8
 
(S
h
ep
p
ar
d
, 
Fi
gu
ei
re
d
o
 e
t 
al
. 2
0
0
8)
 
U
SA
 
A
d
ju
va
n
t 
ch
em
o
th
er
ap
y.
 
P
at
ie
n
t 
n
av
ig
at
o
rs
 
fo
r 
La
ti
n
as
. 
N
il 
P
h
as
e 
1
: 
q
u
al
it
at
iv
e
. 
P
h
as
e 
2
: P
ilo
t 
o
f 
in
te
rv
en
ti
o
n
 
p
re
/p
o
st
. 
1
: L
at
in
a 
w
it
h
 
EB
C
 a
n
d
 
ad
vo
ca
te
s.
 
2
: L
at
in
a 
w
it
h
 
EB
C
, 4
-2
0 
w
ee
ks
 
af
te
r 
d
ef
in
it
iv
e 
su
rg
er
y.
  
1
: 2
2
 
2
: 1
5
 
1
: E
n
ab
le
rs
 f
o
r 
SD
M
: r
es
p
ec
t,
 
p
er
so
n
al
it
y,
 f
am
ily
, p
at
ie
n
t-
p
ro
vi
d
er
 c
o
m
m
u
n
ic
at
io
n
. 
2
: H
ig
h
 s
at
is
fa
ct
io
n
 w
it
h
 
in
te
rv
en
ti
o
n
: b
et
te
r 
co
m
m
u
n
ic
at
io
n
, i
n
fo
rm
at
io
n
 
an
d
 S
D
M
. 
0
.4
0
 
(Q
u
al
) 
0
.5
 
(Q
u
an
t)
 
73
 (S
h
ep
p
ar
d
, 
W
ill
ia
m
s 
e
t 
al
. 2
0
1
0)
 
U
SA
 
A
d
ju
va
n
t 
ch
em
o
th
er
ap
y.
 
Su
rv
iv
o
r 
co
ac
h
es
 f
o
r 
A
fr
ic
an
 A
m
er
ic
an
 
w
o
m
e
n
. 
N
il 
1
: D
A
 
d
ev
el
o
p
m
en
t.
 
2
: Q
u
al
it
at
iv
e 
ev
al
u
at
io
n
. 
1
: P
at
ie
n
ts
 in
 
ac
ti
ve
 t
re
at
m
en
t 
(1
4
),
 a
d
vo
ca
te
s 
(1
0
),
 c
ar
e 
p
ro
vi
d
er
s 
(1
0
).
 
2
: A
s 
ab
o
ve
 (
1
2
),
 
p
lu
s 
n
ew
ly
 
d
ia
gn
o
se
d
 E
B
C
 
(8
).
 
1
: 3
4
 
2
: 2
0
 
C
o
m
m
u
n
it
y/
cl
in
ic
ia
n
 o
p
in
io
n
 
o
f 
in
te
rv
en
ti
o
n
: 
re
ad
ab
ili
ty
/c
o
n
te
n
t/
fo
rm
at
 
o
u
ts
ta
n
d
in
g 
(6
6
.7
%
),
 
ex
ce
lle
n
t 
(3
3
.3
%
).
 
P
at
ie
n
ts
: H
ig
h
 s
at
is
fa
ct
io
n
 
(1
00
%
).
 
En
ab
le
rs
: p
at
ie
n
t-
p
ro
vi
d
er
 
co
m
m
u
n
ic
at
io
n
, n
ee
d
 f
o
r 
b
et
te
r 
co
m
m
u
n
ic
at
io
n
. 
0
.6
 
(W
h
el
an
, 
Sa
w
ka
 e
t 
al
. 
2
00
3
) 
C
an
ad
a 
A
d
ju
va
n
t 
ch
em
o
th
er
ap
y.
 
D
ec
is
io
n
 b
o
ar
d
. 
U
su
al
 c
ar
e 
R
C
T 
EB
C
, n
o
d
e 
n
eg
at
iv
e,
 
co
m
p
le
te
d
 
p
ri
m
ar
y 
su
rg
er
y,
 
ca
n
d
id
at
e 
fo
r 
ch
em
o
th
er
ap
y.
 
D
A
: 8
2
 
C
o
n
tr
o
l: 
9
3
 
K
n
o
w
le
d
ge
: D
A
 8
0,
 c
o
n
tr
o
l 7
1 
(p
<0
.0
0
1)
. 
Sa
ti
sf
ac
ti
o
n
 w
it
h
 d
ec
is
io
n
-
m
ak
in
g:
 D
A
 m
ea
n
 s
co
re
s 
h
ig
h
er
 o
ve
r 
ti
m
e 
(p
=0
.0
3
2
) 
A
n
xi
et
y:
 n
o
 d
if
fe
re
n
ce
. 
C
h
an
ge
 t
o
 a
ct
iv
e 
ro
le
 in
 
d
ec
is
io
n
 m
ak
in
g:
 D
A
 1
0
%
, 
co
n
tr
o
l 2
%
 p
=0
.0
3
3
).
 
0
.8
2
 
R
ad
io
th
er
ap
y 
(W
h
el
an
, 
Le
vi
n
e 
et
 a
l. 
1
99
5
) 
C
an
ad
a 
R
ad
io
th
er
ap
y 
af
te
r 
B
C
S.
 
D
ec
is
io
n
 b
o
ar
d
. 
C
1
: C
o
n
su
lt
 
C
2
: C
o
n
su
lt
 
+ 
ch
ec
kl
is
t 
N
o
n
-
ra
n
d
o
m
is
ed
 
se
q
u
en
ti
al
 
co
h
o
rt
 
EB
C
 p
o
st
 B
C
S,
 
tu
m
o
u
r 
<5
cm
, 
n
o
d
e 
n
eg
at
iv
e.
 
D
A
: 3
0
 
C
1
: 2
3
 
C
2
: 2
9
 
SD
M
: O
ff
er
ed
 c
h
o
ic
e 
- 
D
A
 
9
7%
, C
1
/C
2
: 7
0
%
 (
p
0
.0
2
);
 
R
ad
io
th
er
ap
y 
re
co
m
m
en
d
ed
 
– 
D
A
 2
0
%
, C
1/
C
2 
9
2
%
 
(p
<0
.0
0
01
).
 
D
A
 A
cc
ep
ta
b
ili
ty
: e
as
y 
to
 
u
n
d
er
st
an
d
 (
10
0%
),
 h
el
p
ed
 
0
.5
9
 
74
m
ak
e 
a 
d
ec
is
io
n
 (
8
1
%
),
 
re
co
m
m
en
d
 f
o
r 
u
se
 (
9
3%
).
 
K
n
o
w
le
d
ge
: n
o
 d
if
fe
re
n
ce
 
o
ve
ra
ll.
 
(W
o
n
g,
 
D
'A
lim
o
n
te
 
et
 a
l. 
2
01
2
) 
C
an
ad
a 
A
d
ju
va
n
t 
ra
d
io
th
er
ap
y 
fo
r 
w
o
m
e
n
 >
7
0
 y
ea
rs
. 
B
o
o
kl
et
 D
A
. 
N
il 
C
o
h
o
rt
 
1
: P
ilo
t 
2
: P
re
/p
o
st
 
EB
C
, >
7
0 
ye
ar
s 
o
f 
ag
e,
 E
R
/P
R
 
p
o
si
ti
ve
, p
o
st
 
lu
m
p
ec
to
m
y,
 
p
la
n
n
ed
 f
o
r 
ra
d
io
th
er
ap
y.
 
1
: 1
2
 
2
: 3
8
 
1
: A
cc
ep
ta
b
ili
ty
 -
 h
el
p
fu
l a
n
d
 
in
fo
rm
at
iv
e 
(1
00
%
).
 
2
: D
C
S 
– 
m
ea
n
 p
re
/p
o
st
 
ch
an
ge
 -
7
.1
8
 (
p
=0
.0
28
).
 
K
n
o
w
le
d
ge
 a
n
d
 c
la
ri
ty
 o
f 
ri
sk
s/
b
en
ef
it
s 
in
cr
ea
se
d
. N
o
 
ch
an
ge
 in
 c
an
ce
r-
re
la
te
d
 
d
is
tr
es
s 
(I
ES
).
 
0
.6
4
 
O
th
er
 
(B
el
ko
ra
, 
V
o
lz
 e
t 
al
. 
2
01
2
) 
U
SA
 
D
C
IS
, s
u
rg
er
y,
 
re
co
n
st
ru
ct
io
n
, A
T,
 
tr
ea
tm
en
t 
o
f 
m
et
as
ta
ti
c 
d
is
ea
se
; 5
 
V
id
eo
 D
A
s 
ad
d
re
ss
in
g 
in
d
iv
id
u
al
 
d
ec
is
io
n
s.
 
N
il 
P
re
-p
o
st
 
p
ro
sp
ec
ti
ve
 
co
h
o
rt
 
N
ew
ly
 
d
ia
gn
o
se
d
 
p
at
ie
n
ts
 w
it
h
 
D
C
IS
 o
r 
b
re
as
t 
ca
n
ce
r 
(s
ta
ge
 0
-
IV
),
 s
in
gl
e 
in
st
it
u
ti
o
n
. 
D
A
: 4
39
 
K
n
o
w
le
d
ge
 c
h
an
ge
: m
ea
n
 
sc
o
re
 a
cr
o
ss
 4
 D
A
s,
 4
5%
 
co
rr
ec
t 
p
re
, a
n
d
 7
4
%
 c
o
rr
ec
t 
p
o
st
 D
A
 (
p
<0
.0
0
1
).
 D
C
S:
 
m
ea
n
 d
ec
re
as
ed
 o
f 
0
.5
2
 u
n
it
s 
(p
<0
.0
0
1)
. L
o
w
 b
as
el
in
e 
kn
o
w
le
d
ge
 p
re
d
ic
te
d
 g
re
at
er
 
ch
an
ge
 in
 k
n
o
w
le
d
ge
. H
ig
h
er
 
D
C
S 
an
d
 H
is
p
an
ic
 r
ac
e 
p
re
d
ic
te
d
 g
re
at
e
r 
d
ec
re
as
e 
in
 
D
C
S.
 
0
.6
8
 
(V
o
d
er
m
ai
er
, 
C
as
p
ar
i e
t 
al
. 
2
01
1
) 
M
as
te
ct
o
m
y 
vs
 B
C
S,
 
ch
em
o
th
er
ap
y 
fo
r 
ER
+
 E
B
C
. 
B
ro
ch
u
re
 
R
C
T 
O
p
er
ab
le
 E
B
C
, 
ag
e 
18
-7
5
, 
D
A
: 5
5
 
C
o
n
tr
o
l: 
5
6
 
D
C
S:
 D
A
 g
ro
u
p
 h
ad
 lo
w
e
r 
sc
o
re
s 
at
 e
ac
h
 t
im
e 
p
o
in
t 
an
d
 
o
ve
r 
ti
m
e 
(p
=0
.0
4
7
).
 
0
.6
8
 
75
 G
er
m
an
y 
A
d
ap
te
d
 d
ec
is
io
n
 
b
o
ar
d
. 
G
er
m
an
 
la
n
gu
ag
e.
 
A
n
xi
et
y,
 d
ep
re
ss
io
n
, q
u
al
it
y 
o
f 
lif
e,
 b
o
d
y 
im
ag
e:
 n
o
 
d
if
fe
re
n
ce
 b
et
w
ee
n
 g
ro
u
p
s 
o
ve
r 
ti
m
e.
 
(P
ea
te
, 
M
ei
se
r 
et
 a
l. 
2
01
1
) 
A
u
st
ra
lia
 
Fe
rt
ili
ty
 a
ft
e
r 
b
re
as
t 
ca
n
ce
r 
d
ia
gn
o
si
s.
 
D
A
 b
o
o
kl
et
. 
N
il 
Si
n
gl
e-
ar
m
 
p
ilo
t.
 
EB
C
 d
ia
gn
o
se
d
 
w
it
h
in
 6
-6
0
 
m
o
n
th
s 
p
ri
o
r,
 
ag
e 
18
-4
0
 y
ea
rs
, 
p
re
m
en
o
p
au
sa
l 
at
 d
ia
gn
o
si
s.
 
D
A
: 1
7
 
A
cc
ep
ta
b
ili
ty
: 4
4%
 v
er
y 
h
el
p
fu
l f
o
r 
fe
rt
ili
ty
 d
ec
is
io
n
. 
C
o
n
te
n
t:
 9
4%
 v
er
y/
q
u
it
e 
re
le
va
n
t,
 8
8
%
 r
ig
h
t 
am
o
u
n
t 
o
f 
in
fo
rm
at
io
n
, 1
0
0%
 c
le
ar
 
an
d
 e
as
y 
to
 r
e
ad
, 1
00
%
 
sa
ti
sf
ie
d
 w
it
h
 b
al
an
ce
. 
0
.3
6
 
(P
ea
te
, 
M
ei
se
r 
et
 a
l. 
2
01
2
) 
A
u
st
ra
lia
 
A
s 
ab
o
ve
. 
U
su
al
 c
ar
e 
N
o
n
-
ra
n
d
o
m
is
ed
 
co
m
p
ar
at
iv
e 
p
re
-p
o
st
. 
EB
C
 s
ta
ge
 I-
III
, 
ag
e 
18
-4
0
, 
p
re
m
en
o
p
au
sa
l, 
p
ri
o
r 
to
 a
d
ju
va
n
t 
ch
em
o
th
er
ap
y,
 
d
es
ir
es
 f
er
ti
lit
y.
 
D
A
: 4
8
 
C
o
n
tr
o
l: 
7
2
 
K
n
o
w
le
d
ge
: D
A
 g
ro
u
p
 h
ig
h
er
 
sc
o
re
. 
D
C
S:
 D
A
 g
ro
u
p
 1
4
.7
 v
s 
co
n
tr
o
l 2
9
.3
 (
p
=0
.0
2
) 
at
 1
2
 
m
o
n
th
s.
 
D
ec
is
io
n
al
 r
eg
re
t:
 D
A
 g
ro
u
p
 
4
5
.8
 v
s 
co
n
tr
o
l 4
9
.1
 (
p
=0
.0
3
) 
at
 1
2
 m
o
n
th
s.
 
In
fo
rm
ed
 c
h
o
ic
e:
 n
o
 
d
if
fe
re
n
ce
. 
A
n
xi
et
y/
d
ep
re
ss
io
n
: n
o
 
d
if
fe
re
n
ce
. 
1
 
A
ET
: a
d
ju
va
n
t 
en
d
o
cr
in
e 
th
er
ap
y;
 A
LN
D
: a
xi
lla
ry
 ly
m
p
h
 n
o
d
e 
d
is
se
ct
io
n
; A
T:
 a
d
ju
va
n
t 
th
er
ap
y;
 B
C
S:
 b
re
as
t 
co
n
se
rv
in
g 
su
rg
er
y;
 C
T:
 
ch
em
o
th
er
ap
y;
 D
A
: d
ec
is
io
n
 a
id
; D
C
IS
: d
u
ct
al
 c
ar
ci
n
o
m
a 
in
 s
it
u
; D
C
S:
 d
ec
is
io
n
al
 c
o
n
fl
ic
t 
sc
o
re
; E
B
C
: e
ar
ly
 b
re
as
t 
ca
n
ce
r;
 E
R
+
: e
st
ro
ge
n
 r
ec
e
p
to
r 
76
p
o
si
ti
ve
; I
ES
: i
m
p
ac
t 
o
f 
ev
en
ts
 s
ca
le
; N
/a
: n
o
t 
ap
p
lic
ab
le
; n
r:
 n
o
t 
re
p
o
rt
ed
; R
C
T:
 r
an
d
o
m
is
ed
 c
o
n
tr
o
lle
d
 t
ri
al
; S
D
M
: s
h
ar
ed
 d
ec
is
io
n
-m
ak
in
g;
 S
LN
B
: 
se
n
ti
n
el
 ly
m
p
h
 n
o
d
e 
d
is
se
ct
io
n
. 
77
 Ta
b
le
 2
. Q
u
al
sy
st
 s
co
re
s:
 Q
u
an
ti
ta
ti
ve
 s
tu
d
ie
s 
 
1.Question fully described 
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Figures 
Figure 1. Systematic review flow diagram 
Records identified = 2185 
Unique abstracts screened = 1791 
Full text records assessed for eligibility = 73 
Ineligible = 40 
  Not a patient decision aid = 7 
    Duplicate record (conference abstract) = 14 
    Patient outcomes not reported = 10 
    Review article only = 9 
Ineligible based on title and abstract = 1718 
Duplicate records = 394 
Studies included in analysis = 33 
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APPENDIX A 
Search strategy 
1. exp Breast Neoplasms/
2. ((breast) adj6 (cancer$ or neoplasm* or carcinoma* or tumor* or tumour*)).tw.
3. 1 or 2
4. (advance$ or metasta$ or recurren$).mp. or exp Neoplasm Metastasis/
5. 3 not 4
6. exp Decision Support Systems, Clinical/
7. exp Decision Support Techniques/
8. exp Decision Making/
9. exp Decision Trees/
10. ((decision or decid*) adj6 (support* or aid* or tool* or instrument* or technolog* or
system* or technique* or program* or algorithm* or process* or method* or intervention* or 
material*).tw. 
11. (decision adj (board* or guide* or counsel*)).tw.
12. Interactive health communication.tw.
13. (interacti* adj (internet or online or graphic* or booklet*)).tw.
14. (interacti* adj6 tool*).tw.
15. (interacti* or evidence based) adj3 (risk information or risk communication or risk
presentation or risk graphic*)).tw. 
16. (decision mak* or choice behav*).tw
17. shared decision making.tw.
18. or/ 6-17
19. exp Drug Therapy/
20. exp General Surgery/
86
21. exp Radiotherapy/
22. exp Radiotherapy, Adjuvant/
23. 21 or 22
24. 19 or 20 or 23
25. 9 and 18 and 24
26. limit 25 to animals
27. 25 not 26
28. limit 27 to English language
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Chapter 3: Methods 
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3.1  Overview of methods 
This chapter describes the overarching approach taken during this candidature, to understand the 
decision support needs of women who are candidates for NAST for operable breast cancer, and to 
develop and evaluate a decision aid for that patient population. Subsequent chapters contain the 
publications associated with those studies which describe the methods used for those individual 
studies. 
 
Two studies were conducted to understand patients’ and clinicians’ experiences of NAST and to 
inform the design and content of the decision aid. Development, data collection and analysis of the 
first study took place prior to this candidate’s Doctorate enrolment and as such has been included as 
an appendix. This study, as described in the introduction, involved qualitative analysis of interviews 
with women who had previously been diagnosed with early stage breast cancer, focussing on 
information needs, decision making process and outcomes. The second study recruited breast 
cancer clinicians from Australia and New Zealand, aiming to understand clinical reasons for and 
against offering NAST, perception of patient experience, and logistic considerations. Chapter 4 
contains two publications arising from the results of the clinician survey. These papers also describe 
the methods used in the studies.  
 
The following chapter (5) contains the published protocol for the DOMINO clinical trial, to 
investigate the feasibility and acceptability of the decision aid. That publication details the 
theoretical basis, validity of, and analysis plan for, the questionnaires used in that study. Chapter 5 
also contains the manuscript that reports the results of the DOMINO study. 
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 Thus, in this chapter only a summary of the clinician studies evaluating their experiences of NAST, 
and a more comprehensive description of the decision aid development process, are provided.  
 
3.2  Clinician survey 
The aim of this study was to understand current clinical practice with neoadjuvant systemic therapy 
in Australia and New Zealand. Survey results were intended to: document the spectrum of clinical 
approaches taken by clinicians when offering and prescribing NAST; inform decision aid content and 
design; inform decision aid evaluation study design; and contribute to implementation 
considerations for the decision aid in routine practice. 
 
Design 
The study used a cross-sectional, questionnaire-based study design. This study design is inexpensive 
and allows for results in a short timeframe (Mann et al., 2003). With an adequate sample it can 
provide representative data for the population of interest at a single point in time. However, the 
design is susceptible to recall and response bias. 
 
Participants 
Clinicians were eligible to participate in the survey if they had responsibility for treatment decisions 
for patients with breast cancer, regardless of whether they routinely offer NAST or not. This group 
was expected to be primarily surgeons and medical oncologists, but other breast cancer specialists 
such as radiation oncologists and breast physicians were also eligible to complete the survey.  
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Recruitment 
Participants were identified via an email invitation that was sent to clinician members of 
professional organisations with substantial breast cancer membership. These were: the Australia 
and New Zealand Breast Cancer Trials Group; the Medical Oncology Group of Australia; Breast 
Surgeons of Australia and New Zealand; and the New Zealand Breast Special Interest Group. It was 
expected that there would be overlap in the membership lists, however to maintain confidentiality, 
only publicly available membership lists were screened for duplicates. Therefore, the denominator 
for the response rate was likely to be over-estimated. Non-responders to the initial email were 
subsequently sent 2 reminder emails. The email was brief, and contained 3 hyperlinks, offering 
recipients the option to: (1) complete the survey; (2) decline to complete the survey; or (3) indicate 
that they do not treat breast cancer. Option (3) was intended to reduce the denominator to improve 
the accuracy of the response rate. 
Measures 
A similar survey was not found in a search of the literature, so a custom-designed questionnaire was 
developed in consultation with a multidisciplinary group including medical oncologists, surgeons, a 
psychologist, a breast care nurse and a consumer representative. The resultant survey included 
questions on: respondent demographics; criteria used by clinicians to identify patients eligible for 
NAST; barriers and facilitators to the use of NAST; and interest in NAST in routine practice and as 
part of a clinical trial.  
An optional supplementary questionnaire was included to provide additional information on: 
clinician perception of patient attitudes towards NAST; criteria used by clinicians to select patients 
for NAST clinical trials versus NAST in routine care; clinicians’ interest in a decision aid for patients 
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 offered NAST; and typical patient pathways from diagnosis to treatment. This approach was used on 
the understanding that not all clinicians would have time to complete the full survey, but that some 
would be willing to provide additional useful data. Surgeons and medical oncologists, as the primary 
decision-makers for NAST, were offered the full questionnaire, while other clinicians were only asked 
to complete demographic and barrier questions due to their more peripheral role in guiding 
decisions about NAST. 
 
The survey was broadly relevant to gain a better understanding of current and future neoadjuvant 
clinical practice, and more specifically relevant to decision aid development, evaluation study design 
and implementation. Questions about the proportion of patients treated with NAST, and whether 
clinicians were interested in increasing that proportion, were included to give an indication of clinical 
need at the time, and into the future. The question on preparedness to use a neoadjuvant decision 
aid if it were made available, was included to estimate clinicians’ interest in implementing the 
decision aid. Questions about treatment options in routine care were included to inform the 
description of treatment options included in the decision aid. Questions about patient and system 
barriers were intended to ensure that decision aid content addressed the spectrum of potential 
questions and concerns that clinicians and patients might consider relevant to the decision about 
NAST. Survey questions about patient selection for NAST were included to determine selection 
criteria for the study. Questions about typical referral and treatment patterns were to identify the 
optimal timing of decision aid administration and the appropriate follow-up questionnaire time 
points. 
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Analysis 
Responses were recorded in an online database. Descriptive statistics were used to describe 
responses. Demographics were reported as frequencies, medians and proportions. Pearson chi-
squared tests were used for categorical data for the control preferences scale, and t-tests for 
continuous data to compare the responses of surgeons and non-surgeons to the questions about 
barriers. Statistical significance was set at a p-value of 0.05 for all tests. A logistic regression model 
was fit, including potential predictors for offering NAST. The results of this analysis are presented in 
Chapter 4.  
3.3 Decision aid development 
Based on the analysis of data from patient interviews and clinician survey, it was concluded that a 
decision aid was appropriate for the decision about NAST: clinicians and patients indicated interest, 
and there was potential for ongoing implementation of the decision aid if it was developed. 
Therefore, a decision aid was developed, according to internationally accepted criteria (Coulter et 
al., 2013, Joseph-Williams et al., 2014). First, in March 2014, a literature review identified relevant 
data upon which to base the content of the decision aid, within the framework described by the 
International Patient Decision Aid Standards (IPDAS). The clinician survey took place between April 
and July 2014 and was analysed in August 2014. Content was then revised based on patient 
interview responses, the clinician survey and stakeholder engagement in an iterative process during 
September and October 2014. Between November 2014 and January 2015 the final content was 
professionally formatted into Portable Document Format (PDF) by a graphic design firm (Appendix 
A), before being evaluated in a clinical trial. 
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Development of decision aids 
The IPDAS Collaboration was established in 2003 at the International Shared Decision Making 
Conference in Swansea, Wales, “to enhance the quality and effectiveness of decision aids by 
establishing an evidence-based framework for improving their content, development, 
implementation and evaluation” (page 1, Volk et al., 2013). To standardise decision aid 
development, in 2006 the IPDAS Collaboration developed a checklist to assess the quality of patient 
decision aids (Elwyn et al., 2006), which was updated in 2009 (Elwyn et al., 2009b). The checklist has 
evolved since the inception of the group, and was refined and narrowed using a Delphi consensus 
process in 2012 (Volk et al., 2013). Twelve writing teams were then assembled to write a series of 
manuscripts to update the evidence on each of the 12 core quality dimensions. These manuscripts 
were published in 2013 as a special edition of the journal BMC Medical Informatics and Decision 
Making. A systematic process is recommended for the development of decision aids, including: 
“scoping and design; development of a prototype; ‘alpha’ testing with patients and clinicians; ‘beta’ 
testing in real life conditions; and production of a final version for use and/or final evaluation” (page 
1, Coulter et al., 2013). Key decision aid inclusions are: a clear statement of the choice to be made; a 
balanced description of the advantages and disadvantages of the options available (Feldman-Stewart 
et al., 2013); outcome probabilities associated with the options; graphical representations of data 
(Trevena et al., 2013); and a values clarification exercise (Fagerlin et al., 2013).  
In 2013, the IPDAS Collaboration Delphi consensus resulted in a 44-item checklist (version 4.0) with 
criteria classified as qualifying (n=6), certifying (n=10) and quality (n=28) (Joseph-Williams et al., 
2014b). Nine criteria only apply to decision aids designed for patients considering a diagnostic test, 
rather than a treatment. A study that applied these criteria to a convenience sample of 30 decision 
aids found that most (25/30) qualified as a decision aid, but only three met certification criteria 
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 (Durand et al., 2015). The criteria were feasible to administer, however raters’ scores varied, 
suggesting that clarification of item scoring is required. 
 
Neoadjuvant decision aid development 
Decision aid content was informed by a literature search to identify the most recent, reliable and 
relevant data, which was then critically appraised and summarised according to the criteria 
described by Montori et al. (2013). Chapter 2 of this thesis contains a synthesis of the results of the 
literature search. Sources were: PubMed (https://www.ncbi.nlm.nih.gov/pubmed) (National 
Institutes of Health), Google Scholar (https://scholar.google.com.au/), and The Cochrane Database 
of Systematic Reviews (http://www.cochranelibrary.com/cochrane-database-of-systematic-
reviews/). Search terms included ‘breast neoplasm’, ‘chemotherapy’, ‘neoadjuvant’, ‘endocrine 
therapy’, ‘surgery’. Articles were screened by the PhD candidate by title, and selected based on 
abstract and full text content. Reference lists were checked for additional papers. The expert 
advisory group were asked to provide any additional references that they considered relevant. 
 
The decision aid used in the evaluation study is included as Appendix A. Treatment options in the 
decision aid are: neoadjuvant systemic therapy followed by surgery, or the reverse sequence of 
surgery followed by adjuvant systemic therapy. A general overview of breast cancer treatment is 
presented, with links to additional information. However, the decision aid was not intended to 
replicate currently available resources on these broader treatment options. Advantages and 
disadvantages of neoadjuvant therapy first, or surgery first, approaches are described. A flow 
diagram shows the treatment options and line drawings of breast tumours showed possible 
outcomes with neoadjuvant therapy (complete response, partial response, stable disease, 
progression). To represent probabilities, dot-diagrams were produced to show the likelihood of: 
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 being downstaged from mastectomy to breast conserving surgery; a complete pathological response 
by tumour subtype; and of progression during neoadjuvant therapy. The probability of response, 
and the associated prognostic implications, were informed by breast cancer subtype, as described in 
Chapter 2 (von Minckwitz et al, 2012). 
 
Information presented in a decision aid should be balanced, to avoid introducing biases that might 
influence perception of risk and benefit and treatment choice (Abhyankar et al., 2013). The goal is to 
provide information on options rather than to provide an argument that one option is better than 
the other. Balance can be supported by presenting advantages and disadvantages of options using 
the same text and heading style, and not emphasising one or the other in language or volume of 
information. A neoadjuvant focus required more text and graphics on neoadjuvant therapy, 
compared with the surgery first option. Also, clinician feedback indicated that their offer of 
neoadjuvant therapy was rarely in complete equipoise for each individual patient, which is likely to 
overshadow any possible imbalance in the decision aid (Elwyn et al., 2009a). Despite this, the design 
and content carefully avoided giving any treatment recommendations, whether conditional or 
absolute. 
 
Comparison of two or more options in a decision aid usually requires presentation of quantitative 
outcome probabilities based on best available evidence (Trevena et al., 2013). If presented in an 
appropriate and approachable format, this aims to give the patient a better understanding of the 
likelihood of certain outcomes so that they can put them in context with their personal values. 
Outcome probabilities are ideally presented in written and graphical form, using percentages, 
tailored to the individual (Trevena et al., 2013). For breast cancer patients, probabilities can be 
refined by cancer subtype, such as hormone receptor and HER2, which have different chances of 
pathological complete response (von Minckwitz et al., 2012). Uncertainty about outcomes are 
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presented using text such as ‘around’ and ‘about’ when describing probabilities. A paragraph 
describes five-year survival as a commonly used way of describing outcomes from cancer treatments 
(Early Breast Cancer Trialists’ Collaborative Group, 2005), including the uncertainty of such 
estimates. 
A values clarification exercise towards the end of the decision aid provides an opportunity for the 
user to summarise their perception of the advantages and disadvantages of either option and then 
reach a conclusion about which option they would prefer to choose (Fagerlin et al., 2013). It lists 
potential reasons for choosing either NAST or surgery first, each with space for the patient to 
indicate how important or unimportant each issue is. At the end of the page patients can indicate 
how strongly they are leaning towards either option. Patients are encouraged to write on the values 
clarification exercise page if they have printed it out. This type of values clarification exercise has 
been used in previous decision aids such as that developed for breast cancer prevention (Juraskova 
et al., 2014).  
This decision aid was designed to be easily incorporated into a patient’s diagnostic and treatment 
pathway. It was not intended to be used in isolation, or without external coaching or guidance. 
Guidance is defined by IPDAS as an explicit approach contained within the decision aid to facilitate a 
self-directed approach, while coaching is defined as non-directive support by trained personnel to 
assist decision-making (Stacey et al., 2013). The coach should be someone other than the health 
professional with whom the patient is making a decision. The neoadjuvant decision aid includes 
guidance, with explanations of how a patient would use decision aid to assist with their decision. 
Coaching is not essential, as it is much more resource-intensive. In some centres nurses are available 
in a coaching role (Berger-Hoger et al., 2017). Health professionals who offer patients the decision 
about NAST, and offer the decision aid, are encouraged to demonstrate key features of the decision 
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 aid. This includes showing patients, within the consultation, the graphs and flow diagrams, outcome 
probabilities, tailoring to subtype and demonstrating use of the values clarification exercise. 
 
Health literacy of the target audience is an important consideration when producing a decision aid. 
Patients with low health literacy are less likely to be involved in decisions, ask fewer questions, and 
participate less in patient-centred decision-making (McCaffery et al., 2013). In a systematic review of 
breast cancer decision aids by our group (Chapter 2), only one decision aid was identified as having 
been developed specifically for lower health literacy breast cancer patients (Jibaja-Weiss et al., 
2011), as well as four additional decision aids for specific ethnic or racial groups (Lam et al., 2013, 
Sheppard et al., 2008, Sheppard et al., 2010, Au et al., 2011). To make the neoadjuvant decision aid 
accessible to those with lower health literacy, we aimed to avoid long or technical words, minimise 
sentence and paragraph length, and use pictures and diagrams to represent key concepts. Best 
practice is to write at a year 8 reading level (McCaffery et al., 2013), however we were unable to 
achieve this, despite consumer and breast cancer advocate input. According to in-built Microsoft 
Word literacy analysis software, the Flesch-Kincaid reading grade was approximately year 10. This is 
consistent with such a highly specialised topic area. A trade-off was made between reading level and 
total length of the decision aid, with a decision that a shorter document, supplemented by diagrams 
and pictures, would be preferable to protracted explanations. A glossary was used to define 
technical terms, and reputable resource website links were also provided for additional reading. 
These websites were: Breast Cancer Network Australia, Cancer Australia, The Cancer Council, 
MacMillan Cancer Support and the Australia and New Zealand Breast Cancer Trials Group. 
 
Patient narratives are often used in patient decision aids to provide context and to engage patients 
(Bekker et al., 2013). Narratives can also help lower literacy patients become more informed and 
involved (Jibaja-Weiss et al., 2011). However, a systematic review concluded that these narratives 
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 might introduce bias and should be avoided until improved evidence is available on how narratives 
should be used within a decision aid whilst maintaining balance (Winterbottom et al., 2008). Patient 
narratives were not included in the neoadjuvant decision aid. 
 
The prototype decision aid was sent to a group of key stakeholders for review and feedback as 
suggested by the IPDAS Collaboration decision aid development process document (Coulter et al., 
2013). This group included medical oncologists, a breast surgeon, a psycho-oncologist, breast cancer 
consumer representatives, breast care nurses and a cancer clinical trial coordinator. They were 
asked whether the decision aid information was balanced, comprehensive, and comprehensible, and 
whether there was anything that should be added or removed. Feedback was compiled informally, 
without the use of specific questionnaires, and the decision aid was edited throughout the process. 
Content control was maintained by ensuring that changes were tracked electronically, and that 
changes could only be accepted using a password known to the core editing team. 
 
In a second round of stakeholder review, the revised decision aid was sent to an additional group 
who had not previously seen it. This group included medical oncologists, a radiation oncologist, 
breast surgeons, representatives of a breast cancer support organisation and a breast care nurse. 
The minimal disagreement that occurred was resolved through discussion amongst the core team, 
comprising two medical oncologists (one the PhD candidate) and a psychologist with expertise in 
decision aids. Disagreement related to the level of detail in the content, and the balance between 
the description of adjuvant and neoadjuvant options. The decision aid was sent to the Hunter New 
England Local Health District Human Research Ethics Committee as part of the application for ethical 
clearance to proceed with the decision aid evaluation study. In line with the ethics committee 
suggestions, changes were made to improve the balance in presentation of options. Specifically, 
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 changes included larger headings in the surgery section, and a more detailed description of the 
advantages and disadvantages of a surgery-first approach. 
 
After the initial development process, the final decision aid met 31 of 33 items listed in version 4.0 of 
the IPDAS Collaboration treatment decision aid checklist. The criteria that were not met were: (1, 
quality) the natural history of the untreated condition is not described; and (2, certification) an 
update plan is not specified. Inclusion of a description of the natural history of untreated early stage 
breast cancer was not considered appropriate. With uncertain funding, and pending results of the 
initial study, we were unable to specify an update plan. Two further items relate to the results of a 
study to evaluate the decision aid, which could not be reported until after the study was completed. 
 
The final content of the decision aid was proofread for typographical errors, consistency of language 
and content, then formatted by a professional graphic design firm. Graphics were redesigned, and 
photographs depicting patient discussions with clinical personnel were inserted. PDF format was 
chosen as a widely used fixed formatting electronic document type. The designer was asked to 
minimise the file size, so that it could be downloaded rapidly on a standard household internet 
connection, resulting in a 712-kilobyte file. It was produced in colour to be viewed online or printed. 
Content was not lost if the document was printed in black and white.  The document was 26 pages 
long, including front and back cover, contents page and 2 pages for note-taking and additional 
resources. Because evidence is limited regarding best practice for delivering decision aids on the 
internet, this aspect of the design was predominantly opinion-based and pragmatic (Hoffman et al., 
2013). 
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 In summary, an evidence-based decision aid was developed in line with current best practice. 
Content was refined based on two rounds of feedback from a group with relevant clinical, 
theoretical and consumer perspectives. The final version was then professionally formatted and 
uploaded onto the study website. It was not made available for routine use until after the decision 
aid study had completed recruitment and the results reported.  
 
3.4  Decision aid evaluation study 
One of the core decision aid quality criteria is to field test the decision aid with end-users (both 
patients and clinicians) (Coulter et al., 2013). The methodology for the study to evaluate the decision 
aid is presented as a separate published manuscript in the first part of chapter 5, preceding the 
manuscript that presents the results of that study.  
 
Outcome measures 
The primary outcomes in the decision aid evaluation study were patient and clinician acceptability, 
and feasibility of use in practice. Acceptability was defined as the top two responses to the question 
“I would recommend this decision aid to other women with breast cancer in this situation?” for 
patients; and for clinicians who answered yes to the question “would you use the decision aid in 
routine practice?” The threshold for a positive primary outcome was set at 50% feasibility and 
acceptability based on expert advice, and a lack of available applicable literature. A literature review 
failed to identify relevant studies on which to base these thresholds.  
 
References to support the reliability and validity of the questionnaires that formed the outcomes of 
the evaluation study are included in the publication. Measures were chosen as a combination of 
those that are robust and in common use for decision aid studies, and those that were relevant to 
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 neoadjuvant breast cancer treatment and decision-making. Relevance was determined by an expert 
group including medical oncologists, surgeons, a psychologist and consumers. The statement format 
of the Decisional Conflict Scale was used, with 16 questions each with five response categories 
(O’Connor et al., 1995). The control preferences scale used a single item, as used by Strull et al. 
(1984). 
 
The protocol manuscript describes the decision aid evaluation study as a pre-post study, while the 
results manuscript describes it as a longitudinal study. The reason for this change was that a study 
with four assessment time points over a years’ duration is more consistent with a longitudinal study 
(Lavrakis, 2008). This terminology may also be more familiar to a diverse readership. Hence, a 
change in terminology was considered appropriate. 
 
One additional publication, containing the results and analysis of interviews of study participants, is 
included as an appendix. This is not included as a chapter because that aspect of the study was led 
by another researcher, however the results come from the core study and are directly relevant to 
this thesis. 
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 Chapter 4: Survey of clinicians 
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4.1  Publication 2: A survey of Australian and New Zealand clinical practice with neoadjuvant 
systemic therapy for breast cancer 
 
Zdenkowski N, Butow P, Mann GB, Fewster S, Douglas C, Boyle FM. Decisions about neoadjuvant 
systemic therapy for breast cancer: A survey of Australian and New Zealand (ANZ) specialists. 
Australia and New Zealand Journal of Surgery 2015;85:797-799. 
 
This manuscript reports results from an online survey of Australian and New Zealand breast cancer 
specialists. It focusses on clinicians’ perception of control over the decision about whether a patient 
should receive neoadjuvant systemic therapy. The control preferences scale is one method of 
measuring the degree of shared decision-making in clinical encounters (Degner et al., 1997b). A skew 
in this scale towards clinician-directed decisions supports the need for a shared decision-making tool 
such as a decision aid to redress this imbalance.  
 
Author contributions 
Conception and design: NZ, FB, PB, SF, GBM 
Participant recruitment: NZ 
Data collection: NZ 
Data analysis and interpretation: NZ, FB, PB, CD, GBM, SF 
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Women with operable breast cancer who receive neoadjuvant systemic therapy (NAST) followed by 
optimal locoregional therapy have equivalent disease-free and overall survival outcomes to those 
who receive adjuvant systemic therapy. For women with larger tumours, NAST has some advantages 
over traditional sequencing including: allowing breast conserving surgery for some women who 
would otherwise have required a mastectomy; reducing the resected volume; and providing 
information on prognosis1. Clinical trials using NAST can identify treatment strategies for early breast 
cancer using pathological complete response (pCR) as an endpoint for provisional drug approval. The 
option of NAST for operable breast cancer is endorsed by international guidelines and by patients2,3. 
Read et al. make a reasonable case that any woman who is clearly a chemotherapy candidate should 
have the option to receive it before surgery, particularly those with tumour subtypes, such as triple 
negative or HER2 positive, that are most likely to respond well1. However, the rate of NAST use in 
Australian and New Zealand women with operable breast cancer was found to be only 2.75%, based 
on unpublished data from the BreastSurgANZ Quality Audit. 
Using a cross-sectional cohort design, we sought to understand how NAST is currently used in 
Australia and New Zealand in order to inform strategies to optimise its appropriate use. Here we 
report results of survey questions about decision-making control to determine how involved patients 
are in the decision to receive NAST. Clinician members of major professional organisations 
representing Australian and New Zealand breast cancer specialists were invited to participate by 
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email. This study received ethics committee approval and is registered on the Australia and New 
Zealand Clinical Trials Registry (www.anzctr.org.au, ACTRN12613000658718).  
Control over typical NAST decisions was measured using  an adaptation of the control preferences 
scale, a 5-point scale developed to describe typical decision-making agency for a medical decision4. 
Of 77 respondents, 37 were surgeons and 40 were non-surgeons. Two (3%) felt that the doctor 
should decide, 38 (49%) felt that the doctor should decide, taking the patients view into account and 
37 (48%) felt that the decision should be shared equally. No respondents reported that patients had 
more than equal control over the final decision about whether or not they received NAST. There was 
no difference in the level of decisional control between surgeons and non-surgeons. The decision 
about whether to have NAST was typically made at the time of the initial specialist consultation 
(56%) or at the multidisciplinary team meeting (31%). 
Decision-making control over the decision about NAST was skewed towards clinician-directed care, 
indicating that most respondents felt the need to direct patients in their decision about NAST. An 
Australian study found that breast cancer patients typically want to share decisions about their 
treatment, particularly in the early stages5. In this study around one quarter of patients preferred 
greater than equal control over treatment options, and patients who were involved in decision-
making experienced greater satisfaction and lower decisional conflict5. Decision aids in other areas 
have been associated with decreased decisional conflict, a more active role in the decision and 
greater satisfaction with the decision6. Clinicians who responded to our survey indicated that they 
would offer a patient decision aid for women who have been offered NAST, which may allow women 
to become more involved in the decision and to achieve better decision-related outcomes.  
A shared decision represents the patient and clinician reaching a decision based on the available 
evidence, after informed consideration of the options. Ideally, patients would be offered options 
where they are available and be allowed to make voluntary choices within the bounds of their ability 
to make such choices. Shared decision-making involves a trusting patient-doctor relationship where 
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autonomy is respected, but the decision is still supported by the doctor7. We do not advocate that 
patients should bear all responsibility for their decisions, as this can actually undermine autonomy in 
situations where interdependence is part of effective decision-making. Much of the responsibility for 
initiating the discussion about NAST lies with the surgeon, who has several complex issues to present 
to their patient in a limited period of time. This type of complex decision-making is influenced by 
both evidence and a patient’s intuition, feelings and communication with trusted others8. 
The generalisability of this study is limited by a low response rate, however the denominator is likely 
to have been overestimated. Reasons for this include: recipients who are members of more than 
one organisation being counted more than once; and non-response from clinicians who do not treat 
breast cancer. Reliance on clinicians’ retrospective estimates of their practice may bias results. 
Interpretation of the control preferences scale may have differed between clinicians. 
In conclusion, this group of experienced and engaged Australian and New Zealand breast cancer 
specialists tended to exert control over the decision about NAST, rather than allowing some patients 
to make the final decision. Strategies to increase patient involvement, such as a decision aid, and 
greater awareness about NAST, may improve decision-related outcomes and give more patients 
access to a treatment strategy that they may prefer. The authors are evaluating a new decision aid 
for this population in a prospective observational trial (ANZ1301 DOMINO). This may empower 
patients to have a more equal role in the decision-making about NAST. 
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 4.2  Publication 3: Decisions about neoadjuvant systemic therapy for breast cancer: A survey of 
Australian and New Zealand (ANZ) specialists 
 
Zdenkowski N, Butow P, Mann GB, Fewster S, Beckmore C, Isaacs R, Douglas C, Boyle FM. A survey of 
Australian and New Zealand clinical practice with neoadjuvant systemic therapy for breast cancer. 
Internal Medicine Journal 2016;46:677-683. 
 
This online survey aimed to understand the landscape of neoadjuvant systemic therapy in Australia 
and New Zealand from a clinician’s perspective. This included questions about routine practice, 
barriers and facilitators and shared decision-making. The results informed the design of the 
neoadjuvant decision aid study. Clinical practice patterns were considered to be an important 
contribution to the success of the evaluation study by ensuring that the decision aid could be 
intercalated into routine practice. This study would also inform ongoing implementation of the 
decision aid. 
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Abstract 
Aim 
Neoadjuvant systemic therapy (NAST) has become an established treatment option for women with 
operable breast cancer. We aimed to better understand NAST treatment patterns, barriers and 
facilitators in Australia and New Zealand. 
Methods 
We undertook a cross-sectional survey of the current clinical practice of Australian and New Zealand 
breast cancer specialists. Questions included referral patterns for NAST; patient selection; logistics; 
decision-making and barriers. 
Results 
Of 207 respondents, 162 (78%) reported routinely offering NAST to selected patients with operable 
breast cancer (median 9% of patients offered NAST). Specialty, location, practice type, gender or 
years of experience did not predict for offering NAST. 45% and 58% wanted to increase the number 
of patients who receive NAST in routine care and in clinical trials, respectively. Facilitators included 
the multidisciplinary team meeting and access to NAST clinical trials. Specialist-reported patient 
barriers included: patient desire for immediate surgery (63%% rated as important/very important); 
lack of awareness of NAST (50%); concern about progression (43%); and disinterest in downstaging 
(32%). Forty-three percent of participants experienced system-related barriers to the use of NAST, 
including: other clinicians’ lack of interest (27%); lack of clinical trials (24%); and unacceptable wait 
for a medical oncology appointment (37%).  
Conclusion 
This group of Australian and New Zealand clinicians are interested in NAST for operable breast 
cancer in routine care and clinical trials. Patient- and system-related barriers that prevent the 
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 optimal uptake of this treatment approach will need to be systematically addressed if NAST is to 
become a more common approach. 
 
Body 
Introduction 
Neoadjuvant systemic therapy (NAST) has become a treatment option for selected women with 
larger (>2cm) early stage breast cancer. Patients who receive NAST followed by optimal locoregional 
therapy have equivalent disease-free and overall survival outcomes to those who receive systemic 
therapy after surgery1. NAST has some advantages over a surgery-first approach including: 
downstaging to breast conserving surgery for some women who would otherwise have required a 
mastectomy; reducing the volume of surgically resected breast and axillary tissue; and providing 
prognostic information depending on the degree of tumour response2-4. Novel treatment strategies 
for early breast cancer may receive fast-track provisional regulatory approval based on pathological 
complete response (pCR) as an early endpoint, particularly in triple-negative and HER2 positive 
disease where pCR is more likely to act as a surrogate of survival outcomes. However meta-analyses 
have not yet shown a correlation between pCR and disease-free or overall survival endpoints2,4 and 
confirmatory results from trials powered for these survival outcomes are required for full approval5.  
Given equivalent survival outcomes, NAST is an option that may be preferred by some patients with 
operable breast cancer, however the rate of use in Australia and New Zealand appears low, at fewer 
than 3% of all operable breast cancer patients6. International guidelines support the use of NAST as 
an option for operable breast cancer7-9, patient advocates support the use of neoadjuvant clinical 
trials10, and patients with a past diagnosis of breast cancer also endorse the option of NAST being 
discussed with patients as part of routine clinical care11. As such, NAST is expected to remain an 
important treatment option for women with early breast cancer and their treating clinicians. 
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 Data are limited on routine clinical practice, facilitators and barriers to the use of NAST both 
internationally and in Australia/New Zealand. We sought to understand how NAST is currently used 
in Australia and New Zealand, in order to inform strategies to optimise its appropriate use in routine 
practice and in clinical trials. 
Material and methods 
Population and design 
A cross-sectional cohort study of Australian and New Zealand breast cancer specialists was 
undertaken. Eligible participants were clinicians who treat patients with breast cancer, including 
medical oncologists, surgeons, radiation oncologists and breast physicians. An email invitation was 
sent to clinician members of the Australia and New Zealand Breast Cancer Trials Group (ANZBCTG), 
the Medical Oncology Group of Australia, Breast Surgeons of Australia and New Zealand 
(BreastSurgANZ) and the New Zealand Breast Special Interest Group, the major professional bodies 
representing breast cancer specialists in the region. Some clinicians are members of multiple 
organisations, however to maintain members’ confidentiality, only duplicates between the ANZBCTG 
distribution list and the BreastSurgANZ members on their publically available website could be 
removed. A total of 930 invitation emails were sent, excluding known duplicates. The invitation 
email contained brief description of the study and a hyperlink to participate in an online survey, 
hosted by the ANZBCTG. Two reminder emails were sent.  
Questionnaire 
The questionnaire was developed by a multidisciplinary group including medical oncologists, a 
surgeon, a psychologist and a consumer, then pre-tested and modified based on feedback from a 
small group of clinicians who had not previously seen it. Three levels of participation were possible. 
Surgeons and medical oncologists, as the target audience, were offered (1) a core questionnaire and 
(2) an optional supplementary questionnaire (Appendix). Other specialists were offered (3) an 
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 abbreviated questionnaire about demographics and barriers only. This design aimed to optimise the 
completion rate by allowing clinicians to minimise their time commitment by completing the core 
questionnaire only, and to add value if they were willing to spend additional time on the 
supplementary questionnaire. The core questionnaire included: demographics; neoadjuvant referral 
patterns; patient and tumour characteristics for which NAST was considered appropriate; barriers to 
the use of NAST; and interest in offering NAST as a treatment option for routine care and clinical 
trials. The supplementary questionnaire included questions on clinical workup and management of 
NAST patients; decision making; perceived patient experiences; and patient selection for clinical 
trials compared with routine care.  Data from this survey about clinical decision-making control 
preferences about neoadjuvant therapy have been published previously, and will not be reported 
here12. 
Analysis 
Descriptive statistics were used to describe responses. Demographics were reported as frequencies, 
medians and proportions. Pearson chi-squared tests were used for categorical data, and t-tests for 
continuous data. Statistical significance was set at a p-value of 0.05 for all tests. A logistic regression 
model was fitted including potential predictors for offering NAST. 
This study was designed and conducted according to principles of the Declaration of Helsinki and the 
International Conference on Harmonisation Good Clinical Practice (ICH-GCP) guidelines. All 
participants provided informed, voluntary consent prior to participation. The study was 
prospectively approved by the Hunter New England Human Research Ethics Committee and was 
prospectively registered on the Australia and New Zealand Clinical Trials Registry 
(www.anzctr.org.au, ACTRN12613000658718).  
Results 
Core questionnaire 
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 Between April and July 2014, 225 responses were received. After excluding 13 who reported not 
treating breast cancer patients and 5 who did treat breast cancer but indicated that they did not 
want to complete the survey, 207 responses were analysed, representing a conservative response 
rate of 23% (207/917). Eighty clinicians answered the supplementary questionnaire. Responses were 
received from Australia (n=155) and New Zealand (n=52): 112 surgeons (54%), 87 medical 
oncologists (42%), 6 radiation oncologists (3%) and 2 breast physicians (1%). This included 120 
metropolitan, 81 regional and 6 rural practitioners. Fifty-two were primarily academic, 111 public 
hospital and 44 private practitioners. There were equal numbers of males and females. Forty-five 
respondents (22%) reported not offering NAST, and 162 (78%) reported routinely offering NAST to 
selected women with operable breast cancer. 
Respondents saw a median of 80 newly diagnosed breast cancer patients per year, of whom a 
median of 80% (interquartile range [IQR] 70-80%) were considered to have operable disease at the 
time of diagnosis. Clinicians reported offering NAST to a median of 9% (IQR5-15%) of their patients 
with operable disease, of whom a median of 90% (IQR 70-90%) agreed to see a medical oncologist; a 
median of 85% (IQR 70-90%) of those who saw a medical oncologist started NAST. Reasons for 
recommending or offering NAST, by the 162 respondents who use this treatment strategy, are 
shown in Figure 1. NAST was offered as a treatment option for selected patients with for all breast 
cancer subtypes, shown in Table 1, but more frequently to women with HER2 positive and triple 
negative cancers. Comparison of subtypes, by hormone receptor and HER2 status, did not reach 
statistical significance. The HER2 positive and triple negative subtypes were also numerically more 
likely to be offered NAST for a smaller primary tumour size. In univariate analysis, >10 years of 
experience as a specialist predicted for offering NAST (p=0.048), but specialty, location, practice type 
and gender were not significant predictors. In a multivariate model including specialty, location, 
practice type, gender or years of experience there were no significant predictors for offering NAST 
(data not shown). 
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 Barriers 
Table 2 lists patient, system, clinician and clinical trial-related barriers to the use of NAST. Of the 165 
responses to this part of the questionnaire, more non-surgeons than surgeons reported clinician or 
system-related barriers (37% vs 73%, p<0.001). The most commonly reported barriers overall were 
patient-related: desire for immediate surgery, lack of awareness of NAST, fear of progression on 
NAST, and lack of interest in downstaging. Compared with surgeons, more non-surgeons indicated 
that patients’ lack of awareness of NAST (60% vs 41%, p=0.016), other clinicians’ disinterest in NAST 
(43% vs 13%, p<0.001), and lack of NAST clinical trials (41% vs 7%, p<0.001) to be important barriers. 
Interest in offering NAST in routine care and in clinical trials 
Of 165 responses to this question, 74 (45%) and 96 (58%) indicated a preference to increase the 
number of patients who receive NAST as part of routine care and as part of a clinical trial 
respectively. Ninety-one (55%) felt that the number of their patients given NAST in routine care was 
appropriate, and 69 (42%) felt that the right number of patients are accessing NAST clinical trials. 
Importantly, there were no respondents who believed that NAST is being given too often, as routine 
care or in clinical trials. Fifty-eight (35%) had enrolled one or more patients on a NAST clinical trial. 
Considering only the 45 respondents who did not routinely offer NAST for operable breast cancer, 20 
(44%) were interested in offering more of their patients NAST in routine care, and 29 (64%) were 
interested in offering more patients NAST in a clinical trial. In sum, 193/207 (93%) of respondents 
demonstrated interest in offering NAST to at least some of their patients with operable breast 
cancer. 
Supplementary questionnaire 
NAST patient workup and treatment 
In the supplementary questionnaire, 77/80 (96%) respondents indicated that a core biopsy was 
required to make treatment decisions, and for 64 (80%), a core biopsy was done as the first 
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diagnostic biopsy for these patients. Fifty-six (70%) place a radio-opaque or other marker in the 
breast primary, while only two (3%) place a marker in involved or suspicious lymph nodes. For 
staging of clinically node negative patients, 42/80 (53%), 45 (56%), 1 (1%) and 14 (18%) would order 
a bone scan, CT chest abdomen and pelvis, PET scan and breast MRI respectively. For those with 
clinically involved nodes, the proportions were 61/80 (76%), 61 (76%), 2 (3%) and 13 (16%) 
respectively. In clinically node negative patients at the time of diagnosis, a sentinel node procedure 
was done routinely prior to NAST by 26 (33%) and after NAST by 47 (59%). Six (8%) respondents 
would always recommend an axillary dissection for NAST patients. Seventy-one (89%) felt that it was 
acceptable for up to 14 days to elapse after diagnosis before a treatment decision was made, and 50 
(62%) felt that treatment should start within 14 days of that decision. 
Patient selection for clinical trials 
Respondents were more likely to offer NAST if a clinical trial was available for patients with the 
following characteristics: smaller primary tumour (51/78 [65%] of respondents); oestrogen receptor 
positive (62 [80%]) cancer; and candidates for breast conserving surgery (63 [81%]). 
Decision-making and patient experience 
Patients were presented at the multidisciplinary team meeting (MDT) in every NAST case by 29/76 
(38%) of respondents, most of the time by 19 (25%), some of the time by 24 (32%) and never 
presented at the MDT by 4 (5%). The decision about whether to have NAST was made at the time of 
the initial specialist consultation (43/76 [56%]), the MDT (24 [31%]), at a follow-up appointment (8 
[11%]) or over the phone (2 [3%]). Seventy-six percent of respondents had not identified greater 
rates of anxiety in patients receiving NAST compared to those receiving adjuvant systemic therapy. 
Eighty-six percent (66/76) stated that they would offer a decision aid developed specifically for 
women with operable breast cancer who were candidates for NAST. 
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 Discussion 
The majority of clinicians in this sample reported interest in NAST for operable breast cancer, 
offering and in some instances recommending NAST to their patients. Reasons included: to facilitate 
immediate breast reconstructive surgery and to downstage locally advanced or larger breast cancer. 
However, barriers were also identified. To improve access to this treatment option, these patient, 
clinician, system and clinical trial-related barriers will need to be addressed.  
Our survey could not directly ascertain the total proportion of patients being offered NAST, however 
an indirect estimate is 6-7%, based on the proportion who were offered, agreed to see a medical 
oncologist, and then went on to receive NAST. While respondents reported ‘routinely’ offering NAST 
to operable patients, the proportion was low, suggesting that only highly selected patients are 
offered this treatment strategy. Read et al. report that 2.75% of Australian and New Zealand women 
with operable breast cancer receive NAST, based on an unpublished quality audit6. Our estimated 
rate is likely to be spuriously high due to overrepresentation by respondents with an interest in 
NAST.  
Read et al. reasonably assert that any woman who is clearly a candidate for chemotherapy should 
have the option to receive it before surgery. Increasingly, the decision about chemotherapy is 
strongly influenced by tumour subtype as indicated by hormone receptors, HER expression and in 
some cases multiparametric gene expression profiling. Patients with triple negative and HER2 
positive tumours are more likely to receive chemotherapy compared with those hormone receptor 
positive tumours7. These factors are all assessable in the pre-operative setting, allowing a judgement 
about whether neoadjuvant chemotherapy is indicated. An Australian single institution retrospective 
study found that chemotherapy was recommended for 99% of lymph node positive patients, and 
90% of patients with tumours >2cm in size13. Patients who are candidates for adjuvant 
chemotherapy may prefer to receive their chemotherapy pre-operatively if given the opportunity.  
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 One might consider more recently qualified, metropolitan, or academic clinicians to be more likely to 
offer NAST, however we could not identify predictors of offering NAST. This may be due to 
respondents having a high average level of interest in NAST, and a relatively small sample size. The 
large proportion of clinicians who present their NAST patients at the MDT prior to surgery indicates 
that interdisciplinary communication is occurring in this area. Still, 27% felt that other clinicians’ 
disinterest in NAST was an important barrier.  
Compared with surgeons, medical oncologists’ workflow may require a greater fundamental change 
to adapt to routine NAST. Proffered reasons for offering NAST included allowing time for surgical 
planning and for genetic testing. The use of NAST in these situations shifts the immediacy of 
treatment from surgeons to medical oncologists, who are used to having time after surgery before 
giving adjuvant chemotherapy. Potential solutions include allocating neoadjuvant-specific new 
patient appointments, having a combined clinic with medical oncologists and surgeons, or having a 
rapid response system for NAST referrals. In Germany, the pathway to NAST is more straightforward, 
as breast surgeons also prescribe chemotherapy for their patients. Having one clinician present both 
sides of the story means that biases towards offering one’s own treatment first are less likely to be a 
factor in the discussion, whether overt or implied. 
Considering the large proportion of patients in our study who, when offered NAST, were willing to 
see a medical oncologist and then went on to receive it, patient willingness does not appear to be a 
major barrier11. Despite this, clinicians indicated that patient-related barriers were the biggest 
impediment to NAST use. Barriers such as lack of prior awareness or unfounded concern about 
progression on chemotherapy may be addressed through increased awareness about NAST as an 
option, via breast cancer advocacy organisations and the media. More widespread use of NAST will 
increase awareness via discussions amongst patients, their families and the broader healthcare 
community. The use of a decision aid has been shown to increase knowledge and improve decision-
related outcomes, and may be warranted in this situation14,15. 
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Clinical trials have accelerated the use of NAST, due to the promise of pCR acting as a surrogate 
endpoint for more rapid approval of new drugs and indications5. A lack of available neoadjuvant 
clinical trials was a commonly cited barrier, particularly for medical oncologists. The NeoSphere trial 
demonstrated a significantly higher pCR rate in patients who received pertuzumab along with 
standard chemotherapy and trastuzumab, leading to FDA approval and a change in clinical 
practice16. This finding is controversial due to the lack of a significant difference between 
trastuzumab and trastuzumab/lapatinib in the adjuvant ALTTO trial disease-free survival17, despite a 
21% difference in pCR rate in the similar (but not identical) neoadjuvant NeoALTTO trial18. Statistical 
modelling has, however, demonstrated that a large difference in pCR would be required to show a 
small difference in disease-free survival, concluding that the neoadjuvant model remains an 
important drug development model19. More than half of the clinicians we surveyed wanted to 
increase the number of patients treated on a NAST trial, and were willing to treat patients with 
lower risk characteristics such as smaller tumour size, candidates for breast conserving surgery and 
hormone receptor positive tumours. Access to clinical trial was limited, with only 35% reporting ever 
having a patient enrolled on a NAST clinical trial. 
Patients who achieve pCR in the breast and lymph nodes have a better prognosis than those who do 
not achieve pCR, irrespective of immunohistochemical subtype4. This may be of value to clinicians 
and patients, however thus far no trial has demonstrated an advantage to additional adjuvant 
therapy in patients who did achieve pCR. Lack of pCR is an entry criterion for a number of clinical 
trials, such as the PenelopeB trial (NCT01864746), due to the need for novel treatment strategies in 
these poor prognosis patients.  
Our study is limited by its low response rate, which is likely to be artificially low due to double 
counting of recipients who are members of multiple groups and survey invitations sent to non-
breast cancer clinicians, thus inflating the denominator. It is not possible to quantify the number of 
non-responders who did not treat breast cancer patients and would have been ineligible. Missing 
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data increased with later questions, particularly the last set, regarding barriers. Respondents 
typically had extensive experience treating breast cancer, and may have been more up-to-date on 
current evidence for breast cancer treatment. Rural and private practitioners were under-
represented, which may bias the reported barriers. Techniques attempting to increase the response 
rate by identifying and removing ineligible participants from the denominator were unsuccessful. 
Conclusion 
This group of Australian and New Zealand breast cancer specialists are interested in offering their 
patients NAST in both routine clinical care and in clinical trial settings. There are patient and system 
related barriers that should be addressed in order for clinicians to be able to offer their preferred 
optimal treatment to their patients, and for patients to be able to access a treatment option that 
they may prefer. We are currently evaluating a decision aid for women with operable breast cancer 
who have been offered NAST, which may reduce patient-related barriers. 
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 Figure 1. Clinicians' reasons for offering/recommending neoadjuvant systemic therapy 
 
 
  
0% 20% 40% 60% 80% 100%
Test systemic therapy effectiveness
Plan for definitive surgery
Any adjuvant chemotherapy candidate
Await genetic testing results
Downstage to breast conserving surgery
Neoadjuvant clinical trial
Downstage locally advanced disease
Plan for immediate reconstruction
Recommend Offer Do Not Offer
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 Table 1. Patient characteristics for whom clinicians would consider NAST.  
  
HR+/HER2- HR+/HER2+ HR-/HER2+ TNBC Total 
  N=162† 
NAST offered to this subtype 65% 74% 76% 71% 71% 
Smallest breast tumour size for 
routine NAST 
<1cm 0% 0% 1% 1% 0% 
1-1.9cm 3% 7% 10% 12% 8% 
2-2.9cm 10% 21% 26% 22% 20% 
3-4.9cm 27% 22% 22% 23% 23% 
≥5cm 60% 50% 42% 42% 48% 
Axillary lymph node status + or - 66% 84% 88% 89% 82% 
Inoperable disease only 45% 21% 17% 20% 24% 
If downstaging from mastectomy to BCS desired 51% 63% 64% 62% 60% 
Any mastectomy candidate 22% 31% 33% 31% 29% 
Clinical trial participants only 39% 26% 26% 32% 30% 
†Respondents who reported offering NAST. BCS: breast conserving surgery; HR: hormone receptor; 
NAST: neoadjuvant systemic therapy; TNBC: triple negative breast cancer; +/-: positive/negative; BCS: 
breast conserving surgery 
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 Table 2. Barriers to the use of neoadjuvant systemic therapy 
 Important/very important, N (%) p-value† 
 Surgeon 
n=85 
Non-surgeon 
n=80 
Total 
n=165 
 
Patient factors     
Desire for surgery as soon as possible 54 (64) 50 (63) 104 (63) 0.891 
Fear of progression on NAST 39 (46) 32 (40) 71 (43) 0.446 
Not interested in downstaging 32 (38) 20 (25) 52 (32) 0.081 
Lack of awareness about NAST 35 (41) 48 (60) 83 (50) 0.016 
System/Clinician factors     
Other clinicians not interested 11 (13) 34 (43) 45 (27) <0.001 
Inability to obtain a timely medical 
oncology appointment 
13 (15) 11 (14) 24 (15) 0.779 
Unacceptable wait for chemotherapy 9 (11) 6 (8) 15 (9) 0.490 
Too difficult to coordinate 9 (11) 9 (11) 18 (11) 0.892 
Too difficult to get an appointment with 
other clinicians 
8 (9) 5 (6) 13 (8) 0.451 
Insufficient evidence for the use of NAST 
for operable breast cancer 
7 (8) 8 (10) 15 (9) 0.694 
Clinical trial factors     
No clinical trials available 6 (7) 33 (41) 39 (24) <0.001 
No institutional capacity for clinical trials 8 (9) 9 (11) 17 (10) 0.698 
Competing adjuvant trials 4 (5) 3 (4) 7 (4) 0.761 
†p-value (chi2) for comparison of Surgeon and Non-surgeon for each factor. NAST: neoadjuvant 
systemic therapy.  
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Chapter 5: Decision aid evaluation study 
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5.1  Publication 4: A Decision Aid for Women Considering Neoadjuvant Systemic Therapy for 
Operable Invasive Breast Cancer: Development and Protocol of a Phase II Evaluation Study 
(ANZ1301 DOMINO) 
 
Zdenkowski N, Butow P, Hutchings E, Douglas C, Coll JR, Boyle FM. Development of a decision aid for 
women considering neoadjuvant systemic therapy for operable invasive breast cancer; and protocol 
of a phase II study evaluating that decision aid (ANZ1301 DOMINO). JMIR Research Protocols 
2016;5:e88.   
 
This manuscript describes the protocol for the study to evaluate the feasibility, acceptability and 
decision-related outcomes of the neoadjuvant systemic therapy decision aid. It presents the 
rationale for the study, describes decision aid design, and justifies primary and secondary study 
outcomes measure selection. Study processes are outlined, including recruitment, consent, 
questionnaire administration and analysis. 
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Abstract 
Introduction 
Neoadjuvant systemic therapy is offered to selected women with large and/or highly proliferative 
operable breast cancers. This option adds further complexity to an already complex breast cancer 
treatment decision tree.  Patient decision aids are an established method of increasing patient 
involvement and knowledge while decreasing decisional conflict. There is currently no decision aid 
available for women considering neoadjuvant systemic therapy. 
Methods 
We describe the development of a decision aid for women diagnosed with operable breast cancer 
and considered suitable for neoadjuvant systemic therapy, and the protocol for a multi-centre pre-
post study evaluating the acceptability and feasibility of the decision aid.   
Decision aid: Developed through literature review, expert advisory panel, adherence to the 
International Patient Decision Aid Standards and iterative review. 
Protocol for evaluation of the decision aid: Eligible women will undertake a series of questionnaires 
prior to and after using the decision aid; the primary endpoint is decision aid acceptability to 
patients and investigators and the feasibly of use. Secondary endpoints include: change in decisional 
conflict; participant knowledge; and information involvement preference. Feasibility is defined as 
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the proportion of eligible participants who use the decision aid to help inform their treatment 
decision.  
Results 
This study has recruited 29 out of a planned 50 participants at 4 Australian sites. A 12-month 
recruitment period is expected with a further 12-months follow-up. 
Discussion 
The decision aid has the potential to allow patients with operable breast cancer, who have been 
offered neoadjuvant systemic therapy, decreased decisional conflict and greater involvement in the 
decision. If this study finds that an online decision aid is feasible and acceptable, it will be made 
widely available for routine clinical practice. 
Trial registration 
Australian and New Zealand Clinical Trials Registry (www.anzctr.org.au), number 
ACTRN12614001267640. 
Keywords: Breast neoplasm, decision aid, neoadjuvant, chemotherapy, protocol. 
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Introduction 
Neoadjuvant systemic therapy (NAST) has become a routine treatment option for selected women 
with operable breast cancer, endorsed by international guidelines [1, 2], patients [3], doctors [4] and 
breast cancer advocates [5]. We estimate that at least twenty percent of patients with breast cancer 
might benefit from NAST, however this rate varies amongst clinicians [6]. It has the advantages of 
downstaging some larger tumours from mastectomy to lumpectomy [7]; providing prognostic 
information depending on the degree of tumour response [8]; and facilitating translational research 
for early biomarkers of response [9]. In tumours with higher rates of proliferation such as triple 
negative and HER2-positive, pathological complete response is considered a surrogate outcome for 
the approval of novel therapies [10]. Additional potential benefits include additional time for surgical 
decision-making, genetic testing and downstaging of the axilla [11]. Overall survival and disease-free 
survival are equivalent following either neoadjuvant or adjuvant systemic therapy with appropriate 
local therapy [12]. Despite these advantages, NAST is not frequently used for women with operable 
disease, with one Australian study reporting an estimated rate of 2.75% [4], and in the USA 3.8% 
[13]. Possible reasons for this low rate of NAST use include the need for changes in workflow 
practices, patient expectation for upfront surgery and lack of awareness of NAST, and lack of 
available clinical trials [6]. Potential disadvantages to NAST include: the loss of detailed pathology to 
guide multidisciplinary management; the (low) potential to delay surgery in patients who do not 
respond to NAST; and reduced time between surgery and radiotherapy, which may impact on breast 
reconstruction outcomes [4].   
In a series of semi-structured interviews conducted by our group, women with breast cancer 
expressed interest in NAST, for downstaging, prognostication and to allow additional time to plan 
surgery [3]. However, they were not able to be as involved as they would like in the decision to 
receive NAST rather than adjuvant systemic therapy. They reported a lack of information, meaning 
that they did not feel adequately informed about the options available. They felt that clinicians 
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 tended to direct them toward one option, rather than their preference of shared control. This 
skewed distribution of decisional control was echoed in a survey of 207 Australian and New Zealand 
breast cancer specialists, where the majority of clinicians directed the decision about whether NAST 
would be given for operable breast cancer. This study, using an adaptation of the Control 
Preferences Scale [14], found that no clinicians reported that their patients made the final decision 
about NAST [15]. This indicates a mismatch between patient wishes and the experience of shared 
decision-making [16], and suggests that strategies are required to better involve patients in the 
decision about NAST.  
Women with early stage breast cancer typically desire involvement [17] and decisional control over 
their treatment [18]. Those who are at least as involved as they wanted experience better decision-
related outcomes including consultation satisfaction, satisfaction with decision-making, perception 
of clinician shared decision-making skills, and decreased decisional conflict [18]. Being involved in 
decision-making about breast cancer is associated with improved quality of life up to 10 years post-
diagnosis [19]. However, it may be particularly difficult to involve to engage women in decisions 
about NAST due to the complexity of the decision, distress from breast cancer diagnosis, perceived 
urgency and an expectation that surgery will be the first treatment offered [3]. Patients may also 
want to proceed with up-front curative surgery in the hope that chemotherapy, which is seen as 
toxic and intrusive [20], may be avoided entirely. 
Patient decision aids (DA) are an established method to improve the quality of shared decision-
making. Patient decision aids for treatment decisions have been shown to decrease decisional 
conflict, increase knowledge about options, improve risk perception and improve patient-
practitioner communication [21]. Decision aids are particularly suited to decisions where the various 
risks and benefits of the alternative treatment options may be valued differently by different 
individuals [22].  The choice between NAST and conventional sequencing (surgery followed by 
chemotherapy) is such a decision.  In a systematic review of decision aids for patients with early 
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 stage breast cancer, we could not find any reports of a decision aid for NAST [23]. In our Australian 
survey 86% of breast cancer specialists expressed interest in using a decision aid for women with 
operable breast cancer who are offered NAST. Women who were interviewed endorsed the 
development of a NAST DA, and expressed a preference for a tool in print form that was accessible 
from a trusted source. Here we describe the development of such a DA and the protocol for a study 
that will evaluate that DA. 
 
Methods 
Decision aid development 
A DA (Appendix A) was developed based on a literature review and then refined in an iterative 
process by an expert advisory panel comprising medical oncologists, breast surgeons, a psycho-
oncologist, consumers, a breast care nurse and a breast cancer advocacy organisation representative 
according to the systematic process described by Coulter et al. [24]. A skilled consumer advocate 
with personal experience of breast cancer reviewed the decision aid on multiple occasions and 
provided constructive advice. The structure of the DA was based on the International Patient 
Decision Aid Standards (IPDAS) Collaboration statement, to include a balanced description of 
adjuvant and neoadjuvant therapy, including advantages and disadvantages, outcome probabilities 
for each option, graphics and a values clarification exercise. The DA was then circulated to an 
additional stakeholder group with similar composition to the first, who had not seen the DA, for 
further refinement. It was then professionally formatted in portable document format (.pdf) to be 
downloadable and printable in either colour or black and white. 
The final DA includes an introduction; brief general information about breast cancer and the 
treatments used; explanation of the options for the timing of chemotherapy and surgery; the 
advantages and disadvantages of neoadjuvant and adjuvant therapy; a values clarification exercise; a 
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 page for notes; a glossary; and information about where to find additional resources. Using the 
readability statistics package embedded in Microsoft Word®, the decision aid has a grade 10 Flesch-
Kincaid readability level. The introduction is necessary for newly diagnosed breast cancer patients to 
understand basic concepts about treatment modalities, because they may not have received other 
written general information at the time that NAST is being discussed. A diagram represents the 
options of either: chemotherapy followed by surgery, or surgery followed by chemotherapy. 
Radiotherapy (if indicated), HER2-directed therapy (if HER2 positive) and endocrine therapy (if 
oestrogen [ER] and/or progesterone receptor [PR] positive) follow in the flow diagram. The diagram 
is designed to demonstrate that treatment duration is expected to be similar with either option. 
Key components of risk are presented using visual, numeric and narrative formats with appropriate 
labelling, tailored to individual tumour characteristics [25]. The likelihood of a pathological complete 
response is presented according to breast cancer subtype: ER/PR (hormone receptor [HR]) positive, 
HER2 negative; HR positive, HER2 positive; HR negative, HER2 positive; and HR negative and HER2 
negative (triple negative [TNBC]). The probability of remaining alive and free of breast cancer at five 
years is presented, based on whether a pathological complete response was achieved, or not. These 
estimates are based on a meta-analysis of neoadjuvant clinical trial results reported by von Mickwitz 
et al. [26] and Cortazar et al. [8]. A 1000-dot diagram, with each dot representing one patient, 
illustrates the likelihood of tumour progression (3%) or becoming inoperable (0.3%) on neoadjuvant 
chemotherapy, based on a case series by Caudle et al. [27].  
The values clarification exercise in this DA is a diagram with statements about advantages and 
disadvantages of either option [28]. Patients can nominate how important each factor is to them and 
then make a mark on a linear analogue scale to show which option they prefer, and how strong their 
view is. Patients are encouraged to discuss their options with friends, family and other health 
professionals if they wish. The final decision is made at a follow-up visit with their surgeon or 
medical oncologist. 
148
  
Evaluation of decision aid (ANZ1301 DOMINO) 
ANZ1301 is a multi-centre study using a pre-post design to evaluate the acceptability and feasibility 
of the Decision Aid (DA) described above.  The project is being led by the Australia and New Zealand 
Breast Cancer Trials Group (ANZBCTG) in collaboration with the Psycho-oncology Co-operative 
Research Group (PoCoG). It is funded by an HCF research grant with central trial coordination by the 
ANZBCTG, and registered on the Australian New Zealand Clinical Trials Registry with registration 
number ACTRN12614001267640.  All four sites have received ethics approval from the Hunter New 
England Local Health District Human Research Ethics Committee, under the Australian National 
Mutual Acceptance multicentre ethics scheme.  
Study participants 
Clinicians 
Twenty-six clinicians from four ANZBCTG sites have been recruited to identify women eligible for the 
DOMINO study.  Participating sites are: Calvary Mater Newcastle, Waratah, NSW; The Breast and 
Endocrine Centre, Gateshead, NSW; The Mater Hospital, North Sydney, NSW; and Royal Melbourne 
Hospital, Parkville, VIC. Patients are screened at those four sites and in the private practices of 
associated clinicians.   All participating clinicians, and site study personnel, receive training on the 
online system developed for this study.  
Patients 
Patients are eligible to participate in the DOMINO study if they: 
• are female and aged over 18 years; 
• have a histological diagnosis of invasive breast cancer; 
• have an operable, invasive breast tumour 
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 • are considered appropriate for neoadjuvant systemic therapy (NAST) with curative intent 
using chemo- and/ or endocrine therapy; 
• are able and agree to access study information via the internet;  
• are able to comply with the study procedures for the duration of the study; 
• give voluntary, informed consent. 
Patients are ineligible if they: 
• are expected to receive less than 3 months of NAST; 
• have a hearing or other impairment that would preclude a phone interview; 
• are unable to access the internet using a laptop or desktop computer, or do not have an 
active email address with which to participate in the study; 
• have insufficient English language skills for participation in online surveys and oral 
interviews; 
• have inflammatory, metastatic or inoperable breast cancer; 
• have a medical or psychiatric condition that precludes informed consent or prevents 
adherence to study procedures. 
Study design 
Screening 
Potentially eligible patients are identified during the planning of their initial treatment strategy at 
participating Australian sites during multidisciplinary meetings and at surgical and medical oncology 
appointments. Patients are approached by their clinician during their appointment to consider 
receiving additional information about the DOMINO study via a web link which is sent to the patient 
via an auto-generated email. At the time of the initial offer of study participation, patients are asked 
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to indicate written consent on a screening form for their personal information (name, email address 
and telephone number) to be provided to the ANZBCTG.  A web link to the study consent page and 
questionnaires is then sent to them by email. Patients who consent to share personal information 
are provided with a copy of their signed screening consent form along with study-specific written 
information about their breast cancer. This information is intended to aid understanding of their 
diagnosis when using the decision aid. Clinicians are required at this time to record details regarding 
the primary reason for NAST, and an opinion of the patient’s current distress levels and information 
preferences. The completed screening consent form is sent via Teleform (® Hewlett Packard, Palo 
Alto, CA) fax to the ANZBCTG to be verified, and email contact with the patient established.  
If the patient does not consent to share personal information, the clinician records information on 
the screening consent form so a log can be kept of each patient who is: ineligible and screened out; 
eligible but not offered participation; and offered participation but declines. The number of patients 
who consent to screening but do not participate in the study will also be recorded. Screening data 
will be used to describe feasibility of DA use. 
Registration 
Patients are registered to the study through the following process: the screening form is received at 
the ANZBCTG for validation and confirmation of eligibility criteria; patients who consent to release 
their details on the screening form receive an automatically generated email; these patients are now 
considered eligible for the DOMINO study. Patients who access, read the online DOMINO 
Information Statement and Consent page, and agree to participate in the study are redirected to a 
series of demographic questions. On submission of responses to demographics and consent, 
patients are considered registered to the study. Patients at this stage are also given the opportunity 
to opt in to a telephone interview. Eligible patients have a six week window in which to view and 
agree to participate in the DOMINO study before being considered a screen failure. Fifty patients will 
be registered to the DOMINO study.   
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 Electronic Communication Processes 
At the point of registration patients are requested to enter a password for access the DOMINO 
website thereafter; an individual’s username is defined by their email address.  
Site trial coordinators input dates of patient appointments and projected treatment completion 
dates, which are then used to calculate and trigger all communication with the patient and 
reminders to site coordinators. Pre-designed patient and site coordinator emails are sent 
automatically at specific time points, as guided by information entered by sites as to the treatment 
decision (either NAST or surgery), to patients. A reminder email is sent to the patient if the survey 
remains unsubmitted 3 calendar days after the initial email. If after an additional 2 calendar days a 
patient has not submitted a questionnaire an automatically generated email is sent to the ANZBCTG 
study coordinator prompting a telephone call to the patient. Site study coordination staff are sent 
automatically generated emails prompting completion of data via the online system or informing 
them of their patient’s submission of a questionnaire.  
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Figure 1. Study Schema 
Outcome measures 
Primary outcomes 
• DA acceptability, defined as at least half of patients considering the DA useful for their
decision and at least half of clinicians indicating that they would use the DA in their routine
clinical practice. Acceptability will be assessed using a single question from the DA feedback
questionnaire developed by Juraskova et al. [29] about whether the patient considered the
DA useful for their decision. This questionnaire also measures general satisfaction with the
DA.
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• Feasibility of DA use, defined as at least half of patients who were offered participation in
the study accessing the DA, and at least half of those who access the DA stating that they
read it.
Secondary hypotheses and outcome measures 
With use of the DA: 
• Decisional Conflict Scale score will decrease [30];
• Knowledge about NAST, using a custom-designed questionnaire, will increase;
• Information and involvement preference will increase [31];
• Agreement between preferred and achieved decision control will be high, based on an
adaptation of the Control Preferences scale to include achieved control [14];
• Control Preferences Scale score will increase [14];
• There will be no change in cost of health care delivery;
• No change will be seen in the 6-item State-Trait Anxiety Inventory score [32].
• Fear of cancer progression will be unchanged whilst receiving neoadjuvant therapy [33];
• Decisional Regret score after chemotherapy and after surgery will be low [34];
• Fear of cancer recurrence score will be low [35];
• Distress thermometer score will decrease [36, 37];
• Satisfaction with decision score will be high [38];
• There will be no change in outcomes between those who decided to receive neoadjuvant
chemotherapy with those who decided not to have neoadjuvant therapy.
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Exploratory hypotheses 
• Correlation will be good between baseline investigator assessment of participant
information and involvement preference and participant report of DA acceptability;
• Correlation will be good between high baseline participant information and involvement
preference and high acceptability of DA to participants;
• Correlation will be good between baseline investigator assessment of distress and
participant report of distress;
• Participants will be willing to complete the EQ-5D-5L questionnaire, a health utility measure.
Knowledge questionnaire 
A custom-designed 7-item knowledge questionnaire has been developed based on the content of 
the DA to test recall and comprehension (Appendix B). Questions were taken from information 
throughout the DA. The number of correct responses will be transformed to a score out of 100. 
Demographic, tumour and treatment information 
The following demographics will be recorded: age, marital status, level of education, health 
insurance, occupation, native language. Tumour characteristics: tumour size, nodal status, 
oestrogen/progesterone receptor, HER2 amplification and grade. Investigations and treatment 
received: duration of chemotherapy, radiotherapy, surgical procedure(s) performed, biopsies and 
imaging performed. 
Telephone interview 
Participants will be asked to participate in a semi-structured interview using a pre-planned interview 
guide, to gain a deeper understanding of their attitude toward the utility and acceptability of the DA. 
Participants are asked at the time of consent to tick a box indicating their willingness to be contacted 
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 for an interview. Interviews will undergo immediate initial analysis, and will be conducted until 
thematic saturation is reached, defined as no new major themes in three consecutive interviews. 
Further rounds of analysis will be conducted in an iterative fashion after all interviews are complete. 
Interviews will be recorded, transcribed verbatim and analysed using qualitative methodology. 
Qualitative descriptive methodology will be used, as is appropriate when lived experience, views and 
preferences are the target of investigation, and there are little existing data available. This method 
can be used to gain a rich description of an experience, founded in existing knowledge and 
interpreted in the context of the clinical experience of the research group [39]. 
Clinician questionnaire 
After 50 patients have completed their post-DA questionnaire, all clinicians will receive an electronic 
questionnaire. The questions include: specialty (surgeon or medical oncologist), intent to use the DA 
in routine clinical practice, patient selection for DA use, effect on consultation duration and number, 
apparent effect on decision-making and comments on content. The DA will be considered acceptable 
to clinicians if more than 50% report that they would use the DA in routine clinical practice. 
Questionnaire administration 
A series of validated questionnaires where available, and custom designed where a questionnaire is 
not available, are presented to patients at four time points pre and post access to the decision aid 
(Table 1). Prior to access to the decision aid, patients are asked to report demographics and to 
complete 6 questionnaires which address decisional conflict, decision-making preference, 
information and involvement preferences, anxiety, distress and an optional health economic 
instrument.  
At the completion and submission of the first set of questionnaires, patients are able to access an 
electronic copy of the decision aid; this document can be printed, saved and accessed by a patient at 
any stage of the study by logging in to the DOMINO website. Patients are asked to complete and 
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read the decision aid prior to attending their next appointment with their clinician at which time a 
decision regarding treatment may be made. At this visit, the clinician refers to the decision aid and 
asks whether the patient has any questions about it. After the attendance at an appointment where 
a decision was made regarding treatment and specific data has been entered by the site, the patient 
receives an auto-generated email informing her that a second set of questionnaires is available for 
completion. Questionnaires at this time point ask to the patient to reflect on the information 
provided in the DA and its role in their treatment decision. Patients who do not submit both 
questionnaire set one and two will be replaced to ensure that pre-post outcomes are recorded for 
50 patients.  
Based on treatment details supplied by the site trial coordinator about treatment option chosen and 
date of completion, an email link to questionnaire set 3 is sent to the patient. This questionnaire is 
to be completed after the initial treatment strategy of either chemotherapy or surgery. It is expected 
that most participants will then proceed with surgery or systemic therapy respectively as their 
subsequent treatment strategy. This assessment aims to determine the effect of the first treatment 
strategy on decision-related outcomes, without the influence of the alternative strategy. 
Questionnaire set 4 is answered 12 months after registration, to investigate longer-term outcomes 
including anxiety, distress, regret and recollection of pathology results. This is the last questionnaire, 
and participants complete their study involvement at this time. 
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 Table 1. Questionnaire content according to assessment time-point. 
 
Pre-DA 
Assessment 
Post-Treatment 
Decision 
Assessment 
Post-Chemo 
therapy 
Assessment 
(NAST)a 
Post-
surgery 
(Non-
NAST)b 
Post-Treatment 
Assessmentc 
Decision conflict 
scale 
X X    
STAI-6 Anxiety X X X X X 
DMPQ 
Preferred X X    
Actual  X    
Distress 
thermometer 
X X X X X 
Information and 
involvement 
preferences  
X X    
EQ-5D-5L (optional) X X X X X 
Knowledge of DA 
Information 
 X    
158
Pre-DA 
Assessment 
Post-Treatment 
Decision 
Assessment 
Post-Chemo 
therapy 
Assessment 
(NAST)a 
Post-
surgery 
(Non-
NAST)b 
Post-Treatment 
Assessmentc 
Decision Aid 
Feedback 
X 
Satisfaction with 
decision scale 
X 
Fear of progression 
(FOP 12) 
X X X 
Decision regret scale X X X 
Fear of Cancer 
Recurrence 
Inventory 
X X X 
Participant-reported 
Pathology Results 
(NAST only) 
X 
a Post-chemotherapy, before surgery 
b Post-surgery, before adjuvant chemotherapy 
c Twelve months (+/- 1 month) after registration 
Table 1 legend. DA, decision aid; DMPQ, decision-making preference questionnaire; EQ-5D-5L, 
EuroQol 5-dimension, 5-level health status measure; NAST, neoadjuvant systemic therapy; STAI, 
state-trait anxiety inventory. 
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Statistical Analysis 
A sample size of fifty participants is planned. The primary analysis will include all registered patients 
and clinicians as two separate cohorts. The proportion of patients and investigators who consider 
the DA acceptable will be reported with 95% exact confidence limits. The primary outcome will be 
considered positive if more than half of patients and clinicians consider the DA acceptable, and 
feasible if more than half of eligible patients who are offered participation register and subsequently 
use the DA. Assuming a sample size of 50 participants, the primary outcome of percentage of 
participants finding the DA acceptable can be estimated to within ± 15% based on 95% exact 
confidence limits.  To ensure that the lower 95% one-tailed exact confidence limit is greater than 
50%, at least 32 of the 50 participants will need to indicate DA acceptability.  Although the study is 
not powered to test the secondary hypotheses,  there is 80% power to detect a change of at least 
0.40 standard deviations from the pre- to post-DA assessments using a two-tailed t-test with 
alpha=0.05 and a sample size of 50 participants. 
Changes in secondary outcome measures from the pre-DA assessment, including decisional conflict, 
information preference, anxiety, distress and fear of progression, will be evaluated using repeated 
measures analysis of covariance (ANCOVA). All outcomes will be described using mean and standard 
deviation for continuous measures and frequency for categorical outcomes. If data are skewed, 
median and interquartile range will be reported and the appropriate linearising transformation will 
be used. Analyses will be performed unadjusted and adjusted for age, level of education, 
information preferences and tumour characteristics (size, grade, node involvement, ER/PR/HER2). 
Agreement in decisional control before and after using the DA, and between preferred and actual 
control, will be assessed using a weighted kappa statistic with McNemar test. Knowledge will be 
reported as mean proportion of items correct with standard deviation. Cost will be recorded using 
Australian Medical Benefits Scheme item numbers and Pharmaceutical Benefits Scheme prices, and 
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 a comparison made between those who receive surgery first and those who receive systemic 
therapy first. 
Missing Data 
Patients are encouraged to complete all questions, but are not compelled to enter responses to any 
of the individual questions within each set of questionnaires and can submit responses with blank 
fields. Prior to questionnaire submission patients will receive a prompt informing them that not all 
questions have been answered and to amend if they wish. During the study levels of missing data 
are being monitored. If data completion rates drop below 70% remedial action will be taken. An 
analysis of missing data will be completed at the end of the study. 
 
Results 
The ANZ0501 DOMINO study is currently recruiting at four Australian centres. As of February 2016, 
29 out of a planned 50 participants have been registered to the study. Recruitment is expected to be 
complete in mid-2016, with early results available late 2016. 
 
Discussion 
This study intends to evaluate the acceptability and feasibility of a DA for women with operable 
breast cancer who have been offered NAST. It is designed as a single arm pre-post study to allow all 
participants access to the intervention. The population of Australian women who currently receive 
NAST is relatively small, limiting the feasibility of a larger, randomised controlled trial with 
comparative outcomes. However, the proportion of patients receiving NAST in Australia and New 
Zealand is expected to increase as a result of increased awareness, availability of neoadjuvant 
clinical trials, and from the results of ongoing neoadjuvant and post-neoadjuvant trials. 
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 The study primary endpoints are pragmatic. We expect that some participants will not find the DA 
beneficial, based on their decision making style and information seeking behaviour. However, we 
hypothesise that the number who find it helpful in their decision-making process will be greater than 
the number who do not find it useful. Because DAs have variable use across centres and individual 
clinicians[40], feasibility was included as an endpoint. A screening log is designed to quantify the 
number of patients who: are seen at recruiting sites who are candidates for NAST for operable 
breast cancer; are eligible for the study; are offered study participation; accept study participation; 
and go on to access the DA. This will identify the proportion of eligible patients who are not offered 
participation (clinician feasibility) and the proportion of eligible patients who do not access the DA 
after being offered it (patient feasibility). Acceptability will be assessed using direct questions to 
patients and clinicians. 
Outcome measures were selected based on the availability of valid, reliable questionnaires that 
assess outcomes relevant to decision-making in the context of a decision aid. In systematic review of 
the quality of measures to test the effectiveness of decision support strategies, the Decisional 
Conflict Scale and the Control Preferences Scale satisfied the largest number of quality criteria [41]. 
These are commonly used measures of DA effectiveness [21, 42]. Knowledge assessment 
necessitates a custom-designed questionnaire. The Fear of Progression questionnaire is suited to the 
neoadjuvant setting where the primary cancer is present and has the potential to impact on 
psychological and physical domains [33]. The Information and Involvement Preferences 
questionnaire was included to determine the information needs of patients, and to correlate the 
result with patient and clinician acceptability. The EQ-5D-5L is a health economic utility measure 
[43], and was included as an optional measure to determine patients willingness to complete this 
additional questionnaire. If patients are willing to complete it, then it will be considered for future 
comparative studies as a health economic measure. Satisfaction with decision is of interest as an 
acute measure to be assessed after the decision has been made, but prior to experiencing the 
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 consequences of the decision [34]. Decision regret is a longer term outcome measure, to be 
assessed after the consequences of the decision have been experienced [38]. 
Increased anxiety is associated with both more effective decision strategies and stressful health 
interventions, so is not a good measure of the benefit of DA use [44]. Anxiety therefore is not 
expected to decrease as a result of a DA, but nor should it increase and therefore anxiety has been 
included as a safety measure [21]. 
Decision aids are most beneficial if endorsed by a clinician at time it is offered to the patient, and 
referred to after the decision has been made [45]. This decision aid is introduced at a time when 
patients have recently been diagnosed with breast cancer and are faced with a number of complex 
decisions that are influenced by a variety of sources including clinicians, family and the media [46, 
47]. Patients are identified as suitable for the decision aid by their doctor (usually a surgeon), and 
are generally referred to a medical oncologist to discuss systemic therapy. The decision aid is suited 
to this situation as there is often a period of several days (or more) before an available appointment 
with a medical oncologist. If the decision aid is effective, the patient will be more prepared to be 
involved in the decision when they come to the medical oncologist. Balancing the provision of 
complex information with adequate readability proved difficult, as demonstrated by a higher Flesch-
Kincaid grade than would be ideal. 
Decision aids have been shown to have a variable effect on treatment choices [21]. For selected 
treatment decisions, some patients change their preferred treatment after a DA, but for others 
decision aids have been shown to have a neutral effect. We anticipate that study patients will not 
change their decisions after accessing the DA, as decisions such as this tend to be made based on a 
number of information sources [48].  
If shown to be feasible and acceptable, the DOMINO decision aid has the potential to be offered to 
patients as part of routine clinical practice. There is good evidence for the efficacy of decision aids 
that are designed according to international standards [22, 24]. Thus a randomised controlled trial is 
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 not considered a pre-requisite for dissemination. Clinicians who enrol participants in this study will 
be asked whether they would continue to use the decision aid as part of routine practice, as an 
indicator of perceived implementability. 
Use of the DOMINO decision aid has the potential to decrease decisional conflict, increase 
knowledge and increase patient involvement in women who have been offered NAST. Increased 
involvement in decisions by women with breast cancer is associated with improved decision-related 
outcomes [18] and long term quality of life [19]. Neoadjuvant clinical trials are an established drug 
development pathway, and the decision aid may allow better understanding of the rationale behind 
neoadjuvant therapy. The patient may then be able to be better informed about the trial. It may also 
assist clinicians who are introducing neoadjuvant systemic therapy into their practice but have not 
yet become confident addressing the concept with their patients. 
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DA  decision aid 
ER  oestrogen receptor 
EQ-5D-5L  EuroQol 5-dimension, 5-level health status measure 
HER2  human epidermal growth receptor 2 
NAST  neoadjuvant systemic therapy 
PR  progesterone receptor 
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 APPENDIX A 
Decision aid for NAST (included at end of thesis as Appendix A) 
 
APPENDIX B 
Custom knowledge questionnaire 
ALL ASSESSMENTS WILL BE COMPLETED ONLINE. 
NO PAPER COPIES ARE TO BE PRINTED AND GIVEN TO TRIAL PARTICIPANTS 
 
Please read each of these statements and place a mark in the box to show whether you believe it to 
be true, false, or you are unsure: 
 
 Definitely 
true 
Probably 
true 
I am 
unsure 
Probably 
false 
Definitely 
false 
Neoadjuvant treatment involves 
receiving treatment before surgery 
for breast cancer 
□ □ □ □ □ 
Patients who receive neoadjuvant 
treatment have the same chance of 
the cancer coming back as those 
who have surgery first 
□ □ □ □ □ 
There is a chance that my cancer will 
disappear completely □ □ □ □ □ 
If my cancer disappears entirely, I 
may not need surgery □ □ □ □ □ 
If the cancer disappears entirely, it is 
less likely to come back □ □ □ □ □ 
If my cancer shrinks after 
neoadjuvant therapy, I will still have 
to have the same type of surgery 
(e.g. mastectomy) 
□ □ □ □ □ 
The chance of the cancer getting 
smaller depends on the type of 
breast cancer that it is 
□ □ □ □ □ 
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 5.2  Publication: A single-arm longitudinal study to evaluate a decision aid for women who have 
been offered neoadjuvant systemic therapy for operable breast cancer (ANZ1301 DOMINO) 
 
Zdenkowski N, Butow P, Spillane A, Douglas C, Snook K, Jones, M, Oldmeadow C, Fewster S, 
Beckmore C, Boyle FM. A single-arm longitudinal study to evaluate a decision aid for women who 
have been offered neoadjuvant systemic therapy for operable breast cancer (ANZ1301 DOMINO). 
Journal of the National Comprehensive Cancer Network 2018;16(4):378-385. 
 
This paper represents the culmination of a body of research on shared decision making for women 
considering neoadjuvant systemic therapy for breast cancer. It reports the primary and secondary 
results of the study to evaluate the patient decision aid developed for this neoadjuvant population. 
The study was directly informed by interviews with patients, the survey of clinicians and a systematic 
review of breast cancer decision aids. A case is presented supporting implementation of the decision 
aid into routine practice as a new option to support shared decision making for patients with breast 
cancer.   
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 Abstract 
Background  
Neoadjuvant systemic therapy (NAST) is an increasingly used treatment option for women with large 
operable or highly proliferative breast cancer. With equivalent survival outcomes between NAST and 
up-front surgery, the situation specific preference-sensitive nature of the decision makes it suitable 
for a decision aid (DA). We aimed to develop and evaluate a DA for this population. 
 
Methods 
A DA booklet was developed according to international standards, including information about 
adjuvant and neoadjuvant treatment, outcome probabilities, and a values clarification exercise. 
Eligible women, considered by investigators as candidates for NAST, were enrolled in a multi-
institutional single arm longitudinal study. Patient-reported outcome measure questionnaires were 
completed pre- and post-DA, between chemotherapy and surgery, and at 12 months. Outcomes 
were feasibility (percentage of eligible patients accessing the DA); acceptability to patients 
(percentage who would recommend it to others) and clinicians (percentage who would use the DA in 
routine practice); and decision-related outcomes. 
 
Results 
From 77 eligible women, 59 were enrolled, of whom 47 (79.7%, 95% CI 69.4-89.9) reported having 
read the DA. 51 completed the first post-DA questionnaire. 41/51 (80.4%, 95% CI 69.5-91.3) of 
participants found the DA useful for their decision about NAST. 16/18 (88.9%, 95% CI 74.4-103.4) of 
responding investigators would continue to use the DA in routine practice. Post-DA, decisional 
conflict decreased significantly (p<0.01); anxiety and distress decreased significantly; and 86.3% 
(95%CI 73.7-94.3) achieved at least as much decisional control as they desired.  
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Discussion 
This DA was feasible and acceptable to patients and clinicians, and improvement in decision-related 
outcomes were demonstrated when used in combination with clinical consultations. This DA could 
safely be implemented into routine practice for women considering NAST for operable breast 
cancer. 
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 Introduction 
Patient centred care is a key component of high quality health care 1, 2. The process of shared 
decision making supports patient centred care by actively involving the patient along with their 
healthcare provider(s) to choose the best option for that individual 3. One strategy to implement 
shared decision-making is the patient decision aid (DA), which is an evidence-based, structured tool 
to support deliberation between patients, clinicians and others when there is more than one health 
care option 4, 5. 
 
For women with large or highly proliferative operable breast cancer, the decision about whether to 
receive neoadjuvant systemic therapy (NAST) is guided by preferences that may lead to individual 
patients with similar clinical circumstances choosing different options. DAs have been shown to help 
guide patients in such preference-sensitive situations, improving decision-related outcomes 
including reduced decisional conflict, increased knowledge, increased involvement in decision-
making and improved understanding of risk associated with the options 6. Several DAs have been 
developed to address values-sensitive patient decisions for early stage breast cancer 7, however, 
none was available for women considering NAST for operable breast cancer. This treatment option 
involves a complex interplay of preferences 8, presented in the context of a distress-inducing 
diagnosis of cancer. Despite this distress and decisional complexity, previous work has shown that 
patients benefit from being involved in decisions about management of early stage breast cancer 9. 
 
An increasing proportion of patients with operable breast cancer are being treated with NAST 10. 
Advantages include downstaging from mastectomy to lumpectomy and downstaging the axilla 11, 12; 
better oncologic clearance allowing for consideration of immediate breast reconstruction in women 
still requiring mastectomy; improved prognostication based on response 13; time to plan surgery 14; 
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 and participation in a neoadjuvant or post-neoadjuvant clinical trial 15. Disadvantages for some 
patients include fear of progression on chemotherapy 16, the psychological impact of leaving a 
tumour in place rather than immediate surgical removal, and the psychological impact of an adverse 
prognosis if the tumour does not respond to chemotherapy. Importantly, disease-free and overall 
survival outcomes are equivalent, whether NAST or surgery is the first treatment modality for 
operable disease 17. 
 
Involving patients in the decision about NAST can be challenging due to the complexity and 
perceived urgency of the decision. In this study, we aimed to (1) develop a DA for women with 
operable breast cancer who had been offered NAST, and (2) test the feasibility and acceptability of 
that DA in clinical practice. 
 
Methods 
Design, patients and setting 
This was a prospective, single arm, multicentre, longitudinal study. This study received approval 
from a recognized ethics committee, and all participants provided informed consent prior to any 
study processes. A detailed description of study methods and DA development has been published 
previously 18. Participants were Australian women aged 18 or over with a diagnosis of operable 
invasive breast cancer, and were candidates for NAST of 3 months or longer. Exclusion criteria were: 
insufficient English language to complete study questionnaires; inflammatory, metastatic or 
inoperable breast cancer; or inability to access the internet and email to complete study 
requirements. 
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A DA was developed for this study, based on a literature review, patient interviews 19, a clinician 
survey 20, and the International Patient Decision Aid Standards (IPDAS) Collaboration guidelines 4. A 
stakeholder group reviewed the DA, including medical oncologists, surgeons, a psychologist, breast 
care nurse, consumers and a breast cancer advocacy group representative. The DA is a 26-page 
booklet available online or in print. It contains a description of the options of adjuvant and 
neoadjuvant therapy, with advantages and disadvantages, outcome probabilities (pathological 
complete response, downstaging, progression on neoadjuvant therapy), graphical and pictorial 
information, and a values clarification exercise. It is designed for flexibility of use, whether to be 
read cover-to-cover, or only sections of interest. The Flesch-Kincaid reading level is year 10, despite 
consumer input and substantial effort to simplify the language. A full copy of the DA is available as 
appendix C, and Appendix D is the IPDAS checklist for this DA 21. 
Participants were recruited by their breast surgeon or medical oncologist, completed the baseline 
questionnaire (assessment 1), then accessed the DA for on-screen or hard copy review (study 
schema, Appendix B). The DA was intended to be given to patients by their surgeon at the time of 
referral to a medical oncologist, for review prior to that appointment. After the follow-up visit where 
a decision was made about having NAST, or surgery first, they received a follow-up questionnaire 
(assessment 2). Assessment 3 was between completion of systemic therapy and before surgery (or 
after surgery and before chemotherapy if surgery was first), and the final questionnaire (assessment 
4) 12 months after registration. All questionnaires were completed online.
Outcomes 
Co-primary outcomes comprised feasibility of DA use, and acceptability to patients and clinicians. 
Feasibility was defined as the percentage of eligible patients who accessed the DA after being 
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offered participation in the study, which we hypothesized would be greater than 50%. Patient 
acceptability was defined as the percentage of participants who would recommend the DA to others 
in their situation, hypothesized to be greater than 50%. Investigator acceptability was defined as the 
percentage of investigators who would use the DA in routine practice, hypothesized to be greater 
than 50%. Acceptability and feasibility margins were prospectively defined based on the estimated 
proportion of patients and investigators required to warrant routine implementation of the DA. 
Patient reported outcome questionnaires were completed by participants at each time point 
(Appendix A), which have been described in detail previously 18. Measures were: Decisional Conflict 
Scale 22; Information and Involvement Preferences 23; Control Preferences scale 24; 6-item State-Trait 
Anxiety Inventory 25; Distress Thermometer 26; Fear of Cancer Progression 27; Fear of Cancer 
Recurrence Inventory 28; custom knowledge questionnaire; Decision Regret 29; Satisfaction with 
Decision 30; and DA feedback 31. Investigators were also asked to complete a feedback questionnaire. 
Analysis 
Recruitment of 50 participants was planned, so that a primary outcome score of 67% or more would 
provide 80% power with a one-sided alpha of 5% to reject a true rate of 50% or less. To provide 
sufficient numbers for secondary outcome analysis, recruitment was planned to continue until 50 
participants had completed assessment 2. We summarize demographic, tumour and treatment data 
by mean and standard deviation for continuous data, and by number and frequency for categorical 
data. Primary outcomes are analysed using tests of proportions and presented with 95% confidence 
intervals (CI). Those who did not complete assessment 2 were assumed to have not read the DA. 
Differences in decisional conflict subscale and information and involvement preferences (detail) 
were assessed using paired t-tests. Change in information and involvement preference (information 
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type) from baseline was tested using McNemar’s test. Linear mixed models were used to examine 
changes in distress and anxiety with fixed effects for final treatment choice and time (modelled as a 
categorical variable) and a subject level random intercept term. Fear of progression, fear of cancer 
recurrence, and decisional regret are reported using summary statistics and paired t-tests. 
Agreement in decision control and treatment choice (preferred vs achieved at assessment 2) is 
presented using Kappa, with scores defined as: <0, poor; 0-0.2, slight; .021-0.4, fair; 0.41-0.6, 
moderate; 0.61-0.8, substantial; and 0.81-0.99, almost perfect 32. Change in decisional control is 
presented using Bowkers test, collapsing categories into shared (collaborative, guided by either 
patient, doctor, or both equally) vs not shared (only patient or doctor makes the final decision). An 
exploratory analysis of outcomes at assessment 2 was conducted according to whether the 
participant had read the DA or not. A p-value of less than 0.05 was considered significant for all 
analyses. Analyses were computed using STATA/IC version 13.1 (StataCorp, College Station, TX). 
Results 
Between June 2015 and September 2016, 77 eligible women were offered participation and 
consented to demographic details being recorded (figure 1). Fifty-nine completed the online 
consent, first questionnaire and accessed the DA (table 1).  
Feasibility and acceptability of the DA 
The DA was feasible, with 59 of 77 eligible patients accessing the DA (76.6%, 95% CI 67.2-86.1, 
P<0.0001). Of those 59 participants, 47 read all or part of the DA (79.7%, 95%CI 69.4-89.9, 
p<0.0001). There were no significant differences in baseline demographics or outcome measure 
scores between those who read the DA and those who did not. The DA was acceptable to 41 of 51 
participants who completed assessment 2, who would recommend the DA to others in their 
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 situation (82.4%, 95% CI 69.5-91.3, p<0.0001), and 18% (9/51) were neutral.  The DA was acceptable 
to 16 of 18 site investigators (88.9%, 95% CI 74.4-103.4, p<0.001) for routine use. 
 
Patient-reported outcomes 
Overall 51/59 (86.4%) chose NAST.  Agreement was good between desired (post-DA) and actual 
treatment (kappa 0.6, 95% CI 0.290-0.911). At baseline, 18 participants were unsure about whether 
to proceed with NAST or surgery as their first treatment, six of whom proceeded with surgery and 12 
received NAST. Decisional conflict decreased in total and in all subscales (informed, values clarity, 
support, uncertain, effective) after use of the DA in combination with clinical consultation (all p-
values <0.002, figure 2). The post-DA score was less than 25 in all except the ‘uncertain’ subscale. 
Patient reported outcome measure scores are presented in table 3. 
 
There were no differences in baseline demographics or assessment 1 outcome scores between those 
who read the DA and those who did not. At assessment 2, those who read the DA had no difference 
in decisional conflict, anxiety, distress, or decision control preferences. Those who read the DA had a 
higher mean knowledge score. 
 
Most patients preferred, and achieved, a shared approach in their decision about NAST (Table 2). 
Eighty-six percent of patients (44/51) achieved at least as much decisional control as they desired. 
No significant changes were observed between pre-DA preferred decisional control, and actual 
perceived decisional control (p=0.50). Fair agreement was observed between preferred and 
achieved decisional control at assessment 2 (Kappa 0.32, 95% CI 0.16-0.49). Fear of cancer 
progression scores were low in 76.5% of participants, moderate in 19.6% and severe in 3.9% at 
assessment 2. At assessment 3, scores were low in 88.2% and moderate in the remainder.  
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Investigator-reported outcomes 
Eighteen of 24 (75%) participating investigators (7/11 medical oncologists and 11/13 surgeons) 
completed the investigator questionnaire. Sixteen (88.9%) indicated that they would use the DA in 
routine practice. Sixteen also indicated that the decision appeared easier, or no more difficult for 
patients compared with previous patients who had not used the DA. Fourteen felt that the DA did 
not change patients’ decision about NAST, and the remaining four investigators felt that the DA 
increased the likelihood of a patient choosing NAST. Twelve noted no change in consultation time, 
and the remaining six noted a mean increase of 7.5 minutes. 
Discussion 
This study fills a gap in the breast cancer decision literature by producing a neoadjuvant DA that had 
not previously been available 19. The study demonstrates that a DA in this setting is acceptable to a 
majority of patients and clinicians, and could feasibly be used within routine clinical workflow. 
Decision-related patient reported outcome scores improved in the post-DA assessments. These 
findings are consistent with literature showing that systematically developed DAs designed for 
patient use in healthcare decision-making effectively improve decision-related outcomes for a range 
of general medical treatment decisions 6, and for breast cancer 7. 
Previous work has indicated that patients benefit from being at least as involved as they wish to be 9. 
The decision about NAST is complex due to the need to consider the implications of a range of 
individual treatment decisions, in the context of distress from a recent diagnosis of breast cancer. 
Patients in the present study engaged in decision-making despite this inherent complexity. Using the 
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DA did not appear to increase patient anxiety, and, with an additional consultation, appeared to 
resolve decisional uncertainty. 
A DA should be implementable in routine practice, to realize the benefits seen in the study. Whilst 
the hypothesized threshold values for feasibility and acceptability were based on estimated 
likelihood of routine uptake, lower (or higher) thresholds might be appropriate depending on 
individual clinician and patient factors. A minority of patients in this study were neutral in their 
recommendation for the DA to others in their situation and only one indicated that she would 
recommend against it. Most read part or all of the DA, once they had accessed it. Stated reasons for 
not reading the DA were that they had already made their decision, or that the DA was provided too 
late in their decision-making process. The non-randomized analysis of outcomes according to 
whether the participant had read the DA or not is exploratory and should be interpreted as such. 
Study procedures such as the online delivery and pre-DA assessment made access to the DA more 
difficult than it would be in routine practice, where it would be appropriate to hand the patient a 
paper copy for immediate review. We suspect that others did not access the DA because it, and the 
study, were a burden at a time when they are dealing with the impact of their diagnosis, and 
planning for treatment. Therefore, patient uptake in this study may underestimate real-world 
conditions. Broader reach might be gained if the DA were distributed by breast care nurses as well as 
clinicians. 
At baseline, mean decisional conflict scores were high, consistent with patients delaying or feeling 
unsure about decision-making 22. Following use of the DA and a subsequent clinical consultation, 
decisional conflict scores were consistent with patients proceeding with implementation of their 
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treatment choice. This correlates with a significant decrease in the proportion of participants who 
reported being unsure about which treatment they preferred. The relative contributions of clinical 
consultation vs the DA are unable to be enumerated with this single-arm study design. Anxiety 
scores were consistent with participants being in a stressful situation, and did not decrease to 
population norms until assessment 4 25. Lower anxiety in the neoadjuvant group might be explained 
by patients’ expectations of receiving NAST if they were offered that treatment. Alternatively, 
anxious patients might have elected to have surgery first. Lower anxiety might also have been 
associated with seeing their tumour shrink, and with getting a feared treatment ‘over and done 
with’. A decision to have surgery up front might also have been seen as contradicting the perceived 
medical recommendation in patients who had been referred for NAST.  
Fear of cancer progression scores were similar to the mean score of 60.6 (SD 24.6) reported by 
historical breast cancer controls 28. This suggests that these women were no more worried than the 
average breast cancer patient about the impact of the cancer getting larger or developing distant 
metastases whilst on treatment. Mean decision regret at assessment 3 was comparable with 
historical breast cancer patient data indicating low levels of regret related to the decision about 
NAST 29. The strength of clinical recommendation for NAST will depend on the individual patient and 
tumour characteristics. Clinical equipoise was not expected about whether NAST or surgery was the 
best initial approach for individual patients, nor was the DA expected to change patients’ minds. 
Results support this, with no significant changes in preferred treatment following use of the DA. Only 
18 reported being unsure about their preferred treatment schedule pre-DA, which may represent 
clinical influence towards treatment decisions. Six of those 18 chose surgery, while two of the 41 
who were sure about their decision at baseline chose surgery. Unsure patients may choose the 
normative behavior of surgery first, or the DA may influence unsure patients towards surgery. It is 
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possible that the DA was not in fact balanced, however, most patients and clinicians perceived the 
DA to be balanced. 
This study is limited by its relatively small sample size and single-arm design. A single arm design was 
felt to provide adequate confidence in the DA’s safety and acceptability. Positive endpoints allow 
broad implementation of this DA, given the large existing literature on the efficacy of DAs. We 
cannot derive the relative contribution of the DA versus clinical consultations, independent 
information-seeking, discussion with family and friends, or natural history. The study population was 
well educated, which may reduce the generalizability to a less educated group. The DA was written 
at year 10 reading level, higher than the recommended year 8 level, which is a common issue in 
patient information material 33. Strengths include the evidence-based, systematic development 
process and the use of validated patient reported outcome measures. The DA was used successfully 
in a variety of settings as part of this study, supporting ability to be implemented in routine clinical 
care. 
Because DA uptake is typically low 34, implementation implications must be considered. A minority of 
investigators reported a small increase in consultation time when they used the DA, with no impact 
on their intention to use the DA, suggesting the benefits of the DA were considered worth additional 
consultation time. The document was intended to be reviewed in detail outside of the consultation 
to reduce impact on consultation time. The DA is scalable though electronic distribution.  The 
intervention will be made freely available to encourage sustained uptake.  
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 Conclusion 
A DA for women with operable breast cancer who were offered neoadjuvant systemic therapy was 
acceptable to clinicians and patients. It was feasible to integrate into patients’ care pathway, ideally 
after seeing a surgeon and before consultation with a medical oncologist for a final treatment 
decision. Improvements in decision-related outcomes were seen, without evidence of adverse 
effects. Implementation strategies are warranted to ensure optimal use in routine patient care.  
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Tables/figures 
Variable 
Number 59 
Age, years [mean (SD)] 52 (8.9) 
Marital status [n (%)] Married/De facto 48 (81.4) 
Single 11 (18.6) 
Highest education level [n (%)] Postgraduate 17 (28.8) 
Undergraduate 13 (22.0) 
Vocational 13 (22.0) 
High school 15 (25.4) 
Missing 1 (1.7) 
Private health insurance [n (%)] Yes 51 (86.4) 
No 8 (13.6) 
Health Professional [n (%)] Yes 10 (17.0) 
No 49 (83.0) 
English as first language [n (%)] Yes 56 (94.9) 
No 3 (5.1) 
Table 1. Participant characteristics. 
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 Level of control Survey 1 – 
preferred 
(n=59) 
% Survey 2 – 
preferred 
(n=51) 
% Survey 2 – 
actual 
(n=51) 
% 
Doctor makes final decision 7 11.9  5 9.8 6 11.8 
Doctor makes final 
decision, seriously 
considering my opinion  
9 15.3 11 21.6 6 11.8 
Shared 28 47.5 26 51.0 18 35.3 
I make final decision, 
seriously considering my 
doctor’s opinion 
15 25.4 8 15.7 19 37.3 
Patient makes final decision 0 - 1 2.0 2 3.9 
Table 2. Decision making preference questionnaire. 
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 Measure Assessment 
1 (n=59) 
Assessment 
2 (n=51) 
Assessment 
3 (n=51) 
Assessment 
4 (n=29)1 
P-value 
Total decisional conflict 
(mean) 
33.4/100 
(SD 19.3) 
21.0 (SD 
14.1) 
- - <0.0012 
Information detail preference 
(mean) 
8.5/10 (SD 
2.16) 
8.6/10 (SD 
2.02) 
- - 0.732 
Information type     0.693 
All information, good and 
bad 
76.3%  72.6% - -  
Additional information only 
if it is good news  
5.1%  3.9% - -  
Only information needed to 
care for myself 
18.6%  23.5% - -  
Anxiety 55.4/100 
(SD 15.0) 
49.4 (SD 
14.1) 
40.1 (SD 
13.0) 
36.1 (SD 
12.2) 
<0.0014 
Distress (mean) 5.9/10 (SD 
2.9) 
5.0/10 (SD 
2.5) 
3.2/10 (SD 
2.5) 
2.2/10 (SD 
2.5) 
<0.024 
Fear of cancer progression  33.4/60 (SD 
7.2) 
29.9/60 (SD 
7.2) 
- <0.0012 
Fear of cancer recurrence - - 58.9/168 
(SD 25.0) 
57.5/168 
(SD 22.9) 
0.3595 
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 Measure Assessment 
1 (n=59) 
Assessment 
2 (n=51) 
Assessment 
3 (n=51) 
Assessment 
4 (n=29)1 
P-value 
Satisfaction with decision 
(mean) 
- - 25.5/30 (SD 
3.6) 
- 0.0056 
Decision Regret - - 16.4/100 
(SD 20.0) 
10.0/100 
(SD 15.4)  
0.01765 
Knowledge (mean) - 76% (SD 
12.5) 
- - <0.0015 
Feedback (mean) - 74% (SD 
8.4) 
- - <0.0015 
Table 3. Patient reported outcome scores. SD, standard deviation; CI, confidence interval. 1At the 
data cut-off, 20 patients had yet to complete their 4th questionnaire; 2Paired t-test; 3McNemar’s 
test; 4Linear mixed model; 5P-value comparison with pre-specified hypothesis. 
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Figure 1. CONSORT diagram. *At the data cutoff date, 20 participants had not yet reached their 4th 
questionnaire. DOMINO: decision-making about neoadjuvant therapy for breast cancer study; NAST: 
neoadjuvant systemic therapy. 
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Figure 2. Decisional conflict subscales pre- and post-decision aid. Horizontal reference lines at scores 
of 25 and 37.5. P-value<0.002 for all pre-post comparisons. Boxes represent the interquartile range 
(25th to 75th), whisker length is 1.5 times the interquartile range above and below the box, and dots 
represent values outside the whiskers. 
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 APPENDIX A 
 
Pre-DA 
Assessment 
Post-Treatment 
Decision 
Assessment 
Post-Chemo 
therapy (NAST) 
Assessment, or 
post-surgery 
(non-NAST) 
Post-Treatment 
Assessment 
Decision Aid 
Administration 
    
Decision conflict scale X X   
STAI-6 Anxiety X X X X 
DMPQ 
Preferred X X   
Actual  X   
Distress thermometer X X X X 
Information and 
involvement 
preferences  
X X   
EQ-5D-5L (optional) X X X X 
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Pre-DA 
Assessment 
Post-Treatment 
Decision 
Assessment 
Post-Chemo 
therapy (NAST) 
Assessment, or 
post-surgery 
(non-NAST) 
Post-Treatment 
Assessment 
Knowledge of DA 
Information 
 X   
Decision Aid Feedback  X   
Satisfaction with 
decision scale 
 X   
Fear of progression 
(FOP 12) 
 X X  
Decision regret scale   X X 
Fear of Cancer 
Recurrence Inventory 
  X X 
Schedule of assessments. DA: decision aid; DMPQ: Decision Making Preference Questionnaire; NAST: 
neoadjuvant systemic therapy. 
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 APPENDIX B 
 
Study Schema.  
 
APPENDIX C 
Neoadjuvant decision aid 
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 APPENDIX D 
IPDAS Checklist, version 4.0 
Dimensions Criterion Achieved 
Information 
Qualifying 
criteria 
The patient decision aid describes the health condition or 
problem for which the index decision is required. 
Yes 
 The patient decision aid explicitly states the decision that 
needs to be considered (index decision). 
Yes 
 The patient decision aid describes the options available for the 
index decision. 
Yes 
 The patient decision aid describes the positive features 
(benefits or advantages) of each option. 
Yes 
 The patient decision aid describes the negative features 
(harms, side effects or disadvantages) of each option. 
Yes 
Certification 
criterion 
The patient decision aid shows the negative and positive 
features of options with equal detail (e.g., using similar fonts, 
sequence, presentation of statistical information). 
Yes 
Quality 
criteria 
The patient decision aid describes the natural course of the 
health condition or problem, if no action is taken (when 
appropriate). 
Not considered 
appropriate 
 The patient decision aid makes it possible to compare the 
positive and negative features of the available options. 
Yes 
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Dimensions Criterion Achieved 
Probabilities 
Quality 
criteria 
The patient decision aid provides information about outcome 
probabilities associated with the options (i.e., the likely 
consequences of decisions). 
Yes 
The patient decision aid specifies the defined group (reference 
class) of patients for whom the outcome probabilities apply. 
Yes 
The patient decision aid specifies the event rates for the 
outcome probabilities. 
Yes 
The patient decision aid allows the user to compare outcome 
probabilities across options using the same time period (when 
feasible). 
Yes 
The patient decision aid allows the user to compare outcome 
probabilities across options using the same denominator 
(when feasible). 
Yes 
The patient decision aid provides more than 1 way of viewing 
the probabilities (e.g., words, numbers, and diagrams). 
Yes 
Values 
Qualifying 
criterion 
The patient decision aid describes what it is like to experience 
the consequences of the options (e.g., physical, psychological, 
social. 
Yes 
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 Dimensions Criterion Achieved 
Quality 
criterion 
The patient decision aid asks patients to think about which 
positive and negative features matter most to them (implicitly 
or explicitly). 
Yes 
Guidance 
Quality 
criteria 
The patient decision aid provides a step-by-step way to make a 
decision. 
Yes 
 The patient decision aid includes tools like worksheets or lists 
of questions to use when discussing options with a 
practitioner. 
Yes 
Development 
Quality 
criteria 
The development process included a needs assessment with 
clients or patients. 
Yes 
 The development process included a needs assessment with 
health professionals. 
Yes 
 The development process included review by clients/patients 
not involved in producing the decision support intervention. 
Yes 
 The development process included review by professionals not 
involved in producing the decision support intervention. 
Yes 
 The patient decision aid was field tested with patients who 
were facing the decision. 
Yes 
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Dimensions Criterion Achieved 
The patient decision aid was field tested with practitioners 
who counsel patients who face the decision. 
Yes 
Evidence 
Certification 
criteria 
The patient decision aid (or associated documentation) 
provides citations to the evidence selected. 
Yes 
The patient decision aid (or associated documentation) 
provides a production or publication date. 
Yes 
The patient decision aid (or associated documentation) 
provides information about the update policy. 
No 
The patient decision aid provides information about the levels 
of uncertainty around event or outcome probabilities (e.g., by 
giving a range or by using phrases such as “our best estimate 
is…”). 
Yes 
Quality 
criteria 
The patient decision aid (or associated documentation) 
describes how research evidence was synthesized. 
Yes 
The patient decision aid (or associated documentation) 
describes the quality of the research evidence used. 
Yes 
Disclosure 
Certification 
criterion 
The patient decision aid (or associated documentation) 
provides information about the funding source used for 
development. 
Yes 
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 Dimensions Criterion Achieved 
Quality 
criterion 
The patient decision aid includes authors’/developers’ 
credentials or qualifications. 
Yes 
Plain language 
Quality 
criterion 
The patient decision aid (or associated documentation) reports 
readability levels (using one or more of the available scales). 
Yes 
Evaluation 
Quality 
criteria 
There is evidence that the patient decision aid improves the 
match between the preferences of the informed patient and 
the option that is chosen. 
Yes 
 There is evidence that the patient decision aid helps patients 
improve their knowledge about options’ features. 
No 
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 5.3  Abstract and poster presentation: Primary results of a study to evaluate a decision aid for 
women offered neoadjuvant systemic therapy for breast cancer. 
 
Zdenkowski N, Butow P, Spillane AJ, Douglas C, Beckmore C, Jones M, Boyle FM. Annals of Oncology 
2017;28(Suppl. 5). European Society of Medical Oncology Annual Meeting 2017, Madrid, Spain. 
 
This abstract was presented as a poster in the psycho-oncology session of the European Society of 
Medical Oncology Annual Meeting. This is the premier annual European medical oncology 
conference. The abstract and poster were the first publication and presentation, respectively, of the 
primary results of the decision aid evaluation study. 
 
Author contributions 
Conception and design: NZ, FB, PB, CD 
Participant recruitment: NZ, FB, CD, AS 
Data collection: NZ 
Data analysis and interpretation: NZ, FB, PB, MJ, AS 
Abstract drafting: NZ 
Abstract critical review and review of final abstract: All authors 
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 Background 
Women diagnosed with large or highly proliferative operable breast cancer may be offered 
neoadjuvant systemic therapy (NAST) for reasons including downstaging, prognostication or 
expanding surgical options. We aimed to systematically develop, and evaluate a DA for women who 
had been offered NAST. 
 
Methods 
Eligible women who were considered candidates for NAST, from four Australian recruiting centres 
were enrolled in a single arm longitudinal study. Participants completed online questionnaires prior 
to accessing the DA, and on three occasions post-DA. Primary outcomes were feasibility of use, and 
acceptability to patients and clinicians. Secondary outcomes were patient reported measures 
relevant to patient decision-making. 
 
Results 
Seventy-nine women were offered study participation and 59 enrolled. Patients were typically well 
educated, married, had health insurance and were information seekers (mean information needs: 
7.5/10; SD 1.84). 59/79 (74.7%) patients who were offered study participation accessed the DA and 
49 (79.7%) of those 59 participants reported having read it. 41/51 (80.4%) participants who 
completed the post-DA assessment reported that the DA helped them with their decision about 
NAST. 51/59 (86%) participants elected to receive NAST. 16/18 (88.9%) investigators would continue 
to use the DA in routine practice. Post-DA, decisional conflict decreased significantly across all 
subscales (p<0.01); anxiety and distress decreased significantly; 86.3% achieved at least as much 
decisional control as they desired; a high level of knowledge was demonstrated; and 39/51 (76.5%) 
patients had a high (≥24) Satisfaction with Decision score (mean 25.5, SD 3.6). 84.4% reported that 
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they shared responsibility for the decision about NAST. Investigators reported that the DA was able 
to be integrated into patient care. 
Conclusions 
Study primary outcomes were positive, showing the DA was feasible and acceptable to patients and 
clinicians. Improvements in decision-related outcomes were demonstrated, and the DA could be 
included in routine workflow. This DA can be implemented into routine clinical practice for women 
with operable breast cancer who are candidates for NAST. 
[Character count, including title: 1997] 
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Chapter 6: Discussion and conclusion 
213
6.1 Introduction 
This thesis makes an original contribution towards better shared decision-making for women who 
are considering NAST for operable early stage breast cancer. The work was conceived in response to 
a clinically identified need and underpinned by a strong rationale. A step-wise approach was taken in 
the development of a decision aid. First, interviews and a survey were conducted to understand the 
needs of patients and clinicians who are considering NAST. Second, a decision aid was developed, 
based on the work with patients and clinicians. Third, the decision aid was evaluated in a clinical 
study. 
6.2 Summary of findings 
The patient interview study was conducted before this candidature, but is discussed as important 
preliminary data to inform the program of research. This study provided an understanding of the 
context in which women make decisions about NAST. The 22 women who were interviewed 
indicated that the principles of shared decision-making were not being achieved due to perceived 
complexity and urgency of this treatment decision. They were unable to identify sufficient 
information about NAST to become as well informed as they would have liked. Despite that, they 
were highly satisfied with receiving NAST. They placed trust in their clinicians as a proxy for their 
preferred level of involvement in the decision. This work identified a potential role for a decision aid 
for this patient population. 
Breast cancer clinicians and patients form a core dyad for decision-making about breast cancer 
management. Therefore, breast cancer clinicians were surveyed to: understand the spectrum of 
approaches taken by clinicians when offering and prescribing NAST; inform decision aid content and 
design; and contribute to implementation considerations for the decision aid in routine practice. An 
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 email survey invitation was sent to members of Australian and New Zealand breast cancer specialist 
professional groups, to participate in an online survey. Responses were recorded from 207 eligible 
clinicians, indicating strong interest in NAST for operable breast cancer patients with all major breast 
cancer subtypes. Fifty-eight percent wanted to increase the number of patients treated with NAST as 
part of a clinical trial, and 45% wanted to increase the number treated with NAST in routine care. 
Eighty-six percent (66/76) of respondents to a supplementary questionnaire indicated that they 
would offer a decision aid developed for patients with operable breast cancer who are candidates 
for NAST. 
 
We conducted a systematic review to identify the spectrum of decision aids for early stage breast 
cancer treatment decisions and to understand study design and results. The review identified 23 
individual decision aids that had been developed for women who were making treatment decisions 
about early stage breast cancer, reported in 33 original research reports. The published decision aid 
literature demonstrated a decrease in decisional conflict, and increased in knowledge and 
satisfaction, without any changes in anxiety or depression. No decision aid was identified for women 
who had been offered NAST. Similar to other breast cancer decisions for which decision aids are 
available, the decision about NAST is preference sensitive. However, it is informed by factors distinct 
from other breast cancer treatment decisions. Therefore, the need for development and evaluation 
of a separate decision aid was considered justified. 
 
The decision aid, developed as described in chapter 5, was evaluated in a prospective, single-arm, 
longitudinal, multicentre study. All primary endpoints were met, confirming that the decision aid 
was acceptable to patients and clinicians, and feasible to use in clinical practice. Eighty-two percent 
of participants found the decision aid acceptable: 41 out of 51 who completed assessment 2 
considered the decision aid sufficiently useful to recommend to others in their situation. It was 
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acceptable to 89% of clinicians: 16 out of the 18 who responded to the investigator survey planned 
to continue to use the decision aid in routine practice. The decision aid could be feasibly introduced 
into the clinical encounter, with 59 out of 77 (77%) eligible patients accessing the decision aid after 
being offered participation.  
Secondary endpoints were patient reported outcome measures, an investigator survey and patient 
interviews. Patient reported outcome measures are reported in the submitted manuscript (Chapter 
5). Patient reported outcome scores were consistent with a positive effect of the decision aid. 
Decisional conflict declined in all subscales; 86% of participants achieved at least as much decisional 
control as they desired; fair agreement between preferred and achieved decisional control was 
reported; agreement was good between preferred and actual treatment received; knowledge scores 
were high; and satisfaction with decision was high. A majority of investigators indicated that the 
decision aid did not have a significant impact on consultation time, nor did they perceive an impact 
on patient anxiety or treatment choice.  
Patients who participated in the decision aid study were interviewed by another researcher, with my 
guidance, advice and analysis. The publication reporting these qualitative data on women’s 
experiences with the decision aid is included as appendix C (Herrmann et al., 2017). The 20 women 
who were interviewed confirmed the quantitative findings from the decision aid study, perceiving 
the decision aid as a useful decision-making tool. Qualitative analysis of interview data identified 
some unifying themes: integration of the decision aid into the care pathway; improved knowledge 
and understanding; customised, reliable information; and facilitation of shared decision-making. 
Participants felt informed and involved, and could integrate the decision aid into their decision-
making process. The timing of application was appropriate, between the surgical and medical 
oncology appointments, allowing time for at-home review and consideration of options. They 
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appreciated having time to read and consider the information rather than relying only on 
information received during clinical consultations. The information was seen as reliable, relevant and 
sufficient for their deliberation about neoadjuvant therapy. Some respondents would have preferred 
to have received the decision aid directly from their surgeon rather than after the first questionnaire 
so that they could use it immediately. Some felt that the decision aid, as a self-contained resource, 
reduced their sense of being overwhelmed by a diagnosis of breast cancer and by the wide array of 
breast cancer information available.  
As a whole, this research represents a methodical progression of concepts that worked towards 
improving the level of shared decision-making in women considering neoadjuvant systemic therapy 
for operable breast cancer. An understanding of the patient, clinical and system perspectives 
identified a need, and shaped the practical aspects of how that need could be responded to. A 
review of the decision aid literature demonstrated a gap, and gave examples of decision aid design 
and content. The review of decision aids also gave examples of study designs and measures used in 
the evaluation of decision aids for patients with breast cancer. The final study then tied the 
preceding studies into an approach that intended to work with patients, clinicians and the 
healthcare system to improve shared decision-making. 
6.3 Results in context 
This body of work has demonstrated a need for a decision aid for women considering NAST for 
operable breast cancer. We have subsequently conducted a single arm study showing that a decision 
aid designed for that population is feasible and acceptable, and associated with improvements in 
decision-related outcomes. These results are consistent with the most recent update to a systematic 
review of decision aids for treatment and screening decisions by Stacey et al (Stacey et al., 2017). 
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Results are also consistent with the data from studies of decision aids for patients with breast cancer 
(Chapter 2). 
The systematic review of decision aids for general medical treatment or screening decisions included 
only randomised controlled trials comparing decision aids with usual care and/or an alternative 
intervention (Stacey et al., 2017). These findings from randomised trials are relevant, firstly to 
demonstrate the effectiveness of decision aids, and secondly to put the results of our study into 
perspective.  The body of randomised data is substantial, with 105 studies that included 31,043 
participants meeting eligibility for inclusion in the Stacey review, which were pooled using mean 
differences and risk ratios in a random effects model. Compared with usual care, decision aids 
increased knowledge by an average of 13.27/100 (95% CI 11.32 to 15.23), accuracy of risk perception 
(risk ratio of 2.10, 95% CI 1.66 to 2.66), and congruency between informed values and treatment 
choice (risk ratio 2.06, 95% CI 1.46 to 2.91).  
The Stacey meta-analysis showed that decision aids decreased decisional conflict in the uninformed 
subscale (mean difference -9.28/100, 95% CI -12.20 to -6.36), indecision about personal values 
(mean difference -8.81/100, 95% CI -11.99 to -5.63), and the proportion of decisions that were 
clinician controlled (risk ratio 0.68, 95% CI 0.55 to 0.83). In our neoadjuvant population, all decisional 
conflict subscale scores decreased after use of the decision aid. Without a control group, validated 
thresholds were used to determine participants’ decisional conflict (O'Connor, 1995). A score 
exceeding 37.5 is associated with delay or uncertainty about implementation of a decision, while a 
score of less than 25 is associated with implementing decisions. A mean decisional conflict score of 
21 (95% CI 17-25) at assessment 2 indicated that participants intended to follow through with their 
decision.  
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Pre-post studies in breast cancer in which decisional conflict was reported have shown a variable 
effect post-decision aid: no change (Dhage et al., 2013); or decrease (Jibaja-Weiss et al., 2006, Wong 
et al., 2012). Baseline decisional conflict scores were numerically lower in these studies than in our 
neoadjuvant study. In the study by Wong et al., post decision aid total decisional conflict scale score 
was 18.3 (Wong et al., 2012).  Numeric scores were not reported in the Dhage study, which was only 
reported as a conference abstract (Dhage et al., 2013). In the study by Jibaja-Weiss et al., only 
uncertainty and unclear values decisional conflict subscales were reported numerically. The 
uncertainty score was 24.5, and the unclear values score was 27.5. Uncertainty was similar in our 
study with a score of 26.6, but unclear values was lower in our study at 19.9. The decisional conflict 
scale includes a question on which treatment the patient prefers at that time, in this case surgery 
first, NAST, or unsure. There was a significant reduction in the proportion of participants who were 
unsure at assessment 2. 
 
Decision aids are not intended to change patients’ minds about treatment, rather to present a 
balanced view and ensure that their choice is congruent with their values (Abhyankar et al., 2013). 
Consistent with this message, participants in our study who reported a preference at assessment 1 
did not change their preference at assessment 2. However, of those who were unsure at assessment 
1, a significantly greater proportion decided to have surgery compared with those who were sure at 
assessment 1. It could be argued that unsure patients are most in need of a decision aid, but patient 
selection on that basis could exclude those who might experience benefits in decisional involvement, 
reduced decisional conflict, improved knowledge or other outcomes. Some decision aid studies have 
demonstrated changes in treatment preference, with increased rates of Hepatitis B vaccination 
(Clancy et al., 1988), psycho-educational therapies (Mott et al., 2014) and preventative 
cardiovascular medications (Sheridan et al., 2011); and decreased cardiac stress testing (Hess et al., 
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 2012), number of embryos transplanted after in vitro fertilisation (van Peperstraten et al., 2010), 
PSA screening (Frosch et al., 2008) and antibiotic use for respiratory infections (Legare et al., 2011) . 
Most studies, however, have shown a variable effect on treatment choice within studies (Stacey et 
al., 2017). 
 
We also assessed the level of agreement between the preferred treatment and actual treatment 
received. This is a proxy for whether the decision was based on the patient’s values, or whether 
some other factor was influencing their decision. Surveyed clinicians indicated that the decision 
about whether a patient would receive surgery or NAST first was rarely in true clinical equipoise, and 
the clinician would often influence patients’ decision. Congruence between informed values and 
choice of treatment has been measured in some decision aid studies using the Multi-Dimensional 
Measure of Informed Choice (Michie et al., 2002, Stacey et al., 2017). This score was not included in 
the neoadjuvant decision aid study due to the potential for questionnaire non-completion as a result 
of question overload. We found good agreement between preferred and actual treatment, 
suggesting that most participants were not feeling pressure from clinicians or others about their 
treatment choice. 
 
The mean knowledge score across 71 studies in the Stacey meta-analysis, in patients who had used a 
decision aid was 70/100 (Stacey et al., 2017), similar to the score of 76.5 in the neoadjuvant decision 
aid study patients. Knowledge scores are usually derived from a custom questionnaire designed for 
an individual study, making cross-trial comparisons difficult to interpret (Sepucha et al., 2013). 
Health literacy can also impact knowledge scores. A lower health literacy population may not 
achieve a total knowledge score as high as the higher health literacy population, but previous studies 
have shown greater relative increase in knowledge scores in lower health literacy patients (Trevena 
et al., 2008). Our study did not measure health literacy, so it’s impact could not be assessed. 
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In a subgroup analysis of the meta-analysis of randomised trials, decision aids remained effective 
whether they were used in preparation for, or during the consultation (Stacey et al., 2017). Most 
studies evaluated decision aids for use outside the consultation. Our decision aid was intended to be 
introduced in a clinical consultation, typically with the surgeon at the time of referral for NAST for 
use after that consultation. It was intended for use outside the clinical consultation in preparation 
for the initial consultation with a medical oncologist, or for a subsequent consultation with the 
surgeon. These patients would often wait for several days to a week or more for the subsequent 
appointment, giving them time to consider the decision and use the decision aid to refine their 
preferences. The timing is a novel aspect of this decision aid, whereby one clinician offers the 
decision aid in preparation for a visit with another clinician. Other studies that investigated decision 
aid use in preparation for a clinical consultation identified appropriate patients via a telephone call 
to patients awaiting their appointment (Belkora et al., 2012).  
 
Nurses were an important resource in the neoadjuvant process, acting as a liaison between clinicians 
and patients. This nursing role was not explicitly specified in the study protocol, but was 
implemented at sites to support patients to navigate the health system and to become better 
informed about the options. Nurses helped identify patients suitable for neoadjuvant therapy at the 
time of diagnosis, and then helped to arrange timely medical oncology review. They were available 
by phone for questions that arose in between clinical appointments. Specific data was not collected 
on the impact of nurses on patients’ decision about neoadjuvant therapy. 
 
The results of the neoadjuvant decision aid study are also broadly consistent with results from other 
early stage breast cancer decision aid studies (Chapter 2). Our systematic review of breast decision 
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 aids used less stringent inclusion criteria than the Cochrane review of all decision aids, because we 
wanted to include all available breast cancer decision aids in a gap analysis (Stacey et al., 2017). This 
resulted in inclusion of randomised controlled trials, cluster randomised trials, non-randomised 
comparative studies, single arm pre-post studies and cross-sectional cohort studies. Outcome 
measures were heterogeneous, precluding meta-analysis. Outcomes included treatment choice, 
decisional conflict score, knowledge, satisfaction with decision, decisional regret, acceptability and 
values-choice agreement. These outcomes were also measured in the neoadjuvant decision aid 
study. In some instances, the same outcome measure scales were used in these studies, but in other 
instances different scales were used to measure the same or similar constructs. 
 
Twelve out of 17 comparative breast cancer decision aid studies demonstrated efficacy in reducing 
decisional conflict or increasing knowledge. Treatment choice was altered in six out of the 12 studies 
that reported this outcome, including: decreased (Whelan et al., 2004) or increased (Jibaja-Weiss et 
al., 2011) mastectomy rate; increased use of autologous reconstruction (Lee et al., 2010); decreased 
mastectomy rate combined with immediate reconstruction (Lam et al., 2013); and lower use of 
adjuvant chemotherapy in lower recurrence risk patients (Peele et al., 2005) or in those with more 
accurate risk perception (Belkora et al., 2012). The neoadjuvant decision aid study did not show a 
significant change in preferred treatment before or after the decision aid, which is more likely to 
relate to the clinical context around the decision rather than the decision aid itself. 
 
The results from the nine single arm pre-post studies identified and described in the systematic 
review of breast cancer decision aids (Chapter 2) are similar to those from our neoadjuvant decision 
aid study, with the caveat of cross-trial comparisons compounded by the variety of outcome 
measure definitions that were used in these studies (Belkora et al., 2012, Dhage et al., 2013, Jibaja-
Weiss et al., 2006, Levine et al., 1992, Peate et al., 2011, Sheppard et al., 2008, Sherman et al., 2014, 
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 Sivell et al., 2012, Wong et al., 2012). These decision aids were developed for several breast cancer 
treatment decisions in several populations, using a variety of formats, and then distributed in 
person, by post, or electronically. Results of our study are presented in detail in the manuscript in 
Chapter 5.  
 
Feasibility and patient acceptability were reported in most pre-post breast cancer studies; however, 
clinician acceptability was not reported in any. Feasibility, defined as the proportion of patients who 
either participated in the study or accessed the DA, was more than 50% in all but one study. Three 
studies used a similar acceptability definition to our neoadjuvant study (Levine et al., 1992, Peate et 
al., 2011, Wong et al., 2012). Consistent with our results, more than eighty percent of participants in 
those studies would recommend the decision aid to others in their situation. These results suggest 
that within a study environment, breast cancer decision aids can be used in clinical practice and are 
considered helpful by patients. 
 
Patient reported outcome measures varied in these breast cancer studies. All five studies that used a 
variation of the decisional conflict score demonstrated a decrease in either total or subscale scores. 
Knowledge scores increased in these studies, however in a single arm study, factors other than the 
decision aid may confound the second score. We did not evaluate knowledge prior to the decision 
aid, but the post-decision aid score of 76% is consistent with other studies, which by necessity used 
custom-designed knowledge questionnaires (Belkora et al., 2012, Dhage et al., 2013, Peate et al., 
2011, Sheppard et al., 2008, Sivell et al., 2012, Wong et al., 2012). Custom knowledge questionnaire 
results are often specific to a study, limiting cross-trial comparisons (Sepucha et al., 2013). As in our 
study, most patients in these studies preferred either shared or patient-led decisional control. In 
contrast to our neoadjuvant study, satisfaction with decision, anxiety, distress, regret or information 
and involvement preferences were not usually reported. 
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There has been little published work comparing different decision aids formats. Several breast 
cancer decision aids are online- or computer-based, using either an interactive or a didactic format, 
with positive study outcomes (Dhage et al., 2013, Sivell et al., 2012, Sherman et al., 2014, Vickers et 
al., 2009). The neoadjuvant decision aid was presented online without an interactive element, and 
for flexibility could be printed as a booklet if patients preferred that format. Booklet or decision-
board style decision aids were also effective, suggesting that format is not critical to the success of 
the decision aid on average. A variety of formats might be effective, or certain populations might 
benefit from a particular decision aid format. 
 
6.4  Limitations 
These results must be considered in the context of some limitations that have potential to affect 
their interpretation and, in the case of the clinician survey and decision aid study, generalisability to 
a broader population. The interviews, clinician survey and the decision aid study were all potentially 
impacted upon by response bias. The decision aid study was not a randomised comparative study, 
limiting the conclusions that can be drawn about the contribution of the decision aid toward the 
observed improvements in decision-related outcomes. 
 
Women who responded to the invitation to participate in the interview study were members of a 
group whose purpose is to match potential study participants with research projects. They were 
willing to be interviewed by a medical oncologist, suggesting a higher level of confidence and 
interest in being involved in clinical encounters and decision-making. Whilst qualitative research is 
not intended to be generalisable, trustworthiness is relevant, as assessed by credibility, 
transferability, consistency and neutrality (Thomas & Magilvy, 2011). The views of women with less 
224
 interest in being involved in the decision are not known. Despite the interview guide being as 
balanced as possible, subtle cues may have been introduced in the interviews to sway participants 
towards affirmative responses about interest in being involved in the decision, about the option of 
neoadjuvant therapy, and about role of decisional support. Women who had a good experience with 
NAST and were cancer-free were more likely to be willing to be interviewed than women who had a 
bad experience or had relapsed. Because neoadjuvant therapy for operable breast cancer has not 
previously been widely used in Australia, the number of potential interview candidates was small, so 
it was felt that in depth qualitative analysis would provide greater insight than a quantitative survey. 
These limitations may have overstated the potential role of a decision aid, however the study results 
overall were strongly supportive of ongoing research in patient decision-making about NAST. 
 
The clinician survey was also subject to bias towards a higher level of interest in NAST in respondents 
compared with non-respondents. The invitation was sent to members of specialist professional 
groups, and stipulated subspecialty interest in breast cancer meaning that respondents were likely 
to be more up to date with current international research and clinical practice. This is not a barrier 
to the development and testing of a decision aid, but is likely to overestimate both the proportion of 
patients offered NAST in routine practice, and the reported interest in a decision aid for those 
patients. The response rate was low, despite attempts to reduce the denominator by providing a 
hyperlink in the invitation so that recipients could indicate that they were ineligible. The survey, in 
hindsight, was too long for busy clinicians and could have been more focussed on the questions that 
were of prime importance to understand the population and the decision-making process. The 
questions about the finer details of the logistics of managing patients on neoadjuvant therapy could 
potentially have been removed to shorten the time required to complete the questionnaire. Overall, 
the number of responses remains sufficiently large for the data to be considered robust. An 
alternative method of understanding practice patterns would have been to interrogate linked 
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 databases including CHeReL (www.cherel.org, incorporating Medicare and admitted patient 
databases), the Australian Pharmaceutical Benefits Scheme, the BreastSurgANZ national audit 
database, and state cancer registries. This gives direct information rather than relying on self-report 
from clinicians, and could be obtained on a larger scale, without response bias. However, the data 
that could be obtained does not provide sufficient detail about variables including cancer subtype 
and clinician preference. 
 
Limitations of the study to evaluate the decision aid include limitations related to study design and 
conduct, and limitations related to the data. The non-randomised design limits the ability to draw 
conclusions about the magnitude of difference in patient reported outcomes attributable to the 
decision aid, in distinction from other influences on patients’ decision-making process. Clinical 
consultations, other information sources, family and friends, and time itself are expected to have 
impacted on outcome measure results. This meant that patient reported measures were secondary 
study outcomes. The single arm study design was pragmatic, to contain costs, maximise recruitment 
and minimise the study duration. Previous decision aid evaluation studies have demonstrated 
benefits in decision related outcomes for a broad range of medical treatment decisions (Stacey et al., 
2017), and specifically for breast cancer decisions (chapter 2 of this thesis). The IPDAS collaboration 
guidelines propose criteria for decision aid qualification, certification and quality, as discussed in 
chapter 3 (methods) (Durand et al., 2015). Only one criterion, the demonstration of increased 
knowledge, out of a total of 35 IPDAS criteria, requires a comparative study design to fulfil. 
Therefore, data from a single arm study was considered sufficient to determine if the decision aid 
was appropriate to be introduced into routine practice. 
 
Implementation of a decision aid without randomised data may not be universally accepted. There 
may be concern that a non-randomised trial does not give enough efficacy data to support 
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widespread use. We argue that the decision aid should be made available, and that clinicians who 
wish to use it should base that decision on the available evidence, without the need for a large, 
costly, randomised efficacy trial. This decision aid was developed based on best available evidence, 
and was evaluated in a prospective clinical trial. There were no adverse safety signals to suggest that 
patients might be harmed from the use of this tool. Eight of the studies in the systematic review that 
forms Section 2.9 were single arm studies with a similar design to the design that was used in the 
neoadjuvant breast cancer decision aid. We believe that clinicians should have the option to use the 
decision aid for their patients if they wish. 
The study was conducted in a predominantly online environment to give participants flexibility for 
questionnaire completion and decision aid access; to minimise transcription time and errors; and to 
allow streamlined central study coordination. Online or electronic data collection is consistent with 
recommendations for collection of patient reported outcomes in oncology (Basch et al., 2012). 
Results from electronic data capture are equivalent to data from paper and pencil questionnaires 
(Gwaltney et al., 2008) and have been shown to be feasible to use (Bennett et al., 2012). Participants 
needed to have an email address so that they could receive emailed links to access study 
questionnaires and the decision aid, and access to a computer to complete the questionnaires. Four 
otherwise eligible participants were screened out because they did not have email or computer 
access. On one hand, the decision aid may be less relevant for patients who were ineligible because 
they did not have email and internet access due to differences in characteristics such as age and 
health literacy. However, patients of lower socio-economic status can also benefit from web-based 
decision aids (Alam et al., 2016).  
This study was offered to patients at a time of distress from a recent diagnosis of breast cancer, 
which may have reduced both the number of patients who were offered study participation, and the 
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 rate of consent if the study was offered. Reasons for screen failures were requested from 
investigators, however this number is likely to be an underestimate due to non-submission of 
screening data. The requirements for participation, such as questionnaire completion, may have 
been a barrier to study entry for some potential participants who would have otherwise benefited 
from a decision aid. Of the 18 who agreed to participate but then did not access the study consent 
online, ten made an explicit decision not to participate and one did not receive the invitation email. 
The reason for non-participation was not recorded for the other seven. Patients’ reason not to 
participate was not routinely collected data, but two volunteered that they did not have sufficient 
time.  
 
If the decision aid was handed out as a paper booklet by surgeons at the time of referral for NAST, 
patterns of usage and outcomes may have been different. In a study of men with prostate cancer, an 
electronic decision aid was less likely to be accessed than the paper version (Tomko et al., 2015), 
suggesting that a print-based option should be made available. A larger number of patients may 
have been able to access the decision aid if their access had not been limited by study-specific 
processes such as questionnaires. Decision aids are more likely to be used and valued by the patient 
if the doctor introduces them within the consultation, and prompts patients to use them (Volz et al., 
2015). In this study, the pre-post design prevented the decision aid from being introduced in the 
consultation. 
 
Outcome measures were selected to include relevant information as determined by an expert 
advisory group, with validated scales commonly used in decision aid and breast cancer studies. The 
total number of questions was limited to avoid questionnaire fatigue and non-completion or 
dropout amongst study participants (Basch et al., 2012). The knowledge questionnaire was created 
for this study because a validated neoadjuvant knowledge questionnaire was not available. The 
228
 threshold for acceptable knowledge was therefore based on expert opinion. The fear of cancer 
progression questionnaire was developed for studies of patients with metastatic cancer, but was 
relevant for this study population who had localised cancer that had the potential to progress during 
treatment (Simard and Savard, 2009). Generic quality of life measures are available, such as the 30-
item European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire in 
Cancer (EORTC QLQ-C30), however these were unlikely to be sufficiently sensitive to give useful data 
in this setting (Aaronsen et al., 1993). Exploratory data from the EuroQol 5-dimension 5-level health 
economic scale was collected, but this score is designed for comparative studies so did not provide 
additional useful data (Pickard et al., 2007). Missing data was minimal, suggesting that either 
participants were motivated, and/or the assessments were not excessively long. Whilst many 
additional patient reported outcomes could have been included, I do not believe that important 
outcomes measures were omitted. 
 
Study participants were younger than the average breast cancer patient (Australian Institute of 
Health and Welfare, 2017, Yu et al., 2014), well educated, English speaking, most had private health 
insurance, and one-sixth had worked as a health professional. Whilst a direct measure of health 
literacy was not included, these demographic data suggest that the study population had relatively 
high health literacy and a high level of health care engagement (Halverson et al., 2015, Wigfall and 
Tanner, 2016). This demographic profile was due to recruitment sites in private healthcare facilities 
enrolling the majority of participants. These sites were selected on the basis of high numbers of 
neoadjuvant patients, and pre-existing collaborations with the research team.  
 
Patients with higher health literacy experience greater engagement in shared decision-making and 
are likely to obtain better outcomes from a decision aid compared with patients with low health 
literacy (McCaffery et al., 2010). The patient outcomes reported in this study may not fully translate 
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into similar outcomes in low health literacy patients, who remain an understudied population 
(McCaffery et al., 2010). The decision aid was designed to be accessible to patients with a range of 
health literacy, by using both written and graphical representations of information (Trevena et al., 
2013). On average, the reading level of text was grade 10, which is higher than the grade 8 reading 
level that is recommended, however relevant information could still be obtained without reading all 
the text (McCaffery et al., 2013). Studies in low and high health literacy populations have found that 
decision aids consistently increase knowledge (Smith et al., 2010, Trevena et al., 2008). While the 
absolute levels knowledge and engagement achieved by lower health literacy patients may not be as 
high as patients with higher health literacy, relevant improvements may still be seen. Ideally the 
neoadjuvant decision aid study would have included a wider range of education levels and health 
literacy, but the decision aid should still be considered appropriate for lower health literacy patients. 
6.5 Implementation of decision aids 
Despite the substantial body of evidence supporting decision aid efficacy, it is acknowledged that 
decision aid use in routine clinical practice is variable at best, and typically low (Elwyn et al., 2013). 
Additional research is needed to ensure that patients who are most likely to benefit from a decision 
aid are able to access the relevant one (Herrmann et al., 2016). Patient-, clinician- and system-
related barriers were described in Chapter 2. Experience with the neoadjuvant decision aid has 
raised insights into implementation implications that will have a bearing on gaining maximum 
uptake. 
Assessing the impact of an intervention: RE-AIM 
Several implementation assessment frameworks are available to conceptualise the impact of a 
health intervention, including the RE-AIM model, an acronym for reach, efficacy, adoption, 
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 implementation and maintenance (Glasgow et al., 1999). This model can be applied to any health 
intervention to maximise its public health impact. Reach is the extent to which the at-risk population 
are able to access the intervention. Whilst the neoadjuvant decision aid had good uptake within the 
eligible population at recruiting centres, the challenge will be to expand the reach of this 
intervention to the broader population being offered NAST in treatment centres around Australia 
and the world. The decision aid can easily be transmitted to clinicians and patients in electronic 
format. It has been made available online at the Breast Cancer Trials (BCT, formerly known as 
ANZBCTG) website, and has a link from the BCNA website. There is no fee to access the decision aid. 
It is a low-cost intervention in terms of the time required to print it out, explain its use to patients, 
and then address any questions the patient has after they had used it. 
 
The second element of RE-AIM is the efficacy of the intervention. This criterion places emphasis on 
patient reported outcome endpoints. These outcomes have been described in detail in this chapter 
and the manuscript describing the primary study results. While it is not a randomised study, the 
outcomes support the efficacy of this intervention, without any evidence of adverse effects. 
 
Adoption refers to “the proportion and representativeness of settings…that adopt a given policy or 
program” (Glasgow et al., 1999). For this decision aid, adoption could be measured by the 
proportion of clinicians and institutions that use it within a given area, and the number of 
organisations that endorse its distribution and use. The decision aid has the support of BCT 
(comprising the former ANZBCTG and BCIA) and the BCNA. It has also received endorsement from 
the organisation that represents breast surgeons in Australia and New Zealand (BreastSurgANZ), 
including publicity in their regular newsletter. To expand adoption, I have reached out to 
international groups with substantial experience in neoadjuvant therapy for breast cancer. The 
decision aid has received positive feedback from the German Breast Group and the I-SPY study 
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 group in the United States. These collaborations remain active, but have yet to lead to concrete 
implementation plans. As mentioned in the limitations section of this chapter, implementation in a 
broad range of settings would give a more representative population access to the decision aid. This 
could include rural and urban locations, a range of settings with patients of diverse sociocultural and 
language backgrounds, and both high and low health literacy. With broader access, outcomes should 
be measured to ensure that the decision aid has similar impact to the original study population. 
 
Implementation in the RE-AIM model is considered to be the extent to which the intervention is 
delivered as intended (Glasgow et al., 1999). The decision aid was designed for any patient who had 
been offered NAST for operable breast cancer, with the ability to read English or have it translated. It 
would typically be given to patients by their breast surgeon at the time of referral to a medical 
oncologist, for reference prior to the visit at which they would aim to finalise their decision about 
NAST. The decision aid evaluation study introduced several components that would not usually be 
part of this process, that may have facilitated or inhibited use of the decision aid for both patients 
and clinicians. An implementation study would be required to accurately measure whether the 
decision aid is being used as intended. This implementation study might also identify novel, 
unexpected adaptations of clinical processes used by individual sites that facilitate decision aid use 
at that site.   
 
Maintenance, the final component of RE-AIM, is about measuring the sustained use of the 
intervention at both an individual and systemic level (Glasgow et al., 1999). With increasing 
competing demands on health resources and time, the sustainability of a psychosocial intervention 
is a key aspect of translation into patient impact (Ryba et al., 2017). Most of the clinicians who 
responded to the survey did not think that introduction of the decision aid added to the duration of 
the consultation. A minority did take extra time with the decision aid, reporting a mean increase of 
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 7.5 minutes. The primary results indicate sufficient feasibility and acceptability to support the 
sustainability of the intervention. 
 
Implementation strategies 
Several implementation strategies have evidence to support their effectiveness in improving the 
uptake of a variety of health interventions (Powell et al., 2015). Methods that have been shown to 
result in change in providers’ practice include academic detailing, involvement of key opinion 
leaders, endorsement by professional bodies and audit and feedback (O’Brien et al., 2007, Flodgren 
et al., 2011). Implementation strategies for decision aids are an emerging area of research, but 
remain under-studied (Elwyn et al., 2013). We have shown that whilst cancer-related decision aid 
efficacy studies are increasing in number over time, low numbers of decision aid implementation 
studies are available, and the number has not increased over the last decade (Herrmann et al., 
2016). 
 
A Cochrane Systematic Review of studies that evaluated interventions for the adoption of shared 
decision making by healthcare professionals was published in 2014 (Legare et al., 2014), and a 
review from the patient’s perspective (discussed in the next paragraph) published in 2012 (Legare et 
al., 2012). The quality of the 39 eligible health professional studies was low, according to GRADE 
criteria (Balshem et al., 2011). The primary outcome was a measure of healthcare professional 
adoption of shared decision-making in only five of the studies, with the remainder including 
healthcare professional measures as a secondary outcome. Taking into account the low quality of 
the evidence, it was concluded that using an intervention is better than none, and that targeting 
both health professionals and patients is better than either alone, in improving the quality of shared 
decision-making. Health professional strategies included educational meetings, audit and feedback, 
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 barriers assessment and distribution of educational materials alone or as part of a multifaceted 
intervention (Legare et al., 2014). 
 
The systematic review on improving shared decision-making in routine clinical practice from the 
patient’s perspectives was conducted by many of the same authors as the review on clinician factors 
(Legare et al., 2012). The implementation methods from the 21 identified studies were targeted at 
health professionals, but in this case patient-centred outcome measures were analysed. Only the 
three studies that included a decision aid, in combination with health professional training, reported 
positive shared decision-making outcomes for the patient (Bieber et al., 2006, Krones et al., 2008, 
Loh et al., 2007). This indicates that health professional training should be included in the 
distribution of decision aids for optimal patient outcomes. 
 
The implementation of an intervention is impacted upon by clinician, patient, system, financial and 
educational factors. It has been suggested that an integrated approach should go beyond enablers 
and barriers, towards a theoretical domain framework to identify the most salient aspects of 
implementation of an intervention (Elwyn et al., 2013, Lipworth et al., 2013). Because of the wide 
variation in health care settings, implementation studies must take the context of those settings into 
account when designing the implementation intervention (Edwards and Barker, 2014). In 
implementation studies, the intervention is the vehicle that enables the healthcare intervention to 
be used in routine practice. Previous work has been published describing the implementation of 
breast cancer decision aids, albeit in a single high-volume centre with significant resources (Belkora 
et al., 2012). Another potential design is the implementation-effectiveness hybrid design, which has 
a dual aim, to examine the impact on patients in a setting as close as possible to routine care and to 
set up processes to ensure ongoing implementation of the intervention (Curran et al., 2012). 
234
  
Online or electronic distribution of decision aids has potential for faster and wider dissemination 
compared with a paper-based format, if they are similarly effective and feasible. A randomised study 
comparing an online or paper-based decision aid to usual care for prostate cancer screening found 
that the decision aids increased patient involvement in decision-making, without any difference 
between the two decision aid formats (Krist et al., 2007). When individual components of the 
decision aids are examined, not all aspects of decision-making improve with computer-based 
decision aids, as demonstrated in a systematic review by Syrowatka et al (Syrowatka et al., 2016). 
Decision aids that allowed patients to control what information they accessed were associated with 
improved knowledge and lower decisional conflict. On the other hand, decision aids that were 
tailored to individual patient characteristics, and inclusion of patient narratives, reduced the quality 
of decision-making. The reason for this detriment is unclear. Other results were heterogeneous, 
including for explicit values clarification, patient feedback, and recommendation for inclusion of 
social support in the decision. 
 
Online delivery of a decision aid has been shown to be acceptable to patients and feasible to deliver, 
however uptake may not be as high as with paper-based decision aids (Mathieu et al., 2010). In this 
study by Mathieu and colleagues, drop out was moderately high with online questionnaires and 
decision aid compared with historical values, possibly due to the questionnaires rather than the 
decision aid itself. This online study format was similar to our neoadjuvant decision aid study, 
suggesting that online delivery should be one option, but not the only option. Ideally, clinicians and 
patients should have access to more than one format, such as online decision and paper-based 
options. 
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 To maintain relevance, decision aids should be updated at regular intervals with the most recent 
evidence, reflecting current practice patterns (Montori et al., 2013). Over time, the available options, 
outcome probabilities and practice patterns may change, rendering a decision aid obsolete. The 
preference-sensitive nature of the decision about neoadjuvant systemic therapy is not expected to 
change in the short to medium term, affirming the need for sustainability strategies for the decision 
aid (DeMichele et al., 2015). As the evidence and clinical practice patterns evolve, I will update this 
decision aid, maintaining an advisory group including collaborators from the original decision aid 
study and other interested parties. Along with updated information, adjustments to the format are 
planned to make the decision aid more interactive for online users, while maintaining a printable 
format for patients who prefer a hard copy. 
 
In summary, to improve patient outcomes in routine care, it is not sufficient to create an evidence-
based patient decision aid and demonstrate feasibility, acceptability, and preliminary efficacy data. 
Within the complex and varied health care system, implementation strategies must be considered to 
gain optimal adoption and ongoing use of an intervention such as a decision aid. 
 
6.6  Directions for future research 
This body of work, which has given insight into attitudes and the practice of neoadjuvant systemic 
therapy for operable breast cancer, has opened several avenues of potential further research. There 
is a clear need for additional research into implementation of the neoadjuvant decision aid, along 
with other breast cancer decision aids. Further iterations of the decision aid may include updates of 
content and improvements in user control. Along with the implementation of decision aids, 
implementation research into neoadjuvant systemic therapy for operable breast cancer may be 
warranted, given the variability in Australia and around the world (Read et al., 2015, Mougalian et 
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 al., 2015, Onkologie, 2015). Pertinent and as yet unexplored factors in the decision about a 
neoadjuvant therapy vs surgery-first approach include cost-effectiveness and patient reported 
outcomes analyses by treatment received. Despite workflow differences in each treating centre, 
there are likely to be elements that support the efficient application of NAST, such as the presence 
of nurse coordinators, that need to be better understood.  
 
Organisations such as the Cancer Institute NSW, the Australian National Health and Medical 
Research Council, Sydney Vital, Hunter Cancer Research Alliance and the University of Washington St 
Louis provide targeted funding and support for implementation projects. The Churchill Fellowship 
scheme is an opportunity for Australians to travel overseas to perform short-term research projects, 
attend relevant conferences and develop international collaborations. 
 
Whilst we have done preliminary work to support the implementation of the neoadjuvant decision 
aid in routine practice, more work is needed. Strategies used thus far include: online availability at 
no cost; design of the decision aid to minimise time commitment from the treating clinician and 
streamline inclusion in the clinical workflow; endorsement by professional bodies and consumer 
organisations; and awareness through presentations at national and international scientific 
meetings. A multifaceted approach may be needed, including education, educational materials, 
endorsement by professional bodies and guidelines, and audit and feedback. Strategies may have 
different levels of impact in different settings, requiring a modular or tailored intervention. A 
broader range of geographical, socioeconomic, cultural and language settings should be included. 
International studies to evaluate the decision aid would be a significant test of its generalisability 
and might assist with broader dissemination.  
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 A formal implementation study gives an opportunity to test the relative contributions of strategies 
used to optimise use of the decision aid. A variety of designs are appropriate, including 
implementation-effectiveness hybrid; stepped-wedge; randomised or wait-list randomised; or 
observational (Brown and Lilford, 2006, Campbell et al., 2000, Hemming et al., 2015, Curran et al., 
2012).  Ideally, the study processes such as questionnaires would not impact on the results of the 
study, giving results that are closer to ‘real world’ clinical practice.  
 
The role of nurses in supporting patient decision-making is well established: as nurse navigators (Lee 
et al., 2011, Gunn et al., 2014), decision coaches (Stacey et al., 2012), specialist breast nurses or care 
coordinators (Campbell et al., 2006). Nursing involvement in decisions and coordination of NAST has 
not been described. A strategy that became apparent during the decision aid study was the role of 
nurse co-ordinators in facilitating decision-making. McGrath Nurses are now employed at many 
breast surgery centres to assist patients with both the physical and psychological impact of the initial 
diagnosis and management of breast cancer (Anonymous, 2012, Fordham, 2012). The decision aid 
has been made available to McGrath nurses around Australia via their online professional resource 
portal. Based on experience with the neoadjuvant decision aid study, nurses are fundamental to the 
effective application of the neoadjuvant decision aid and to NAST in general. Further exploration of 
how best to place nurses within the neoadjuvant pathway is warranted. 
 
The decision aid is located on the Breast Cancer Trials website (www.breastcancertrials.org.au). 
Ideally, other internet sites will link to this site, providing a single location for future updates. The 
Cancer institute NSW EViQ website (www.evig.org.au) provides information on cancer treatment to 
users from around the world. The EViQ development team have agreed to add a link to the decision 
aid on their website. BCNA have a link from their website to the decision aid. Several high volume 
cancer centres have started using this decision aid. 
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With rising health care costs, it is relevant to consider health economic analysis of any new or 
altered treatment strategy (Folland et al., 2013), however I have not found any such studies of 
neoadjuvant therapy. It is possible that costs are increased, due to a greater number of clinic visits 
and in some cases extra imaging. The choice of local therapy after neoadjuvant therapy may have a 
financial impact, either if patients are downstaged to lumpectomy and then require radiotherapy, or 
if they elect to have an immediate reconstruction rather than a staged procedure. These costs could 
be offset if patients assign greater utility to receipt of neoadjuvant therapy compared with surgery 
followed by adjuvant therapy. A sufficiently sensitive health utility measure would be required in 
both neoadjuvant and surgery-first populations to determine If there is a difference (Peasgood et al., 
2010). The EQ-5D-5L measure was included as an exploratory item in the neoadjuvant decision aid 
study, but interpretation was difficult due to the lack of a comparator group in that study (Pickard et 
al., 2007). Because survival outcomes are equivalent between adjuvant and neoadjuvant therapy, a 
cost-utility analysis is not appropriate. A cost-benefit analysis could be conducted from registry data, 
as it does not require a health utility measure, but is a less commonly used health economic analysis 
due to the difficulty in assigning dollar values to health care costs (Spence, 2012). In planning a 
health economic analysis, these issues would need to be explored with relevant content area 
specialists. Data linkage of admissions may allow assessment of trends to increases in chemotherapy 
before surgery over time as patient and clinician awareness increases. 
 
The neoadjuvant decision aid study provides data on patient reported outcomes for neoadjuvant 
therapy, but without a sufficiently large adjuvant therapy group to make robust conclusions about 
the differences between the neoadjuvant and adjuvant groups. Without randomisation, imbalance 
in patient characteristics may bias the results. It is possible that patients receiving neoadjuvant 
therapy have better, or worse, outcomes on certain measures, such as fear of cancer progression, 
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 anxiety, distress, fear of cancer recurrence. These factors could assist in guiding certain patients 
towards either neoadjuvant or surgery as the first treatment modality. 
 
Future iterations of the neoadjuvant decision aid will use the results of the feasibility and 
acceptability study to refine and improve the content and utility. One possibility is to create a 
“Neoadjuvant online” or other more interactive version of the decision aid that allows a level of 
customisability. The Adjuvant!Online internet resource is a decision-making tool that has been 
commonly used by oncology professionals around the world (Love et al., 2005), due to the ability to 
give prognostic information to early stage breast cancer patients, and to overlay the relative benefits 
of adjuvant chemotherapy and endocrine therapy (Siminoff et al., 2006). A similar tool could be 
developed for neoadjuvant patients. This has the advantage of giving tailored information, which 
attracts clinicians, who could then give patients access to a decision aid linked to that information. 
 
The ideas above require refinement and elaboration before embarking on further research. Overall, I 
aim to investigate implementation methods for neoadjuvant therapy, including the neoadjuvant 
decision aid developed as part of this thesis. 
 
6.7  Conclusion 
Breast cancer is the most common female malignancy, with large numbers of long term survivors. 
Increasing numbers of women are being offered, and prescribed, neoadjuvant chemotherapy for 
operable breast cancer. Patient centred care and shared decision-making are key aspects of quality 
health care. The aim of this thesis was to support shared decision-making in women diagnosed with 
early stage breast cancer who are considering neoadjuvant systemic therapy.  
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 Literature review and clinical experience suggested that a decision aid might be an appropriate tool 
to achieve this aim. A systematic review identified a gap in the breast cancer decision aid literature 
that could be filled by a neoadjuvant decision aid. Preliminary studies explored the clinical context in 
which women and clinicians make decisions about neoadjuvant therapy. These indicated potential 
for a decision aid to be feasible to include in clinical practice, and useful for patient’s decision-
making. A decision aid was developed, and tested in a multicentre, single-arm clinical trial. This trial 
found that the decision aid was feasible to use and acceptable to patients and clinicians. Secondary 
decision-related outcomes suggested benefits in shared decision-making outcomes.  
 
Therefore, we were able to achieve the aim of supporting shared decision making in early stage 
breast cancer. Much work remains to be done, most pressingly the implementation of this decision 
aid in routine clinical practice, in order for the potential patient benefits to be fully realised. 
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 Appendix A 
 
Neoadjuvant decision aid 
 
This is the decision aid that was developed as part of this Doctorate. It is designed for women 
considering neoadjuvant systemic therapy for operable breast cancer. It was developed in response 
to an identified need, and evaluated in the study described in Chapter 5. 
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A guide for women who are considering 
breast cancer treatment with chemotherapy 
and/or hormonal therapy before surgery
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Introduction 
Over the last thirty years there have been significant improvements in the treatments available to women 
diagnosed with breast cancer. More treatment options are available to help cure more women of their 
cancer, and to keep women alive and well for longer. Treatment has also become more complicated, may 
be offered at different times and may continue for many months. Whenever possible, your treatment will be 
planned to best fit your personal situation and preference. Your treatment team is here to help you through 
this difficult time and to answer questions that you may have. This booklet is designed to help with some of 
those questions.
In certain situations, doctors may offer treatment with chemotherapy or hormonal (systemic) therapy 
before surgery. You have been given this booklet, called a ‘Decision Aid’, because your doctor thinks that 
this option may be suitable for you. 
The purpose of this decision aid is to help women to choose whether to have chemotherapy or hormonal 
therapy before surgery (neoadjuvant) or after surgery (adjuvant). After reading the information, you may 
wish to weigh up reasons for and against having neoadjuvant therapy using this decision aid. You can then 
discuss your thoughts with your doctor and make a decision.
As well as using this decision aid, you might like to talk to your doctor(s), family and friends and read other 
information that you may have. You may find resources from the Australia and New Zealand Breast Cancer 
Trials Group, the Cancer Council, Cancer Australia, the Breast Cancer Network Australia (BCNA) and others 
to be valuable. These resources will give you extra information about breast cancer that you may find useful 
to help your decision about whether to have systemic therapy before or after surgery. A resource list is 
available at the end of this booklet along with space for you to make notes.
To summarise, this decision aid booklet is for women who have recently been diagnosed with breast  
cancer, for whom chemotherapy or hormonal therapy before surgery (neoadjuvant therapy) might be a 
treatment option.
1
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What type of breast cancer do I have?
There are several different types of breast cancer. It is important to know which type you have when thinking 
about the pros and cons of treatment prior to surgery. Your doctor will be able to give you information about 
your type of breast cancer. There is also an explanation in the glossary on page 18. You may wish to mark 
which type you have, as a reminder (just tick the box that describes your cancer).
The main types of breast cancer are:
  Hormone receptor (HR) oestrogen and/or progesterone positive (ER+/PR+), HER2 negative (HER2-)
  Hormone receptor (HR) oestrogen and/or progesterone positive (ER+/PR+), HER2 positive (HER2+)
  Hormone receptor (HR) oestrogen and progesterone negative (ER-/PR-), HER2 positive (HER2+)
  Hormone receptor (HR) oestrogen and progesterone negative (ER-/PR-), HER2 negative  
     (HER2-)(triple negative)
Women with any of these types of cancer may be offered chemotherapy, surgery and radiotherapy. If you 
have hormone receptor positive breast cancer, you may also be offered hormone blocking medication such 
as tamoxifen, anastrozole (Arimidex®) or letrozole (Femara®). Similarly, if you have HER2 positive breast 
cancer, you may be offered a drug called trastuzumab (Herceptin®). 
Your doctor may take into account other factors when offering treatment options, including the grade of the 
tumour (how much tumour cells look like normal cells), stage of the tumour (describes the size and location 
of cancer), and whether there are cancer cells in the lymph nodes under your arm.
You can make notes about the important features of your cancer here:
2
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What treatments might be given for my breast cancer?
Your doctors and nurses will explain the details about the exact treatments that you could receive. There are 
usually two types of breast cancer treatment: Local and Systemic.
LOCAL TREATMENTS: Treat cancer cells in the breast area only
Surgery
Surgery involves removing any visible cancer. The whole breast can be removed (a mastectomy) or just 
the cancer and the area around it (a lumpectomy, or breast conserving surgery). You would also have a 
procedure to check whether the lymph nodes (glands) in your armpit have any cancer in them. This may be 
done as a sentinel node biopsy at the same time as your breast operation. If there is cancer in the lymph 
node(s) that were removed, you may also have an operation to remove some more lymph nodes from under 
the arm (axillary dissection). Sometimes a second operation is needed because some cancer has been left 
behind in the breast. Having chemotherapy before surgery does not make this more or less likely to occur. 
Radiotherapy
If you have breast conserving surgery, then you are likely to be offered radiotherapy. You may also be 
offered radiotherapy after a mastectomy, depending on the size of the cancer, whether any lymph nodes are 
involved, or other factors that your doctors think are important. Radiotherapy kills cancer cells in the area it 
is aimed at and is similar to the rays that are used when you have a chest X-ray. 
SYSTEMIC TREATMENTS: Using drugs that can reach all parts of the body
Chemotherapy
Chemotherapy is a medicine that is given to kill cancer cells throughout the body. For breast cancer, it is 
usually given intravenously (though a drip or injection into the vein) every 1-3 weeks, for a total of 12-24 
weeks. There are many different types of chemotherapy, and your doctor will be able to describe the risks 
and benefits of the treatments that are most suitable for you. 
Targeted therapy
Targeted therapy, such as trastuzumab (Herceptin®), is given to women with HER2 positive breast cancer. 
This type of treatment works by targeting the HER2 receptors on the tumour cells, stopping the cells from 
dividing and growing. They are usually given intravenously (through an IV drip) once every three weeks for a 
year in total, including any trastuzumab that you might receive before surgery.
Hormonal therapy
Hormonal (endocrine) therapy is a tablet that is taken every day, for women with oestrogen (ER) and/or 
progesterone (PR) receptor positive breast cancer. It works by interfering with the signal that oestrogen 
sends to cause this type of breast cancer to grow. Hormonal treatments are usually given for 5 years  
or longer. 
Why might it be necessary to have chemotherapy or hormonal therapy?
Chemotherapy and hormonal therapy are given to some women with early breast cancer, to reduce the 
chance that the cancer will return in the future. 
3
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How soon do I need to have treatment?
You might think that treatment for breast cancer needs to start within a very short time. However, research 
has shown that it takes several years for the majority of breast cancers to grow to a size that can be 
detected on mammogram. Therefore in most situations there is no harm in taking up to several weeks 
to make a decision about which treatment is right for you. After you have made a decision, surgery or 
chemotherapy may take days to a couple of weeks to commence, depending on local scheduling at the 
hospital where you are planning to have treatment. Again, there is no evidence to suggest that waiting those 
few weeks makes any difference to the success of your treatment. 
What are my options for the timing of chemotherapy and surgery?
Neoadjuvant: This means you will start with chemotherapy, targeted therapy or hormonal therapy, and 
then have surgery, usually after several months of treatment. Hormonal therapy or targeted therapy (such 
as trastuzumab) may also continue after surgery. You may also require radiotherapy, which is usually given 
after surgery. This option does not usually mean that you will receive more therapy or receive treatment for a 
longer time, just that the timing is different.
Adjuvant: This means you will have surgery first. You will then be offered further therapy, including 
chemotherapy, targeted therapy, hormonal therapy and radiotherapy depending on the stage and type of 
cancer you have. 
Figure 1. Your options for the sequence of treatments
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Women with breast cancer
Surgery
Surgery
Neoadjuvant (pre-operative) chemotherapy 
(with targeted therapy+) or hormonal therapy*
Adjuvant (post-operative) hormonal  
therapy* (with targeted therapy+)
+ Targeted therapy eg. trastuzumab is for HER2 positive breast cancer
* Hormonal therapy is for hormone receptor positive breast cancer
Adjuvant (post-operative) chemotherapy   
 (with targeted therapy+)
Adjuvant (post-operative) hormonal therapy*
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Neoadjuvant therapy (treatment begins before surgery) has been commonly used around the world 
for the last 15 years, and is increasingly used in Australia. Breast cancer clinical trials have shown that 
chemotherapy given to women before surgery is just as effective as having chemotherapy after surgery in 
terms of the cancer coming back (recurrence), and survival.
Being offered neoadjuvant therapy does not mean that your cancer is worse than cancer treated with 
adjuvant therapy. Neoadjuvant therapy has in the past been given to women who have larger breast 
tumours than average, but more recently this type of treatment has been given to women with moderately 
sized tumours. 
Regardless of which treatment you choose, your doctor will ensure that you receive the best possible care.
NEXT, we describe the pros and cons of neoadjuvant therapy, and then the pros and cons of adjuvant 
therapy. 
Why might I choose to have treatment before surgery?
There are several reasons why your doctor might have raised the possibility of treating your cancer with 
chemotherapy and/or hormonal therapy before it is removed surgically. These reasons include:
   To reduce the size of the tumour so that you can have a lumpectomy (rather than a mastectomy -    
     removing the whole breast);
   To reduce the size of the tumour so that a smaller operation is possible;
   To be eligible to participate in a neoadjuvant clinical trial;
   To give time for more information to become available, such as the results of genetic testing, which can      
     influence the type of surgery and treatment you may choose to have;
   To be able to see or feel the effectiveness of chemotherapy on the cancer;
   To give you a better idea of your prognosis (the chance of your cancer coming back).
These reasons are explained in the following pages. There are other reasons why your doctor may have 
suggested treatment before surgery, and your doctor will explain these to you, if relevant. 
There is space provided for you to make notes at the end of this booklet. If you think of a question or have a 
concern or comment please write them in the back of the booklet as soon as possible so that you can take 
this list with you to your next visit.
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Reducing the size of the tumour so you can have breast  
conserving surgery rather than a mastectomy
Your surgeon may have told you that you need a mastectomy (removal of the entire breast). This may be 
due to the size of the tumour, the type of breast cancer, the size of your breast, or for other reasons. 
Neoadjuvant therapy (chemotherapy or hormone therapy before surgery) can reduce the size of the cancer 
in some patients, so that they may safely have breast conserving surgery (removal of only the part of the 
breast containing the tumour). The breast cancer is more likely to shrink if it is triple negative or hormone 
receptor negative/HER2 positive and thus women with these types of breast cancer are more likely to be 
able to have breast conserving surgery after neoadjuvant therapy. 
If you were going to need a mastectomy as initial treatment, but you choose chemotherapy or hormonal 
therapy before the surgery, you have around a 25% chance of having breast conserving surgery after 
these treatments. In other words, 25 out of every 100 patients treated in this way will be able to avoid a 
mastectomy, but 75 in every 100 patients will still require a mastectomy. The diagram below shows this. 
Figure 2. If each of the 100 dots below is a woman who was going to need a mastectomy, then after 
neoadjuvant therapy about 25 women will be able to have breast conserving surgery (empty circles). About 
75 women will still need to have a mastectomy (shaded circles).
Even if your surgeon has told you that you can have breast conserving surgery now, before chemotherapy 
is given, then neoadjuvant therapy may shrink the cancer further. This may mean that less breast tissue will 
need to be taken and your breast is more likely to retain its natural shape. 
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Reducing the size of the cancer to make surgery easier so  
that less breast tissue needs to be removed
If scans (ultrasound or MRI) or physical examination show your tumour is more than 2cm in size, then 
neoadjuvant chemotherapy might shrink the tumour enough so that less breast tissue needs to be removed 
at the time of surgery.
Planning surgery
In some cases, it may be worthwhile to delay surgery on the breast. You may wish to delay surgery if:
  you are waiting for the results of genetic testing. If you are offered genetic testing, and are found to 
have an inherited breast cancer gene, then you may wish to consider having a double mastectomy 
(both breasts removed) to reduce your risk of developing breast cancer again. Having the results before 
surgery means that you can have one operation, rather than two;
  breast reconstruction is planned, and you wish to allow time for both your breast cancer surgeon and 
your reconstruction surgeons to be available to perform their specific surgeries at the same time;
  you wish to delay decisions about surgery, and take one decision at a time;
  your doctors feel that it is important to start chemotherapy first because your cancer appears to be  
fast-growing.
Research has shown that if chemotherapy is required, you will get the same outcomes if you have it 
before surgery, as having it afterwards. If surgery is delayed for any reason, you might want to get the 
chemotherapy over and done with and have surgery afterwards. 
Taking part in a breast cancer clinical trial
In some situations, neoadjuvant therapy is given as part of a clinical trial (research study). Your doctors will 
discuss this option with you if there is a trial available that is suitable for you. This may involve a new drug, 
or a new way of using currently available therapies. For more information about breast cancer clinical trials, 
visit the Australia and New Zealand Breast Cancer Trials Group website at www.anzbctg.org and/or the 
Australia and New Zealand Clinical Trials Registry at www.anzctr.org.au. 
Observing the effect of the chemotherapy
If you have chemotherapy or hormonal therapy before surgery, it is possible to check whether the 
chemotherapy is shrinking your cancer. This occurs for about 90% of women (90 out of every 100 cases 
treated in this way). If you have surgery first, there is no way of knowing whether the cancer has 
shrunk in response to the treatment, because there is no cancer left in the breast to observe.  
The reason this is important is discussed below.
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Figure 3. Possible results of neoadjuvant chemotherapy.
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284
Chances of the tumour disappearing completely
As shown above, there is a chance that neoadjuvant therapy will completely clear the cancer from 
your breast and from the lymph nodes under the arm. In that case, you should still have an operation, as 
otherwise the cancer may grow back. Your doctor may organise for a special metal ‘clip’ to be injected into 
the breast cancer before you start or during the course of neoadjuvant chemotherapy so that your surgeon 
knows where the cancer was and can remove tissue from that area.
The number of patients with no cancer visible on surgery after neoadjuvant chemotherapy varies depends 
on the type of breast cancer:
Figure 4.
Hormone receptor (HR) positive, HER2 negative: 1 out of every 10 women
Hormone receptor (HR) positive, HER2 positive: 3 out of every 10 women
Hormone receptor (HR) negative, HER2 positive: 5 out of every 10 women
Hormone receptor (HR) negative, HER2 negative (triple negative): 3 out of every 10 women
If each of these dots is one woman, the open circles show the number of women (out of 10) who do not 
have any tumour visible at the end of chemotherapy.
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Prognosis (How likely is the cancer to return?)
There is no difference in survival following a diagnosis of breast cancer if you have chemotherapy before 
or after surgery. If you have chemotherapy or hormonal therapy before surgery, your cancer may shrink. In 
some cases, the cancer can disappear entirely. Whether or not this happens tells us something about your 
chances of doing well. If chemotherapy completely clears the cancer from your breast and lymph nodes, 
you will have gained some “good news” – that your breast cancer is responding to the treatment and is less 
likely to come back. On the other hand, if your cancer doesn’t shrink, or even grows, you will have gained 
some less good or even “bad” news – that your breast cancer is not so responsive and is more likely to 
appear elsewhere in your body.
The following information is about women who are alive and free of cancer five years after being 
diagnosed with breast cancer. For some women the cancer comes back before 5 years, for some 
it comes back after 5 years, and for most women it never comes back. However, the statistics are 
often described using the 5 year mark.
For women who have had neoadjuvant chemotherapy, the prognosis depends on the type of cancer:
   Hormone receptor positive, HER2 negative: 85 out of every 100 women whose cancer has 
disappeared entirely are alive and free of breast cancer 5 years after diagnosis, compared with 75 out of 
100 women whose cancer did not disappear entirely.
   Hormone receptor positive, HER2 positive: 90 out of every 100 women whose cancer has disappeared 
entirely are alive and free of breast cancer 5 years after diagnosis, compared with 65 out of 100 women 
whose cancer did not disappear entirely.
   Hormone receptor negative, HER2 positive: 85 out of every 100 women whose cancer has 
disappeared entirely are alive and free of breast cancer 5 years after diagnosis, compared with 50 out of 
every 100 women whose cancer did not disappear entirely.
   Triple negative: 85 out of every 100 women whose cancer has disappeared entirely are alive and free 
of breast cancer 5 years after diagnosis, compared with 50 out of every 100 women whose cancer did 
not disappear entirely.
The chance of your cancer disappearing completely also depends on which type of cancer you have. This is 
explained in the following pages.
If the cancer does not shrink or disappear during chemotherapy, it means your cancer is more resistant to 
the treatment that you were given. It does not mean that the cancer will definitely come back. If you have a 
hormone positive cancer, not all the work is done by the chemotherapy, hormone blocking treatment is an 
important part of the treatment of this type of breast cancer.
Even if the cancer cannot be seen on scans and cannot be felt by you or your doctor after neoadjuvant 
therapy, surgery is still recommended to make sure that all cancer is removed. Looking at the cancer under 
the microscope after surgery can also give you additional information on the chances that your cancer  
will return. 
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Some other issues with having therapy before surgery
There is no increase (or decrease) in problems with surgery
Having chemotherapy and/or hormone therapy before surgery does not increase or decrease the chance of 
having problems from surgery, such as an infection or delayed wound healing.
Radiotherapy
If you have breast conserving surgery, radiotherapy is usually offered. If you have a mastectomy, 
radiotherapy may or may not be needed. A good response to neoadjuvant therapy does not mean that 
radiotherapy can be avoided.
What if the cancer does not get smaller?
As discussed above, there is a chance that the cancer may not seem to be getting any smaller during 
neoadjuvant therapy. This can cause worry that the treatment is not working. If the cancer does not get any 
smaller, it does not necessarily mean that the chemotherapy is not working, and you and your doctor may 
decide to continue with chemotherapy as planned.
In some cases you may still be able to feel a lump in your breast after you have started neoadjuvant therapy. 
What you can feel or see may only be scar tissue and no cancer is left. On the other hand, even if the 
cancer can no longer be felt, there is still a possibility that some cancer cells remain. So what we can see 
and feel from the outside does not tell the whole story. Scans and pathology are needed to make a decision 
on whether the treatment is working.
What if the cancer gets bigger?
Some people might worry about their cancer getting larger or spreading elsewhere, while receiving 
treatment prior to surgery. It is uncommon for this to happen. It happens in about 3% (3 in 100) of patients, 
and in almost all these patients (90%) surgery can still be successfully performed to remove the cancer,  
with outcomes remaining the same as if they had had surgery before adjuvant treatment. Figure 5 shows 
this risk. 
What if I can’t have surgery?
Less than 3 in every 1,000 patients (0.3%) who have neoadjuvant therapy before surgery are not then able 
to have surgery because the cancer became too large, or because cancer became visible elsewhere in the 
body (metastatic breast cancer). 
In the rare situations that this occurs, it means that surgery would not have cured the cancer anyway, even 
if an operation was done first. This is because there was already cancer that had spread beyond the breast 
and lymph nodes, which would not have been completely removed by surgery and chemotherapy.
Your doctor will check regularly with physical examination and scans such as ultrasound or MRI to see 
whether the cancer is smaller, larger or the same size. If it does grow, your surgery may be moved to an 
earlier time, before your planned neoadjuvant therapy is finished. 
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287
Figure 5. The chance of cancer growing whilst receiving chemotherapy (3%).
Of 1000 people who have neoadjuvant therapy (the blue dots), 30 will have their cancer grow while having 
treatment (the red dots). 27 of these 30 people are almost certainly still able to have surgery aimed at cure. 
3 out of every 1000 (0.3%) would not be able to have surgery, however surgery would not have cured these 
3 if done before chemotherapy.
12
BLUE dots show the patients 
whose tumour will either 
shrink or stay the same size 
after neoadjuvant therapy
ORANGE dots show the 
patients whose cancer 
will get bigger or spread 
elsewhere in the body, and 
surgery will not be possible
RED dots show the patients 
whose tumour got bigger 
during neoadjuvant therapy, 
but could still have surgery
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The pros and cons of adjuvant therapy (surgery first)
The chance of the cancer coming back over time is the same if you have chemotherapy first or surgery first. 
If an operation is possible now, then you may prefer to have surgery first, and then make a decision about 
any other treatments such as chemotherapy and radiotherapy, once surgery is complete. 
Advantages of surgery first
Information about the cancer
A possible advantage of having surgery first is that you may have more precise knowledge of the type and 
stage of the cancer before decisions are made about any further treatment. If the cancer is removed in an 
operation before chemotherapy is given, the pathologist can look at the cancer cells under a microscope 
and provide information about it. This helps you and your doctors to make decisions about the best 
treatment options for you. Occasionally this suggests that chemotherapy is not required after all, because 
the pathologist can see the whole cancer, rather than just a small part of it. The presence of cancer in the 
lymph nodes near the breast is one of the most useful predictors of prognosis (whether the cancer is likely 
to return) and it also guides whether radiotherapy is needed. If neoadjuvant chemotherapy (chemotherapy 
before surgery) has made the cancer shrink or disappear from the breast or lymph nodes, then some of that 
information may no longer be available. 
Immediate removal of the cancer
Some women may be uncomfortable leaving the cancer in place for several months whilst receiving 
chemotherapy. The idea that the cancer is still in their body can cause some women to feel more anxious 
and stressed. There is a possibility of anxiety about whether the cancer is growing or not. If the cancer is 
removed first, then the small chance that it might grow is taken away.
Radiotherapy
If you have a mastectomy, then you are less likely to need radiotherapy after surgery. Radiotherapy might 
still be needed in certain situations, such as if there is cancer in your lymph nodes under the arm, or if your 
cancer is large. If you have breast conserving surgery, then radiotherapy is usually offered.
Many women in Australia have surgery first
Having surgery first is common, particularly for small breast cancers where breast conserving surgery is 
already possible, or in cases where chemotherapy may not be needed. Some women might prefer having 
a treatment that many others have. The use of neoadjuvant therapy is not rare, but it is less common than 
having surgery first.
13
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Disadvantages of surgery first
Higher chance of needing a mastectomy
A possible disadvantage of having surgery first is that you may need a mastectomy which could have been 
avoided if you had neo-adjuvant therapy to shrink the cancer. 
No way to see if systemic therapy is working
Another disadvantage is that you will not be able to see the effect that the chemotherapy or hormonal 
therapy is having on your cancer and so you may have less information about the chance of your cancer 
coming back. This is discussed in detail in the sections about neoadjuvant therapy titled ‘Observing the 
effect of chemotherapy’ and ‘Prognosis’.
Infection after surgery
Sometimes after surgery, an infection may develop in the breast, or the wound may be slow to heal, which 
could delay the start of chemotherapy. While it is usually OK to wait for a short period before starting 
chemotherapy, it is generally recommended to start within 2-3 months to give the chemotherapy a chance 
to work. In other words, if an infection causes a delay of more than 2-3 months between surgery and 
starting chemotherapy, the chemotherapy may be less effective.
14
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 Remember: 
Being offered treatment prior to surgery does not necessarily mean that there is anything unusual or worse 
about your type of breast cancer. Neoadjuvant therapy was previously given for larger breast tumours, but 
more recently this type of treatment is being given to women with moderately sized tumours. 
Treatment prior to surgery is commonly used around the world, and is increasingly used in Australia.  
Having chemotherapy before surgery is just as effective as having chemotherapy after surgery in terms of 
the chance that the cancer will come back (recurrence) and survival. 
The decision to have neoadjuvant or adjuvant therapy is one that you, your surgeon and your medical 
oncologist can make together. Your doctors will ensure you get the best care regardless of the decision  
you make. 
15
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Arriving at a treatment decision
The previous pages have outlined the main options available to you now. The following steps may help you 
to make a decision whether or not to have chemotherapy or hormonal therapy before surgery. 
The decision-making process may be easier if you follow these seven steps: 
1. Understand your diagnosis and your risk of breast cancer recurring (coming back) as fully as you can.
2. Understand your options for treatment and the risks and benefits of these options.
3. Review the pros and cons of those options.
4. Assess the importance to you of the pros and cons.
5. If you are offered neoadjuvant treatment through a clinical trial, prioritise the pros and cons of the trial for 
you (and your family). 
6. Get more information from your doctor or breast care nurse if you are unsure of anything or have more 
questions. 
7. Discuss your preferred treatment option with your surgeon, medical oncologist, family doctor, your family 
and other significant people in your life.
You have already gone through steps 1-3. To help you complete steps 4-7, and come to the decision that 
suits you best, we have prepared a worksheet on the following page. 
16
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Worksheet
After reading this booklet you may feel you understand more about treatment options for your breast 
cancer. You may wish to weigh up the positives and negatives, to help you work out which treatment option 
is right for you. You may not come to a decision now, but this may assist you at your next visit with your 
medical oncologist or surgeon.
This page lists reasons that are relevant to the decision about whether to receive chemotherapy or hormonal 
therapy, either before or after surgery for your breast cancer. Indicate which issues are important to you. 
That will help you work out which way you are leaning. 
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I want to have breast conserving  
surgery if at all possible
“I would like to avoid a mastectomy”
Waiting for surgery would worry me
“Even if I am having treatment, leaving  
the tumor there will be stressful”
I am worried about the tumor growing or 
spreading before surgery
“It is rare, but concerning”
I want to know as much as possible about the 
cancer before considering chemotherapy
“It will help my decision about chemotherapy”
I think it is important to see whether 
chemotherapy has shrunk the cancer or not
“It may give me information about my prognosis”
Other Other
I have reasons to delay surgery
Eg. Genetic testing, planning surgery
Not at all 
important
Fairly 
important
Very 
important
No 
Concern
Small 
Concern
Big 
Concern
No 
Concern
Small 
Concern
Big 
Concern
No 
Concern
Small 
Concern
Big 
Concern
No 
Concern
Small 
Concern
Big 
Concern
Not at all 
important
Fairly 
important
Very 
important
Not at all 
important
Fairly 
important
Very 
important
Not at all 
important
Fairly 
important
Very 
important
Favours neoadjuvant  
(pre-operative) treatment
Favours adjuvant  
(post-operative) treatment
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Any further questions? Write down any questions you want to ask your surgeon or medical oncologist (there 
is more space at the end).
Which way are you leaning? Circle the star which best indicates whether you are leaning towards 
neoadjuvant therapy or adjuvant therapy. The closer the star is to either option, the more certain you feel 
about that option. 
Which way are you leaning?
What happens now?
Your treating doctor, often your surgeon, will have brought up the possibility of neoadjuvant therapy. Your 
doctor has given you this document to help you find out more about the option of receiving neoadjuvant 
therapy to assist you to make a decision about whether it is right for you.
Your doctor and other health care professionals (such as a breast care nurse) will continue to support you 
through the decision-making process, and will be able to answer any questions you might have. You may 
be referred to see a medical oncologist to discuss the matter further. A referral to a medical oncologist does 
not mean that you must proceed with treatment before surgery. Neoadjuvant therapy may be recommended 
as the preferred option, it may be presented to you as a “genuine choice” for you to make, or your medical 
oncologist may recommend against it, with immediate surgery being the preferred option.
Once you and your doctor(s) have made a decision, treatment will be arranged for you.
18
Neoadjuvant 
therapy
Adjuvant  
therapy
H H H H H H H H H H
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Glossary
Adjuvant: treatment that is given after surgery, with the intent of cure
Chemotherapy: Anti-cancer medicine that is usually given through an intravenous (IV) drip
Clinical trial: Research that is testing a new way of treating a disease
Decision aid: a document that contains information to help people make a decision about medical treatment
Early breast cancer: breast cancer that is only in the breast and lymph nodes under the arm on the same side of the body
Endocrine or hormonal therapy: tablets that are taken daily for at least 5 years for hormone receptor positive breast cancer, such 
as tamoxifen, anastrozole (Arimidex®) or letrozole (Femara®)
HER2 receptor: a protein on the surface of cells that helps them grow and divide
HER2 positive (HER2+) breast cancer: a type of breast cancer that has a larger number of HER2 receptors on the cells than 
usual. It can be treated with drugs such as trastuzumab (Herceptin®)
Hormone receptor: either the oestrogen receptor or progesterone receptor, which indicates that hormonal treatments such as 
tamoxifen may be used
Hormone receptor positive breast cancer (ER+/PR+): a type of breast cancer that has hormone receptors on the cells. These 
receptors are special proteins that the hormones estrogen and progesterone bind to, causing the cancer to grow. Hormonal therapy 
can be used for this type of breast cancer
Inflammatory breast cancer: breast cancer that affects a large area of the breast, but may not be felt as a distinct lump. It is a less 
common type of breast cancer; your doctor will be able to tell you if you have this type.
Local therapy: Treatment that affects part of the body, eg. surgery or radiotherapy
Metastatic (secondary or advanced) breast cancer: breast cancer that has spread beyond the breast and lymph nodes, to other 
parts of the body, such as bones, liver or lungs
Neoadjuvant: treatment that is given before an operation to remove the breast cancer
Pathological complete response (pCR): when no cancer can be seen by the pathologist in the breast or lymph nodes that have 
been surgically removed, after neoadjuvant chemotherapy or hormonal therapy has been given
Systemic therapy: Treatment that affects the whole body, eg. chemotherapy or hormonal therapy
Triple negative breast cancer: breast cancer that does not have oestrogen (ER), progesterone (PR), or HER2 receptors on its 
surface
19
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Further information and support
Australia and New Zealand Breast Cancer Trials Group: www.anzbctg.org
Australian New Zealand Clinical Trials Registry: www.anzctr.org.au
Breast Cancer Network Australia: www.bcna.org.au  
Phone 1800 500 258
Cancer Australia: www.canceraustralia.gov.au 
Phone 1800 624 973
Cancer Council www.cancercouncil.com.au 
Phone 131 120
Macmillan Cancer Support: www.macmillan.org.uk (United Kingdom based information)
Local contact information:
20
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Full title: Decision aid for women considering having chemotherapy or hormonal therapy prior to surgery for breast cancer
This document has been developed by researchers of the Australia and New Zealand Breast Cancer Trials Group (ANZBCTG) 
and the Patricia Ritchie Centre for Cancer Care and Research, with funding support from the HCF Research Foundation, and the 
fundraising and education department of the ANZBCTG, the Breast Cancer Institute of Australia (BCIA). It has been endorsed by the 
ANZBCTG Consumer Advisory Panel. The Breast Cancer Network Australia (BCNA) have provided input into content.
1st edition, December 2014.
© Australia and New Zealand Breast Cancer Trials Group
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Additional publication 1: Patient interviews about neoadjuvant therapy 
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Zdenkowski N, Butow P, Fewster S, Beckmore C, Wells K, Forbes JF, Boyle F. Exploring decision 
making about neoadjuvant chemotherapy for breast cancer. The Breast Journal. 2016;22:133-134. 
This publication describes the results of interviews undertaken prior to this candidature. It is 
included as an appendix because it relates directly to the research within the thesis. These data 
informed the development of the decision aid and the design of the decision aid study. 
Author contributions 
Conception and design: NZ, FB, PB, SF 
Participant recruitment: NZ, KW, CB 
Data collection: NZ 
Data analysis: NZ, FB, PB 
Manuscript preparation: NZ 
Manuscript critical review: All authors 
Review of final manuscript: All authors 
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Neoadjuvant chemotherapy (NACT) has become a routine treatment option that may be offered as a 
choice to women with large operable breast cancer, which may add to the burden of an already 
complex decision-making process. Published data are lacking on women’s involvement preferences in 
the decision about NACT, and what level of information complexity might reasonably be presented to 
a patient to achieve the benefits of shared decision-making (1). Here we report on a study that aimed 
to understand women’s NACT decision making process as the first step to better supporting women 
through this process, so that treatment can be matched with individuals’ personal values and 
preferences.  
We interviewed 22 women, identified via the Breast Cancer Network Australia Review and Survey 
Group, with a past diagnosis of invasive breast cancer, who had been offered either neoadjuvant or 
adjuvant chemotherapy, and had completed surgery and chemotherapy. A semi-structured interview 
guide included questions about demographics; treatments and outcomes; information needs; decision 
making preferences; and associated psychological issues. Responses were  analysed using qualitative 
descriptive methodology to identify overarching themes. 
NACT was offered to 19 women, accepted by 13 and declined by 6. Three women had not been offered 
NACT. Participants’ age (median 51), metropolitan residential status and high levels of education 
employment health insurance imply high health literacy. All major breast cancer subtypes were 
represented, determined by self-report of hormone receptor and HER2 results. Two participants had 
taken part in a NACT clinical trial. 
Few women were aware of NACT before the option was raised by their surgeon. Women were not 
given, and were unable to find, written patient information specific to NACT. The internet was seen as 
302
an unreliable information source, to the extent that many women avoided it. Women were aware of 
many information sources, but were reluctant to pursue them due to a fear of information overload 
and increased decisional conflict. In typical medical encounters most women preferred to have 
sufficient information available to allow them to be the primary decision maker. However the majority 
preferred to leave the decision about NACT to their doctor or, at most, take equal part in making the 
decision. Reasons included a perceived lack of time for decision making and information gathering, 
the complexity of the multiple factors to be considered, and a sense of being overwhelmed by their 
breast cancer diagnosis.  
Women were very trusting of their treating clinicians to guide treatment decisions about NACT, which 
translated into a high level of decisional satisfaction. Trust in clinicians allows women to avoid the 
burden of decision-making when they are highly vulnerable, and places responsibility for the decision 
with the clinician. Hillen et al suggest that women facing a life-threatening condition such as 
breast cancer have a ‘need for trust’, which underscores the power imbalance between 
cancer patients and their oncologist (2). Sensitive communication, clear information and 
additional support may be needed to effectively share decision-making, if that is what 
patients prefer.  
Most women, with better information, would have preferred more control over the decision about 
NACT. Most women felt that having access to a decision support tool would have helped their 
decision-making. Patient decision aids have been shown to improve decision-related outcomes such 
as decisional conflict, patient involvement, knowledge and satisfaction, without raising anxiety (3). 
Women with breast cancer who participate actively in decision-making have higher quality of life, 
physical and social functioning, and less fatigue than those who take a passive role (1). They are more 
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likely to adhere to their treatment plan and to cope well with illness. Given equivalent survival and 
recurrence whether adjuvant or neoadjuvant chemotherapy is used for operable breast cancer, a 
decision aid may be appropriate to improve patient engagement patients and facilitate a values-based 
decision (4).  
Reasons patients gave for considering NACT, in descending frequency were: tumour downstaging to 
optimise surgery; to observe the effect of chemotherapy on the tumour; earlier access to highly 
effective systemic therapy; to delay other decisions about breast cancer treatment such as whether 
to have a mastectomy or breast conserving surgery, or to plan for an immediate reconstruction; and 
to await genetic test results. Barriers included: a lack of awareness of NACT and scepticism about its 
validity as a standard treatment option; prior expectation for up-front surgery; and concern about 
being offered NACT because their situation was unusual. Women who had not been offered NACT 
expressed interest in pursuing it if it had been offered. Some women’s decision about NACT was 
influenced by factors unsupported by available evidence, such as fear of progression and perceived 
lack of efficacy. A decision aid may help to balance these cognitive biases for patients and families (3). 
During NACT, a clinical response was seen as highly reassuring that the treatment was working. Five 
women were worried that their tumour would progress while receiving NACT. One woman was 
pleased that she did not have a complete response due to concern about her surgeon finding the 
tumour. Eleven women were pleased to know whether their tumour had responded or progressed. 
Women whose cancer responded to NACT correctly identified that their cancer was less likely to recur 
and thus were optimistic. However, fear of recurrence remained prevalent, with potential negative 
impact on quality of life, social functioning and psychological wellbeing.  
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In conclusion, the principles of shared decision making did not appear to be upheld in women who 
were offered NACT (1). The overarching themes that emerged from the data were of a desire for 
trustful information; an interest in shared decision-making; and reliance on trusted health 
professionals to direct decision-making as a surrogate for shared or greater control on the part of the 
patient. In order to make high quality decisions about the timing of chemotherapy and surgery for 
early breast cancer, women need access to appropriate information. Women endorse NACT as a valid 
option, but a lack of awareness seems to contribute to decreased uptake of NACT by women. A 
decision support tool may assist women to meet their desired level of involvement in this values-based 
decision. 
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Herrmann A, Boyle FM, Butow P, Hall A, Zdenkowski N. Exploring women’s experiences with a 
decision aid for neoadjuvant systemic therapy for operable breast cancer. Health Science Reports 
2017;e213. Published online 22nd August 2017. 
This publication describes qualitative analysis of interviews with women who participated in the 
neoadjuvant decision aid study, focussing on the use of the decision aid. It provides additional 
information about these women’s experiences with the decision aid that may not have been 
captured using patient reported outcome measures. This work was primarily undertaken by Anne 
Herrmann, with oversight and input by this candidate along with senior supervisors. 
Author contributions 
Conception and design: NZ, FB, PB 
Participant recruitment: NZ, FB, A Herrmann 
Data collection: A Herrmann 
Data analysis and interpretation: All authors 
Manuscript preparation: A Herrmann 
Manuscript critical review and review of final manuscript: All authors 
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ABSTRACT 
Background: Some women with operable breast cancer have a choice between receiving upfront 
surgery followed by chemotherapy or neoadjuvant systemic therapy (NAST) prior to receiving 
surgery. Whilst survival outcomes are equivalent for both options, the decision about treatment 
sequence can be difficult due to its complexity and perceived urgency. A decision aid has been 
developed to help patients decide on whether to receive NAST. 
Aims: To explore, qualitatively, women’s use and perceived benefit of a decision aid to help with 
their decision on NAST. 
Methods: A framework analysis process was conducted on a purposeful sample of 20, one-on-one, 
semi-structured phone interviews with early-stage breast cancer patients eligible for NAST. 
Participants had recently decided on whether or not to have NAST. 
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Results: Patients perceived the decision aid as useful to becoming more informed and involved in 
making a decision as to whether they receive NAST. They described the information provided in the 
decision aid as reliable, relevant, sufficient in terms of amount, and tailored to their needs. Reading 
and rereading the decision aid at home in-between the consultations with their surgeon and their 
medical oncologist allowed women to better understand their treatment options and easily 
integrate the decision aid into their care. The decision aid seemed to confirm but not change 
women’s decisions on NAST.  
Conclusion: The decision aid appears to help breast cancer patients support their decision about 
whether to receive NAST. Patients’ ability to review the decision aid in-between two consultations 
seems to be an acceptable and feasible way of integrating the decision aid into patients’ care. 
Key words: Breast cancer, decision making, decision aid, qualitative research  
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Exploring women’s experiences with a decision aid for neoadjuvant 
systemic therapy for operable breast cancer 
Background 
Breast cancer treatment decisions can be challenging 
To maximise their outcomes, patients should be involved in treatment decisions to the extent they 
desire.1 This can decrease patients’ distress and anxiety, and increase their satisfaction with the 
consultation and overall quality of life.2 However, breast cancer patients can be overwhelmed by the 
number of treatment options available to them.3 In addition to the large number of treatments 
options available, the complexity of each treatment choice can further complicate the decision 
making process. For instance, treatment choices are increasingly involving differing outcomes, such 
as efficacy and toxicity, which may be valued differently by different patients. Such decisions are 
called “preference-sensitive”.4, 5 They can be very difficult for patients, as the “best choice” cannot 
be pre-defined, it depends on the patients’ preferences and involves each individual patient 
weighing up the risks against benefits of the options available. It is essential that women are 
adequately supported by the healthcare system when deciding on their treatment.6 
Deciding on neoadjuvant systemic therapy can be particularly difficult for patients  
Some early stage breast cancer patients with larger operable or highly proliferative disease may be 
offered a choice about whether to have neoadjuvant systemic therapy (NAST), i.e. chemotherapy or 
endocrine therapy before surgery. This is a particularly difficult decision to make as the concept of 
NAST adds complexity and uncertainty at a time when patients are likely to be distressed from the 
initial diagnosis of cancer. However, patients may value the neoadjuvant approach due to a higher 
chance of breast conserving surgery rather than mastectomy.7 NAST also allows a better 
understanding of tumour response and biology which can facilitate prognostication.8 Improved 
prognostication can decrease patients’ anxiety and depression associated with their cancer and 
potential treatment outcomes.9, 10 Survival and recurrence rates are equivalent for NAST followed by 
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surgery compared to receiving surgery first.8 However, some patients fear that their cancer could get 
worse while receiving NAST, and thus prefer to have the tumour surgically removed as soon as 
possible.11 Therefore, for women with operable breast cancer, the decision for or against NAST relies 
heavily on patients’ preferences.12 In order to allow these patients to make informed treatment 
decisions, they need to be provided with adequate, evidence-based information. 
Decision aids can improve patient outcomes  
Decision aids provide patients with evidence-based information regarding the healthcare options 
available to them. Decision aids aim to assist patients with clarifying and communicating the value 
they associate with each option.13 They are designed to engage patients in the decision making 
process and to guide them towards making deliberated decisions that align with their preferences.14 
A number of Cochrane reviews have shown that decision aids are effective in improving certain 
patient outcomes, including increased knowledge and understanding of the options available, and 
reduced decisional conflict, when compared to usual care.15 Although decision aids have been 
developed for numerous health conditions, one was not available for the decision on NAST before 
this study commenced.16 To fill this current gap, our group designed a decision aid to help women 
become more informed and more involved in decisions about NAST. The decision aid is being 
evaluated in a prospective, single-arm pre-post trial. Here, we report on the qualitative analysis of 
phone interviews included in the larger trial to assess women’s use of, and perceived benefit from, 
the decision aid. This sub study aims to provide in-depth insights into women’s perspective on the 
effectiveness of the decision aid and helps explore whether it might be a valuable tool to facilitate 
decision making on NAST in clinical practice.  
Aims 
To explore, qualitatively, in a sample of early-stage breast cancer patients eligible for NAST, the use 
and perceived benefit of a decision aid which was designed to provide women with relevant 
information to assist their decision on NAST. 
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Methods 
Development and testing of a decision aid on NAST 
The development of the decision aid was informed by: 1) a qualitative study conducted to examine 
the information needs of patients receiving NAST 11; 2) a literature review to define treatment 
options and the positive and negative outcomes associated with those options; and 3) identification 
of relevant issues important to the decision on NAST by a an expert consensus panel. The structure 
of the decision aid was based on the International Patient Decision Aid Standards Collaboration 
(IPDAS) statement in order to include a balanced description of adjuvant and neoadjuvant therapy. 
The decision aid includes an introduction which helps newly diagnosed breast cancer patients 
understand basic concepts about their treatment modalities. This was important as these patients 
may not have received other written general information at the time when NAST was discussed. The 
decision aid further includes brief general information about breast cancer and the treatments 
commonly used, explanation of the options for the timing of chemotherapy and surgery, the 
advantages and disadvantages of neoadjuvant and adjuvant therapy, a values clarification exercise 
(i.e. a worksheet to help patients consider how they value key aspects of the decision on NAST), a 
page for notes, a glossary, and information about where to find additional resources.  To improve 
patients’ risk perception and lead to better informed decision making, key components of risk are 
presented in visual, numeric, and narrative formats using appropriate labelling. The decision aid is 
designed to be compatible with online and paper delivery. The IPDAS criteria for judging the quality 
of decision aids have been adhered to (please see Appendix 1 for a completed IPDAS checklist).17-19 
Consumers and members of a breast cancer support organisation (Breast Cancer Network Australia) 
reviewed and helped refine the content and comprehensibility of the decision aid. Care was taken to 
make use of the shortest word and simplest sentence structure possible. Word and sentence length 
had to be balanced against the overall length of the decision aid. An excessively long decision aid 
was not considered likely to be approachable by those with low literacy. To avoid duplication of 
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information, the decision aid refers to other information sources, which are routinely made available 
by breast care nurses to women who have been diagnosed with breast cancer.  
Setting and sample 
A purposeful sample of 20 patients attending breast cancer treatment centres in New South Wales 
and Victoria were interviewed one-on-one via telephone. Recruitment continued until data 
saturation (no new themes in three consecutive interviews) was achieved.  
Inclusion and exclusion criteria 
Patients were eligible for this study if, at the time of enrolment, they (i) were female; (ii) were aged 
≥18 years; (iii) had a histological diagnosis of operable invasive breast cancer; (iv) were considered 
for neoadjuvant systemic (chemo or endocrine) therapy (NAST) as a treatment option with curative 
intent; (vi) were willing and able to access the trial information and the decision aid via the internet 
and complete the telephone interview. Patients were excluded if (i) < 3 month duration of NAST was 
planned; (ii) they had hearing or other impairment that would preclude a phone interview; (iii) they 
had insufficient English language skills for participation in a phone interview; (iv) they had 
inflammatory, metastatic or inoperable breast cancer; (v) they were considered by the treating 
investigator to have a medical or psychiatric condition precluding informed consent; (vi) they were 
unable to be contacted via telephone. We excluded those patients who were going to receive less 
than three months of chemotherapy because the outcome probabilities presented do not apply to 
those patients. The intent was to include patients who were going to receive a full course of 
neoadjuvant chemotherapy, which is typically three months or more. This duration is required for 
maximal benefit from neoadjuvant chemotherapy. 
Recruitment  
The treating clinician identified eligible patients attending their clinic for a consultation, introduced 
the trial and obtained written consent to be contacted by the Australia and New Zealand Breast 
Cancer Trials Group (ANZBCTG) for study registration. The clinician then completed a screening form 
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and faxed it to ANZBCTG. The screening form contained an eligibility checklist, investigator 
assessment of information needs and distress at that time, consent for release of information to the 
ANZBCTG and patient email address and phone number for further contact. Patients who consented 
to further study contact were emailed a link with access to the trial information letter and online 
consent form, which patients could access after the consultation with their treating clinician. The 
consent form asked patients to provide consent to take part in the larger intervention trial and gave 
participants the option to opt out of a follow-up telephone interview. Once patients had consented 
to participate in the trial they entered their demographic details and completed a series of patient 
reported outcome measures in an online survey. Patients were then provided with access to the 
decision aid, which they could read online or print out. Patients who consented to a telephone 
interview were contacted via phone by a member of the research team (AH) to schedule the 
interview. Most interviews took place two to three months after study consent (median time 
between study consent and interview: 93 days). Women were not asked to have the decision aid on 
hand during the interview. 
Data collection 
All interviews were conducted by a single researcher (AH) who has been trained in qualitative 
research methods. Participants were informed that the interviews would be audio-recorded and 
transcribed but that their information would remain confidential and de-identified. They were then 
asked to tell the interviewer how they made their decision to have chemotherapy before or after 
surgery. Participants were encouraged to tell their story in the way they preferred, without 
interruption from the interviewer. This narrative was followed by semi-structured open-ended 
questions which included asking patients about the information provided to them, their information 
seeking behaviour, the decision making process, psychological concerns and experiences with the 
decision aid. The question guide is described in Appendix 2. At the end of the interview, patients 
were given the option to provide additional comments. The questions were informed by a previous 
study and discussions amongst the research team.11, 19 Participants were asked as many questions as 
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needed in order to gain the required information, with prompting used to elicit topics not 
spontaneously spoken about by patients. 
Data analysis 
Interviews were transcribed verbatim. Transcripts were checked for accuracy by one researcher (AH) 
and analysed using a framework analysis process. Transcripts and conclusions drawn from the data 
were double-checked by another member of the research team (NZ). Disagreement was resolved by 
discussions between AH and NZ. The framework method was considered appropriate to develop a 
profound understanding of patients’ experiences with the decision aid, as it provides a systematic 
model for managing and mapping the interview data and for generating themes by making 
comparisons within and between cases.20 After familiarising ourselves with the data, AH examined, 
compared and categorized segments of content in order to assign codes and to start the 
development of categories. A category in this sense was a group of codes that share a 
commonality.21 After identifying initial codes and categories, AH developed a coding matrix and 
assigned data to the codes and categories in the coding matrix.22 This coding matrix was then 
discussed and refined with two members of the research team (NZ and PB). Throughout the coding 
process an iterative approach was applied. Newly developed categories and existing ones were 
constantly compared with each other and revised if necessary. To do this, the interviews were 
analysed individually and then compared with each other.23, 24 The coding process was accompanied 
by writing analytical memos. This helped document the research process and preliminary findings. 
These techniques contributed to the intersubjectivity of the procedure and allow to reconstruct or 
repeat the analysis.25 Demographics are presented using appropriate summary statistics. 
Ethics 
This study was developed and conducted in accordance with the tenets of the Declaration of Helsinki 
and principles of Good Clinical Practice. All participants provided voluntary informed consent. The 
study was approved by a recognised Human Research Ethics Committee and conducted according to 
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local site governance processes. The parent intervention trial was prospectively registered on the 
Australia and New Zealand Clinical Trials Registry (www.anzctr.org.au, ACTRN12614001267640). 
Results 
Demographics 
Patients were interviewed via phone between February and September 2016 by one researcher 
(AH). Of 59 patients who consented to the larger trial, 42 consented to be interviewed and 20 were 
interviewed, by which time saturation was achieved. Interviews lasted between 15 and 37 minutes. 
Participants’ median age was 52 (SD=6.9), median time since diagnosis was 82 days (IQR=49,141). 
The majority of patients decided for NAST (85%), while the remaining 15% underwent upfront 
surgery. Most patients were married or living with a partner (85%) and had a University level degree 
(75%, see Table 1).   
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The use and perceived benefit of the decision aid 
The following themes emerged from the data: i) integration of the decision aid into care, ii) 
improved knowledge and understanding of treatment options, iii) providing customized, reliable 
information, and iv) facilitating involvement in decision making. Our data suggests that by providing 
customized and reliable information to patients, the decision aid helped women better understand 
their options and thus facilitated the decision making process. Most women used the decision aid in-
between the consultations with their doctors. As such, the decision aid could be easily integrated 
into women’s care pathway. The themes are described in detail below. 
Integration of the decision aid into care 
Most women used the decision aid just after the initial consultation with their surgeon about their 
treatment options, prior to their consultation with the medical oncologist, and perceived this as the 
right timing. A mean of 5 days (SD 2.3) elapsed between study consent and treatment decision. 
Reading and rereading the decision aid at home in-between the two consultations allowed women 
to easily integrate the decision aid into their care. They appreciated the opportunity to reconsider 
their options at their own pace after consulting their surgeon. This was particularly important for 
those women who thought that the initial consultation with their surgeon did not provide sufficient 
time to answer all the questions they had. Many women felt that the decision on NAST needed to be 
made quickly and welcomed using the time in-between the consultation with their surgeon and their 
medical oncologist to think about their options with the help of the decision aid.  
 “I think it was important to speak to the surgeon and get his view on it all, but I think it was 
also very helpful to have the written information that was in the decision aid so I could sit 
and read that at my own pace. […] When you are in a surgeon appointment, it's only a 
limited amount of time. […] I was able to absorb it better because I could sit down and take 
the time to read it.” [patient ID: 13010041] 
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While most women received the decision aid after the initial consultation with their surgeon, many 
women made the decision during or just after this initial discussion and some wished they had the 
decision aid “right from the start” [patient ID: 13010035], i.e. just after their diagnosis. Although 
using the decision aid in-between two consultations seemed appropriate, some patients reported 
they would have liked to receive the decision aid during rather than after the initial consultation 
with their surgeon.  
“The book that I was sent after I did that survey, […] I would have loved to have had access 
to that book from the get go.” [patient ID: 13010034] 
Some patients did not use the decision aid as they felt that they (or their doctors) had already made 
the decision. However, most women read the entire decision aid at least once and then reread the 
passages they perceived to be most relevant to them. The amount of information provided was seen 
to be appropriate. Patients appreciated that they could read the decision aid from beginning to end 
or only focus on those parts they were most interested in.  
“You could read more into it if you wanted, but […] I read bits and pieces of the bits that 
weren’t relevant to me – and all of what was relevant to me [...] I think it was enough 
information that if you weren’t quite sure you could always go and get more if you wanted 
[…] for me it was the right amount of information.” [patient ID: 13010033] 
Improved knowledge and understanding of treatment options 
The decision aid enhanced patients’ knowledge and understanding of the treatment options 
available to them by summarising and extending the information provided by their doctors. It helped 
women comprehend and make sense of their cancer and treatment options. Many women reported 
that the decision aid made up for their perceived lack of medical expertise by providing structured, 
objective information and by answering questions patients had after the consultation with their 
doctor. 
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“Sometimes you just need it clearly laid out in front of you, this is your options, without 
having different people who had their own agendas telling you what is right and what is 
wrong, or what you should do.” [patient ID: 13010033] 
“It enhanced what my surgeon had told me and allowed me to process it and understand it 
at a greater depth than I would have been able to if I hadn't had the decision aid.” [patient 
ID: 13010034] 
“It was very simply written and also to-the-point.  I suppose there were some questions that 
I might have been asking myself and they were being answered in that booklet.” [patient ID: 
13010035] 
Some women indicated that the included graphs and statistics were particularly helpful to 
understand the potential risks and benefits of their treatment options. Others found that the 
explanation of different types of breast cancer helped them better understand why different 
patients received different treatments. Some participants with a medical background felt that the 
decision aid could have provided them with more detailed information, for example on potentials 
risks and benefits of NAST and upfront surgery according to different age groups. However, they 
thought that the decision aid provided the right depth and breadth of information to suit the needs 
of the heterogeneous group of breast cancer patients which includes patients with very different 
educational backgrounds and literacy levels. 
“It did give figures for chances of it [=the cancer] disappearing altogether and chances of it 
coming back, the different types of cancer and yeah, I became a bit more of an expert about 
breast cancers and the different types that I had been before.” [patient ID: 13010048] 
“I found it interesting to read a little bit about the other cancers and make the decision on 
me and my situation rather than everyone's situation.” [patient ID: 13010033] 
“I think that the particularly relevant bit was understanding the different types of cancer and 
the explanation of the HER2 and the other types of cancer, and how they are all slightly 
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different, because I didn't know any of that before I got cancer. […] so yes the relevant thing, 
I think, was understanding all the different types of cancer and how one size doesn't fit all. 
Not everyone should have the same approach.” [patient ID: 13010041] 
The decision aid also helped women deal with the fears associated with their treatment options and 
assisted them in making an informed, rational decision based on their individual circumstances and 
preferences. 
“I felt after reading it [=the decision aid] that my fears about the tumour remaining there 
were abated really. […] my cancer was triple negative and I understood that it had 
potentially grown quite fast. Once I understood the rationale for why I might have 
chemotherapy first, I actually felt it was a better option for me to start the chemotherapy 
sooner rather than later, given that I also had spread to my lymph nodes.” [patient ID: 
13010033] 
Providing customized, reliable information 
Women appreciated that information was provided in both face-to-face and written format. Many 
women preferred the printed decision aid over the online version due to ease of access, viewing, 
portability and ability to make notations. Also, patients preferred using the decision aid instead of 
information they found by searching online. They perceived the information provided in the decision 
aid to be more trustworthy and targeted to their needs, compared with sources that they identified 
on the internet. 
“I just found that the information that I was Googling on the internet, it was too much, it 
was too airy fairy.  Whereas this [=the decision aid] was just straight to the point, it was just 
in great user friendly language and that’s what I really loved about the book.” [patient ID: 
13010035] 
“I was a little bit overwhelmed and I wanted reliable information, so I chose not to Google, 
not to do a Google doctor.” [patient ID: 13010034] 
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All patients who used the decision aid described the information provided in the decision aid as 
reliable and tailored to their needs. They liked how the decision aid was organised, including the use 
of graphics, tables, and sufficient white space that reduced the crowding of text. Most patients 
found the decision aid easy to understand and balanced (not in favour of NAST or upfront surgery). 
Some patients perceived it to be in favour of NAST and wished it contained more information on 
upfront surgery.  
“The way it’s laid out, it’s quite spacious on the pages and there are lots of diagrams and 
stuff. So it’s not, you know, it’s quite intimidating if it was all heavy text closely together.” 
[patient ID: 13010015] 
“I think it was more slightly biased in terms of chemotherapy first […] but it could have just 
been my reading of it because I was already in that frame of mind.” [patient ID: 13010041] 
Facilitating involvement in decision making 
The decision aid not only enabled patients to make an informed decision on NAST but also helped 
them become more involved in the decision making process, for example by prompting additional 
questions to ask their doctors during the consultation. Some women took parts of the decision aid to 
the next consultation with their specialist. This served as a platform for further discussion about 
their preferences and concerns, and helped women remember the questions they wanted to ask 
their doctor. One patient found the step-by-step approach for how to arrive at a treatment decision 
particularly helpful. This section of the decision aid included guidance to patients to understand, 
review, prioritise and discuss the information provided (see Appendix 3). 
“I felt like I was more involved in the decision and I was making the decision in a more 
informed way that I maybe would have been able to if I'd just relied on the surgeon's 
information, if that makes sense.” [patient ID: 13010033] 
“It [=the decision aid] was opening up other questions for me to think about, to help me 
think about” [patient ID: 13010024] 
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“I actually then just pulled out pages that I thought were more towards what I was thinking. 
[…] I took that with me to the oncologist appointment. Just so I had things that reminded me 
of what I wanted to ask.” [patient ID: 13010026] 
Some women reported that their family members used the decision aid as well and thus became 
more informed and involved in the decision making process. This saved patients from spending time 
and effort educating their support persons about the risks and benefits of the different treatment 
options available to them. 
“My husband went through the decision aid as well, and also my two adult daughters. I think 
it was quite helpful for them. I saved my breath […] in terms of having to explain and justify 
why one option might be a better choice than another.” [patient ID: 13010034] 
All patients received a treatment recommendation from their doctor and chose the recommended 
option. The decision making process was guided by their doctor’s opinion and based on patients’ 
trust in their doctors’ medical expertise and experience. Although the decision aid helped patients 
understand their options, confirm their decision and increase their involvement in the decision 
making process, it did not change women’s decisions on NAST. Women who felt they made an 
informed decision on NAST and were involved in the decision making process seemed to be more 
satisfied and certain about their decision. 
“It [=the decision aid] just kind of clarified and confirmed to me what I was doing, and the 
decision I made.” [patient ID: 13010032] 
“I felt that having chemo first was the right decision – and the information in there [=the 
decision aid] helped me confirm that that was the right decision. I just think it's something 
that should be out there for all women in this situation […] It's such an important tool to 
have to make sure that you're making the decision that's right for you.”[patient ID: 
13010033] 
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Discussion 
Fitting decision aids into the clinic workflow: a feasible prospect  
These results suggest that the decision aid was a useful tool to support breast cancer patients in 
deciding on whether to have NAST. The themes that emerged from the data were of integration of 
the decision aid into care, increased knowledge and understanding of treatment options, providing 
customized, reliable information and involvement in the decision making process. The decision aid 
supported women’s comprehension of their cancer and the treatment options available to them. It 
facilitated their participation in deciding on NAST and helped women confirm that they made the 
right decision. This is in line with current evidence supporting the effectiveness of decision aids in 
improving patient outcomes.15, 26 The degree of patients’ engagement with this decision aid 
demonstrates the feasibility of patient involvement in decision making in the context of a 
confronting diagnosis accompanied by a variety of decisions, rather than expecting clinician-led 
decision making. 
Although decision aids have been shown to be effective in improving patient outcomes, widespread 
clinical use is not yet commonplace.27 More efforts need to be made to explore how to best 
integrate decision aids into routine doctor-patient-communication. Depending on the format and 
the decision being made, individual decision aids may be better suited to use either during the 
consultation or afterwards.15 The breast cancer patients in our sample appreciated reading the 
decision aid in-between having a consultation with their surgeon and their follow-up consultation 
with their medical oncologist. Patients received the decision aid after the initial consultation with 
their surgeon, whilst waiting to see their medical oncologist. This allowed the decision aid to be 
easily integrated into their care pathway. It also gave women the opportunity to reconsider their 
options and feel more certain about choosing a treatment. This is in line with previous studies 
reporting reduces in patients’ decisional conflict, decisional regret and depression after the use of 
decision aids which had been delivered as a post consultation supplement.15, 28, 29 Further studies 
have suggested that using a decision aid prior to the consultation during which a healthcare decision 
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is made might increase patients’ feeling of being informed about their options, as well as patients’ 
ability and willingness to participate in the decision making process at hand.30-32  
Although using the decision aid in between patients’ consultation with their surgeon and their 
consultation with their medical oncologist seems to be appropriate, some women said that the 
intervention should be introduced and endorsed during the initial consultation with their surgeon. 
Such an approach may be possible with sufficient resources, however might be difficult to broadly 
incorporate into routine practice given many clinicians’ reluctance regarding the provision of 
decision aids during the consultation.33, 34 For example, it has been suggested that clinicians might 
fear that the use of decisions aids could increase their time pressure.35, 36 Further barriers include 
clinicians’ lack of awareness of decision aids or their belief that decisions aids are not applicable to 
the circumstances of each individual patient.37 The study processes precluded investigators from 
providing participants with the decision aid at the initial consultation with their surgeon, because 
pre-decision aid questionnaires were required for the larger intervention trial in which this 
qualitative study was embedded. However, investigators were given a card showing key images and 
graphs from the decision aid to demonstrate within the consultation. In routine clinical practice, the 
decision aid could be briefly introduced during the initial consultation with the surgeon. Face-to-face 
communication between doctor and patient might be best suited to introduce and explain the 
preference-sensitive nature of the decision on NAST and the potential benefits of the decision aid.38 
This is in line with previous studies which suggest that patients might value having important 
treatment decisions discussed with their clinician first and having decision aids delivered during the 
consultation.39, 40 Appropriately selected patients can then use and engage with the decision aid 
after the consultation to broaden and deepen their understanding of the conveyed information and 
prior to making a final treatment decision. 
Exploring the benefits of the decision aid on NAST 
The women included in our sample were well educated and had high health literacy levels, which 
may have contributed to positive feedback about comprehensibility. We do not know whether 
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women with lower health literacy levels would perceive the same benefits from using the decision 
aid. However, there is evidence to suggest that if patients with lower literacy levels are provided 
with appropriate decision support, they participate equally well and benefit by becoming more 
aware of their healthcare options.41 It would be beneficial to administer the decision aid to a more 
representative sample of breast cancer patients in order to investigate whether our findings are 
generalizable. 
The decision aid reassured women that they made the right decision on NAST, but did not change 
their decision. Other decision aid studies have demonstrated a variable effect on treatment choice,15 
however the intent is to inform and involve rather than to change people’s mind. All women trusted 
and followed their doctors’ treatment recommendation. Many patients felt that their treatment 
decision needed to be made quickly and felt overwhelmed by their cancer diagnosis and treatment 
options. Decision aids, such as the one provided within this study, might be an opportunity to 
counteract this “rushed” decision making by allowing patients to reconsider and confirm their 
treatment decision.42, 43 Because all patients in our study received a treatment recommendation, this 
decision aid could be used to educate women on the preference-sensitive nature of the decision on 
NAST and to highlight the benefits of involving patients’ preferences in this decision.44, 45 As such, the 
endorsement by clinicians influenced the decision aid’s success. Also, the decision aid gave patients’ 
support persons specific information about the options available and enabled their participation in 
the decision making process. This mirrors previous studies which reported that decision aids can 
increase families’ knowledge of the options available to patients and their involvement in decision 
making.46, 47
The influence of the decision aid on the decision about NAST 
Although the majority of women felt that the decision aid provided unbiased, balanced information, 
some women perceived that the decision aid was in favour of NAST. When probed to explain why 
they felt this way, women reported that they decided for NAST and felt that they might have read 
the decision aid according to what they had already decided. One could assume that in order to 
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obtain or maintain cognitive consonance women who chose NAST read the decision aid to confirm 
their decision and thus got the impression that NAST was recommended by the decision aid.48 
However, it might be that the decision aid is in fact biased. Further examination is needed to answer 
this question.  
A number of women indicated a preference for more detailed information. Although the decision aid 
includes links to further information sources, it might be worthwhile to provide an optional 
supplement to the decision aid for those patients who would like to receive more information on the 
decision on NAST. Such a supplement could include potentials risks and benefits of NAST and upfront 
surgery according to different age groups. This would be more amenable to an online format, which 
incorporates links and additional pages for those who want more information. Similar approaches 
have been shown to be valued by patients.49, 50 
Limitations 
Our findings are not intended to be numerically representative. They rather provide much needed 
in-depth insights into patients’ use and perceived benefit of this decision aid, and decision aids in 
general. As such, we avoided potentially misleading numerical description of our results. A 
quantitative analysis of the decision aid that includes a larger sample size will be reported 
elsewhere. The majority of study participants (85%) chose NAST over upfront surgery. Thus, 
women’s perceptions of the decision aid may have been influenced by their treatment decision. 
Also, some women used the decision aid months prior to the interview, introducing the possibility of 
recall bias that could potentially lead to inaccurate narratives.51 Some patients noted that the shock 
over their cancer diagnosis and the plethora of information to consider added further difficulty with 
remembering the decision aid’s content. 
“That is a really, really shady period of my life. I can’t remember much. You probably know 
that people do not remember much when they first hear the diagnosis” [patient ID: 
13010023] 
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We do not have recordings of the consultations during which the decision aid was introduced. As 
such, we do not know how the communication skills and styles of the doctors who were involved in 
the delivery of the decision aid might have influenced patients’ use and perceived benefit of the 
decision aid.  
Conclusions 
Our results suggest that the decision aid is a valuable tool for supporting women with their decision 
on NAST. It seemed to increase women’s knowledge and understanding of the options available to 
them and helped them feel more involved in the decision making process. The decision aid assisted 
women with confirming that they made the right decision. For most women, using the decision aid 
in-between the consultation with their surgeon and the consultation with their medical oncologist 
appeared to be an acceptable and feasible way of integrating the decision aid into patient care.   
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Table 1 – Patient characteristics 
Patients (n=20) 
Age in years, mean (SD) 52 (6.9) 
Marital status 
De facto 
Married 
Single 
15% (3) 
70% (14) 
15% (3) 
Education 
Secondary school 
Vocational 
University 
15% (3) 
10% (2) 
75% (15) 
Lymph nodes involved 
Yes 
No 
45% (9) 
55% (11) 
Treatment decision 
Neoadjuvant 
Adjuvant 
85% (17) 
15% (3) 
Surgery 
Mastectomy only 
Breast conserving surgery only 
Both 
45% (9) 
50% (10) 
5% (1) 
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Zdenkowski N, Butow P, Boyle FM. Patient reported outcomes according to receipt of neoadjuvant 
or adjuvant systemic therapy for breast cancer: results of a prospective longitudinal study. Oral 
abstract presentation at the 3rd Annual Controversies in Breast Cancer Conference held in Tokyo, 
Japan, on 26th-28th October 2017. 
 
This conference abstract reports subgroup analyses of patient reported outcome measures from the 
neoadjuvant decision aid study. This analysis aimed to identify whether there was a difference in 
outcomes such as satisfaction with decision; decisional regret; anxiety; distress; and fear of cancer 
progression. Groups being compared were: surgery, or chemotherapy first; and pathological 
complete response vs no pathological complete response. This work suggests that there is no 
psychological disadvantage to neoadjuvant systemic therapy for breast cancer, at the time of 
treatment and in follow-up, whether a complete response is achieved or not.  
 
Author contributions 
Conception and design: All authors 
Participant recruitment: NZ, FB 
Data collection: NZ 
Data analysis and interpretation: All authors 
Abstract preparation and presentation: NZ 
Abstract critical review and review of final abstract: All authors 
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Abstract 
Problem statement 
Neoadjuvant systemic therapy (NAST) has become an important, and increasingly used, treatment 
option for women with large or highly proliferative operable breast cancer. Benefits include: 
downstaging from mastectomy to lumpectomy, less axillary surgery, time to consider surgery 
including reconstruction, time for genetic testing, and prognostication. However, patients who do 
not achieve a pathological complete response (pCR) have a poorer prognosis than those who achieve 
pCR after NAST. It is not known whether psychological outcomes differ in patients who receive NAST 
according to pCR, and whether these outcomes differ from patients who have surgery first followed 
by adjuvant systemic therapy. 
Methods 
These data comprise a substudy of a larger study to evaluate a patient decision aid (DA) for women 
who were considering NAST for operable breast cancer, which recruited participants at four 
Australian centres. Demographics, tumour details, and treatment were recorded. Participants 
completed online questionnaires prior to accessing the DA, and on three occasions post-DA. 
Outcome measures were patient reported measures relevant to patient decision-making including 
anxiety (STAI-6), distress thermometer, satisfaction with decision-making and decisional regret. 
Planned sample size was 50 participants having completed assessment 2. 
Results 
Fifty-nine women enrolled in the study, and 51 completed assessment 2. Median age was 52, 81% 
were married, 51% had tertiary education, 86% had private health insurance. At baseline, mean 
tumour diameter was 31mm, 46% had positive axillary nodes, 38% had HER2 positive, and 19% had 
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triple negative tumours. Fifty-one received NAST, 7 had surgery first and 1 was unknown (withdrew 
consent after assessment 1). Of the 51 neoadjuvant patients, 14 (28%) had pCR in the breast and 
lymph nodes, and a further 20% had minimal residual cancer burden (RCB 1). 54% had a 
mastectomy, 85% had radiotherapy. At baseline, 38 preferred NAST, 2 preferred surgery and 18 
were unsure (1 missing). Of the 18 who were unsure, 12 (67%) went on to have NAST and 6 (33%) 
had surgery; compared to 40 who were sure, where 39 (98%) had NAST and 1 (2%) had surgery 
(Chi2=11.1, p=0.001). 
Baseline anxiety was significantly higher (∆=10 points, 95% CI 0-19, p=0.046) in patients who had 
surgery first compared with NAST, and remained higher to 12 months of follow up. There was no 
difference in distress between surgery first and NAST, with both groups’ scores decreasing over 
time. Mean satisfaction with decision score post-DA was significantly lower in the surgery-first group 
compared with NAST (22 vs 26, p=0.02). 
Comparing those with pCR to those who had residual cancer in breast and/or lymph nodes: distress 
and anxiety were no different after chemotherapy and at 12 months; satisfaction with decision and 
fear of progression during chemotherapy were no different; and decision regret was numerically 
(but not significantly) lower in the pCR group after chemotherapy (18 vs 12, p=0.15) and at 12 
months (12 vs 5, p=0.17). 
Conclusion 
Most patients who were given the option of NAST by their surgeon proceeded with NAST. Compared 
with those who were sure about their decision at baseline, more of those who were unsure elected 
to have surgery first. Anxious patients tended to choose surgery first. In patients who had NAST, pCR 
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does not appear to correlate with anxiety, distress, fear of progression, fear of recurrence, 
satisfaction or regret. 
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 Hunter New England Research Ethics & Governance Unit 
Locked Bag 1 
New Lambton  NSW  2305 
Telephone: (02) 49214950   Facsimile: (02) 49214818 
Email: HNELHD-HREC@hnehealth.nsw.gov.au 
http://www.hnehealth.nsw.gov.au/research_ethics_and_governance_unit 
 
 
 
 
30 January 2015 
 
 
 
Dr Nicholas Zdenkowski 
Australia and New Zealand Breast Cancer Trials Group 
Trials Coordination Department 
PO Box 
Hunter Region Mail Centre   NSW   2310 
 
 
Dear Dr Zdenkowski, 
 
Re: ANZ 1301: DOMINO: A phase II study evaluating a decision aid for women considering 
neoadjuvant systemic therapy for operable invasive breast cancer (14/12/10/4.05) 
 
HNEHREC Reference No: 14/12/10/4.05 
NSW HREC Reference No: HREC/14/HNE/502 
 
Thank you for submitting the above application for single ethical review for a multi-centre study.  
This project was first considered by the Hunter New England Human Research Ethics Committee 
at its meeting held on 10 December 2014.  This Human Research Ethics Committee is constituted 
and operates in accordance with the National Health and Medical Research Council’s National 
Statement on Ethical Conduct in Human Research (2007) (National Statement) and the CPMP/ICH 
Note for Guidance on Good Clinical Practice. Further, this Committee has been accredited by the 
NSW Department of Health as a lead HREC under the model for single ethical and scientific 
review. The Committee’s Terms of Reference are available from the Hunter New England Local 
Health District website.  
 
I am pleased to advise that following acceptance under delegated authority of the requested 
clarifications and revised Participant Information Statements by Dr Nicole Gerrand Manager, 
Research Ethics & Governance, the Hunter New England Human Research Ethics Committee has 
granted ethical approval of the above project. 
 
The following documentation has been reviewed and approved by the Hunter New England Human 
Research Ethics Committee: 
 
- For the NEAF [Submission Code: AU/1/200C110]; 
- For the Victorian Specific Module – Sections 1-5, signed 24 November 2014; 
- For the DOMINO Protocol Administrative Change 1 dated 19 January 2015; 
- For the DOMINO Protocol Administrative Change 1, Summary of Changes dated 19 
January 2015; 
- For the Screening Participant Information Statement (Version 2 dated 19 January 
2015); 
- For the Participant Information Statement (Version 2 dated 19 January 2015); 
- For the DOMINO Decision Aid dated 13 January 2015; 
- For the DOMINO Screening Form dated 19 January 2015; 
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New Lambton  NSW  2305 
Telephone: (02) 49214950   Facsimile: (02) 49214818 
Email: HNELHD-HREC@hnehealth.nsw.gov.au 
http://www.hnehealth.nsw.gov.au/research_ethics_and_governance_unit 
 
- For the DOMINO Screening Form Summary of Changes dated 19 January 2015; 
- For the Withdrawal of Consent Form (Version 1 dated 19 January 2015; 
- For the Participant Questionnaires – Appendix C-P DOMINO Protocol; 
- For the Participant Telephone Interview – Appendix Q DOMINO Protocol; and 
- For the NSW Privacy Form dated 20 November 2014 
 
For the study: ANZ 1301: DOMINO: A phase II study evaluating a decision aid for women 
considering neoadjuvant systemic therapy for operable invasive breast cancer 
(14/12/10/4.05) 
 
Approval has been granted for this study to take place at the following sites: 
 
- Calvary Mater Newcastle, Waratah NSW 
- Mater Adult Hospital, North Sydney NSW 
- The Royal Melbourne Hospital, Parkville VIC 
 
Approval from the Hunter New England Human Research Ethics Committee for the above protocol 
is given for a maximum of 3 years from the date of this letter, after which a renewal application will 
be required if the protocol has not been completed. 
 
The National Statement on Ethical Conduct in Human Research (2007), which the Committee is 
obliged to adhere to, include the requirement that the committee monitors the research protocols it 
has approved.  In order for the Committee to fulfil this function, it requires:  
 
 A report of the progress of the above protocol be submitted at 12 monthly intervals.  Your 
review date is January 2016.  A proforma for the annual report will be sent two weeks prior to 
the due date.     
 
 A final report must be submitted at the completion of the above protocol, that is, after data 
analysis has been completed and a final report compiled. A proforma for the final report will be 
sent two weeks prior to the due date. 
 
 All variations or amendments to this protocol, including amendments to the Information Sheet 
and Consent Form, must be forwarded to and approved by the Hunter New England Human 
Research Ethics Committee prior to their implementation. 
 
 The Principal Investigator will immediately report anything which might warrant review of ethical 
approval of the project in the specified format, including: 
 
- any serious or unexpected adverse events 
 
 Adverse events, however minor, must be recorded as observed by the 
Investigator or as volunteered by a participant in this protocol.  Full details 
will be documented, whether or not the Investigator or his deputies considers 
the event to be related to the trial substance or procedure. These do not 
need to be reported to the Hunter New England Human Research Ethics 
Committee 
 
 Serious adverse events that occur during the study or within six months of 
completion of the trial at your site should be reported to the Manager, 
Research Ethics & Governance, of the Hunter New England Human 
Research Ethics Committee as soon as possible and at the latest within 72 
hours.   
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 All other safety reporting should be in accordance with the NHMRC’s Safety
Monitoring Position Statement – May 2009 available at
http://www.nhmrc.gov.au/health_ethics/hrecs/reference/_files/090609_nhmrc
_position_statement.pdf
 Serious adverse events are defined as:
- Causing death, life threatening or serious disability.
- Cause or prolong hospitalisation.
- Overdoses, cancers, congenital abnormalities whether judged to be
caused by the investigational agent or new procedure or not.
- Unforeseen events that might affect continued ethical acceptability of the project.
 If for some reason the above protocol does not commence (for example it does not receive
funding); is suspended or discontinued, please inform Dr Nicole Gerrand, as soon as possible.
You are reminded that this letter constitutes ethical approval only. You must not commence 
this research project at a site until separate authorisation from the Chief Executive or 
delegate of that site has been obtained. 
A copy of this letter must be forwarded to all site investigators for submission to the relevant 
Research Governance Officer. 
Should you have any concerns or questions about your research, please contact Dr Gerrand as 
per the details at the bottom of the page. The Hunter New England Human Research Ethics 
Committee wishes you every success in your research. 
Please quote 14/12/10/4.05 in all correspondence. 
The Hunter New England Human Research Ethics Committee wishes you every success in your 
research. 
Yours faithfully 
For: Professor M Parsons 
Chair 
Hunter New England Human Research Ethics Committee 
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